

—最終報告書—

表題:ポリオキシエチレン p-ノニルフェニルエーテルのラットにおける 28 日間反復経口投与毒性試験および 14 日間回復性試験

試験番号:SBL 79-02

当該資料は原本の正式な複写であり、原本と相違ないことを保証いたします。

oo/年 3月 30日

試験施設 :株式会社 新日本科学 安全性研究所  
鹿児島県鹿児島郡吉田町宮之浦 2438 番地(〒891-1394)  
電話(099)294-2600, ファクシミリ(099)294-3619

:株式会社 新日本科学 安全性研究所 薬物代謝分析センター  
和歌山県海南市南赤坂 16-1(〒642-0017)  
電話(073)483-8881, ファクシミリ(073)483-7377

## 最終報告書の作成

表題 : ポリオキシエチレン p-ノニルフェニルエーテルのラットにおける 28 日間反復経口投与毒性試験および 14 日間回復性試験

試験番号 : SBL 79-02

本試験の最終報告書は、私の責任の下に作成しました。

[REDACTED] 2001年 3月 30日

本試験の各検査報告書は、私達の責任の下に作成しました。

[REDACTED] 2001年 3月 30日

[REDACTED] 3月 30日

## 陳述書

表題 : ポリオキシエチレン p-ノニルフェニルエーテルのラットにおける 28 日間反復経口投与毒性試験および 14 日間回復性試験

試験番号 : SBL 79-02

本試験は、OECD Principles of Good Laboratory Practice (revision in 1997) および OECD Guidelines for Testing of Chemicals 407 (Repeated Dose 28-day Oral Toxicity Study in Rodents, Adopted: 27th July 1995) に準拠して実施し、また、最終報告書は試験の方法を正確に記載し、生データを正確に反映したものに相違ありません。

試験責任者

(所属) 株式会社 新日本科学 安全性研究所

2001年 3月 30日

## QAU 陳述書

表題 : ポリオキシエチレン p-ノニルフェニルエーテルのラットにおける28日間  
反復経口投与毒性試験および14日間回復性試験

試験番号 : SBL 79-02

本試験は、OECD Principles of Good Laboratory Practice (revision in 1997) および OECD Guidelines for Testing of Chemicals 407 (Repeated Dose 28-day Oral Toxicity Study in Rodents, Adopted: 27th July 1995) に準拠して実施され、また、最終報告書は試験の方法を正確に記載し、生データを正確に反映したものに相違ありません。

査察項目	査察実施日	試験責任者	運営管理者
		への報告日	への報告日
試験計画書	2000年11月14日	2000年11月14日	2000年11月14日
試験スケジュール	2000年11月14日	2000年11月22日	2000年11月22日
試験計画書変更確認書(No. 1)	2000年11月22日	2000年11月22日	2000年11月22日
試験スケジュール	2000年11月22日	2000年11月22日	2000年11月22日
被験物質保管状態	2000年11月23日	2000年12月1日	2000年12月1日
被験物質の調製	2000年11月23日	2000年12月1日	2000年12月1日
調製液の濃度測定	2000年11月24日	2000年12月1日	2000年12月1日
試験室	2000年11月25日	2000年12月1日	2000年12月1日
動物の飼育管理	2000年11月25日	2000年12月1日	2000年12月1日
試験動物	2000年11月25日	2000年12月1日	2000年12月1日
投与	2000年11月25日	2000年12月1日	2000年12月1日
一般状態観察	2000年11月25日	2000年12月1日	2000年12月1日
行動薬理学的側面からの 行動観察	2000年11月25日	2000年12月1日	2000年12月1日
摂餌量測定	2000年12月1日	2000年12月1日	2000年12月1日
体重測定	2000年12月1日	2000年12月1日	2000年12月1日
尿検査	2000年12月20日	2000年12月25日	2000年12月25日
眼科的検査	2000年12月21日	2000年12月25日	2000年12月25日
血液学的検査	2000年12月23日	2000年12月25日	2000年12月25日
血液生化学的検査	2000年12月23日, 2000年12月24日	2000年12月25日	2000年12月25日
剖検	2000年12月23日	2000年12月25日	2000年12月25日
器官重量測定	2000年12月23日	2000年12月25日	2000年12月25日
剖検	2001年1月6日	2001年1月9日	2001年1月9日
器官重量測定	2001年1月6日	2001年1月9日	2001年1月9日

SBL 79-02

査察項目	査察実施日	試験責任者	運営管理者
		への報告日	への報告日
試験計画書変更確認書(No. 2)	2001年 1月 23日	2001年 1月 23日	2001年 1月 23日
病理組織学的検査	2001年 2月 13日	2001年 2月 16日	2001年 2月 16日
試験計画書変更確認書(No. 3)	2001年 2月 27日	2001年 2月 27日	2001年 2月 27日
書類・生データ	2001年 3月 9日, 2001年 3月 12日	2001年 3月 12日	2001年 3月 19日
最終報告書草案	2001年 3月 9日, 2001年 3月 12日	2001年 3月 12日	2001年 3月 19日
最終報告書草案	2001年 3月 14日	2001年 3月 14日	2001年 3月 19日
試験計画書逸脱書(No. 1)	2001年 3月 29日	2001年 3月 29日	2001年 3月 29日
最終報告書	2001年 3月 30日	2001年 3月 30日	2001年 3月 30日

QAU 責任者  
 (所属)株式会社新日本科学



2001 年 3 月 30 日

試験責任者、その他の試験に従事した研究者全員の氏名および業務分担

・試験責任者

〒891-1394 鹿児島県鹿児島郡吉田町宮之浦 2438 番地

・最終報告書の作成

〒891-1394 鹿児島県鹿児島郡吉田町宮之浦 2438 番地

・検疫

・被験物質の調製および分析

・投与

・一般状態観察

・行動薬理学的側面からの

行動観察

・摂餌量測定

・体重測定

・眼科的検査

・尿検査

・血液学的検査 [REDACTED]

・血液生化学的検査 [REDACTED]

・剖検 [REDACTED]

・器官重量測定 [REDACTED]

・病理組織学的検査 [REDACTED]

・統計解析 [REDACTED]

記録、資料、試料および標本の保存場所

株式会社新日本科学内のデータ資料室(記録および資料)、試験物質保管庫  
(保存用被験物質)および器官保管室(標本)

## 目 次

	頁
要 約.....	1
緒 言.....	2
材料および方法.....	3
1. 被験物質およびその調製法.....	3
2. 試験動物および飼育条件.....	3
3. 投与量の設定および投与方法.....	4
4. 群構成.....	5
5. 観察および検査項目.....	5
1) 一般状態.....	5
2) 行動薬理学的側面からの行動観察.....	5
3) 摂餌量.....	6
4) 体重.....	6
5) 眼科的検査.....	6
6) 尿検査.....	7
7) 血液学的検査.....	7
8) 血液生化学的検査.....	8
9) 剖検.....	9
10) 器官重量(絶対および相対重量).....	9
11) 病理組織学的検査.....	9
6. 統計学的手法.....	10
7. 試験成績の信頼性に影響を及ぼしたと思われる環境要因および試験計画書に従わなかつたこと.....	10
結 果.....	11
1. 一般状態.....	11
2. 行動薬理学的側面からの行動観察.....	11
3. 摂餌量.....	11
4. 体重.....	11

5. 眼科的検査.....	11
6. 尿検査.....	11
7. 血液学的検査.....	12
8. 血液生化学的検査.....	12
9. 剖検.....	12
10. 器官重量.....	13
11. 病理組織学的検査.....	13
考 察.....	15
文 献.....	17
別紙	1~3
Figs.	1, 2
Tables	1~11
Appendices	1~11

## 要 約

ポリオキシエチレン p-ノニルフェニルエーテルの 0(対照), 20, 200 および 1000 mg/kg を各群雌雄各 5 例の C<sub>j</sub>:CD (SD) IGS ラットに 1 日 1 回 28 日間反復経口投与し、さらに、0(対照)および 1000 mg/kg 群にそれぞれ雌雄各 5 例の 2 週間回復試験例を設けて、その毒性と回復性を調べるとともに NOEL (no-observed-effect level) を求めた。対照群には媒体の注射用水を被験物質群と同様の方法で投与した。

1. 投与および回復期間中、いずれの群においても死亡はみられず、一般状態観察および行動薬理学的側面からの行動観察においても異常はみられなかった。
2. 摂餌量、体重、眼科的検査、尿検査、血液学的検査、血液生化学的検査、剖検、器官重量および病理組織学的検査では、いずれの検査時期においても被験物質投与に起因した変化はみられなかった。

以上の結果、本試験条件下では一般に反復投与毒性試験の投与量の上限とされる 1000 mg/kg を投与しても被験物質投与に起因する変化がみられなかったことから、ポリオキシエチレン p-ノニルフェニルエーテルの NOEL は雌雄ともに 1000 mg/kg/日を超える量と結論した。

## 緒 言

本試験の目的は、ポリオキシエチレン p-ノニルフェニルエーテルをラットに 28 日間毎日 1 回経口投与し、さらに 14 日間回復性試験を実施して、その毒性について調べることである。本試験は、OECD Principles of Good Laboratory Practice (revision in 1997) および OECD Guidelines for Testing of Chemicals 407 (Repeated Dose 28-day Oral Toxicity Study in Rodents, Adopted: 27th July 1995) に準拠して実施した。

試験開始日:2000 年 11 月 14 日

実験開始日:2000 年 11 月 25 日

実験終了日:2001 年 2 月 26 日

試験終了日:2001 年 3 月 30 日

試験委託者:経済産業省(旧通商産業省) 製品評価技術センター

化学物質安全管理センター

〒151-0066 東京都渋谷区西原 2-49-10

## 材料および方法

### 1. 被験物質およびその調製法

被験物質は、経済産業省(旧通商産業省)製品評価技術センター化学物質安全管理センターから2000年9月25日に提供を受けたポリオキシエチレン p-ノニルフェニルエーテル(商品名: [REDACTED])を使用した。ポリオキシエチレン

p-ノニルフェニルエーテルは、CAS番号 9016-45-9, 示性式  $C_9H_{19}(C_6H_4)O(CH_2CH_2O)_nH$  ( $n=28.8$ ), 分子量 1488, 純度 100 wt%, 融点 29.0°C の白色固体である。溶解性は、水およびイソプロパノールに可溶である。被験物質の安定性は、投与終了後に株式会社新日本科学で純度を測定し、投与期間中の安定性を確認した(Stability of the Test Article, Certificate No.:790210-3, 別紙 1)。被験物質は、株式会社新日本科学試験物質保管所内の温度 20±4°C に設定した常温室[受領日～返却日(2000年9月25日～2001年3月29日):温度 18.0～24.0°C]に遮光下で気密容器内に保存した。なお、残余被験物質は2001年3月29日に保存用被験物質(約 1 g)を除き全て試験委託者に返却した。

被験物質の調製は、ポリオキシエチレン p-ノニルフェニルエーテルを秤量し、2, 20 および 100 mg/mL になるように注射用水(ロット番号 0G76, 0I77, 0J74, 株式会社大塚製薬工場)を加えて溶解した。調製は週 1 回以上行い、1 日分毎に分注した後、使用時まで株式会社新日本科学試験物質保管所内の温度 20±4°C に設定した常温室[初回調製日～最終投与日(2000年11月23日～2000年12月22日):温度 20.3～23.9°C]に遮光下で保存した。

ポリオキシエチレン p-ノニルフェニルエーテルの 0.1 および 200 mg/mL 濃度の調製液は、室温、遮光下 7 日間安定であることが株式会社新日本科学で確認されている(Stability of the Test Article in the Dosing Preparation, Certificate No.:790210-2, 別紙 2)。また、投与開始日および最終週の投与液について HPLC を用いて株式会社新日本科学で確認した結果、いずれも目標濃度の±5%以内であることが確認された(Concentration of the Test Article in the Dosing Preparation, Certificate No.:7902-1, 7902-2, 別紙 3-1, 3-2)。

### 2. 試験動物および飼育条件

試験動物は、4 週齢の Crj:CD (SD) IGS ラット(日本チャールス・リバー株式会社生産)雌雄

各 33 匹を 2000 年 11 月 16 日に入手し、検収時に体重測定を行った。その後、9 日間の検疫馴化期間中に、全例について一般状態観察を毎日 1 回、体重測定を検疫馴化終了日に 1 回、また、摂餌量測定および眼科的検査を各 1 回行い、異常のみられなかった雌雄各 30 匹（群分け時体重：雄 132～169 g、雌 121～138 g）を使用した。

試験動物は、温度  $22 \pm 2^{\circ}\text{C}$ （実測値：18.7～23.4°C）、湿度  $50 \pm 10\%$ （実測値：40～68%）、換気回数 15 回/時間、人工照明 1 日 12 時間（午前 6 時～午後 6 時）に設定した SPF 施設 95 号室内で、サスペンド式ステンレス製ケージ [32.5 cm (D) × 19.5 cm (W) × 18 cm (H)] に個別飼育した。なお、温湿度は SOP の許容範囲内であった。室内は毎日清掃し、ケージは 4 週間に 1 回、オートクレーブ滅菌処理（121°C、30 分間）済みのものと交換した。飼料はコバルト 60 照射滅菌済みの固型飼料（CE-2、ロット番号 E2090, E2100、日本クレア株式会社）を与え、飲水は水道法水質基準に適合した水を自動給水装置（Edstrom Industries, Inc.）で自由に摂取させた。ただし、代謝ケージによる尿採取時には絶食および絶水とし、剖検前にも 16 時間以上絶食させた。なお、飼料はロットごとに、飲水は定期的に分析した結果、いずれも問題のないことが確認されている。

### 3. 投与量の設定および投与方法

先に実施した 14 日間反復投与毒性試験（試験番号：SBL79-02-20、投与量：0, 30, 100, 300, 1000 mg/kg）において、100 mg/kg 以上の群の雄で用量に依存していないもののトリグリセライドの高値がみられたが、そのほかには被験物質投与に起因すると考えられる変化はみられなかった。従って、本試験の投与量は、高用量を 1000 mg/kg とし、以下公比 5 または 10 で 200 および 20 mg/kg に設定した。

投与経路は OECD Guidelines for Testing of Chemicals 407 に従い経口とした。投与回数および期間についても OECD Guidelines for Testing of Chemicals 407 に従い 1 日 1 回 4 週間（計 28 日）連日投与とした。投与は 2000 年 11 月 25 日から 2000 年 12 月 22 日の午前 9 時～正午、ただし、尿検査日は午後 3 時～4 時の間に行い、ラット用胃ゾンデを用いて 10 mL/kg の容量で強制経口投与した。対照群には注射用水を被験物質群と同様の方法で投与した。

#### 4. 群構成

群構成は、対照群1群、被験物質群3群の計4群とし、各群には雌雄各5匹を配分した。さらに、対照群および高用量群には回復性試験のためにそれぞれ雌雄各5匹を加えた。群分けは投与開始前日の2000年11月24日に各群の平均体重がほぼ均一になるよう、体重の層別無作為化によって行った。

各個体は耳パンチ法で、ケージはカラーケージカード(試験番号、群、投与量、性および動物番号記載)でそれぞれ識別した。

試験群の構成を次の表に示した。

群	試験物質	投与量 (mg/kg/日)	投与容量 (mL/kg/日)	動物数(動物番号)	
				雄	雌
1	媒体	0	10	5+5 *(1~10)	5+5 *(11~20)
2	ポリオキシエチレン p-ノニルフェニルエーテル	20	10	5 (21~25)	5 (26~30)
3	ポリオキシエチレン p-ノニルフェニルエーテル	200	10	5 (31~35)	5 (36~40)
4	ポリオキシエチレン p-ノニルフェニルエーテル	1000	10	5+5 *(41~50)	5+5 *(51~60)

\*:回復試験例(動物番号:1~5, 11~15, 41~45, 51~55)

#### 5. 観察および検査項目

投与開始日を投与0日、投与期間終了の翌日を回復0日、また、投与あるいは回復開始週を投与あるいは回復1週と起算した。なお、回復期間は2週間(14日間)とした。

##### 1) 一般状態

投与期間中は毎日3回(投与前、投与後1~2時間、投与後4~6時間)、回復期間中は毎日1回および剖検日に1回、全例について動物の生死と併せて観察した。

##### 2) 行動薬理学的側面からの行動観察

投与0日目の投与前および投与後2~4時間、投与27日目の投与後2~4時間および回復2週に各1回、各群の雌雄とも動物番号の小さいほうから各5例についてIrwin法を参考にした方法で行動観察を行った。また、1分間にみられた立ち上がり動作をカウントした。検査

項目を次に示した。

- |         |   |
|---------|---|
| 行動的側面   | ; 認知力(警戒性, 視覚による位置認知, 受動性, 常同反応), 気分<br>(身づくろい, 鳴啼, 落ち着きのなさ, 被刺激性の亢進, 恐怖), 運動<br>性(反応性, 自発運動, 触反応, 疼痛反応), 立ち上がり動作                           |
| 神経学的側面  | ; 中枢興奮(驚愕反応, 挙尾反応, 振戦, 攣縮, 痉攣), 協調運動障<br>害(体姿勢, 四肢の位置, よろめき歩行, 異常歩行, 正向反射), 筋<br>緊張度(四肢筋緊張度, 握力, 駆幹筋緊張度, 腹筋緊張度), 反射<br>(耳介反射, 角膜反射, 同側屈曲反射) |
| 自律神経的側面 | ; 眼徴候(瞳孔径, 眼裂, 眼球突出), 分泌徴候(排尿, 流涎), 一般<br>徴候(もだえ反応, 立毛, 体温下降, 皮膚色, 心拍数, 呼吸数)  |

### 3) 摂餌量

投与開始前 1 回, 投与および回復期間中週 1 回, 全例について給餌量を電子天秤(FY-3000, 株式会社エー・アンド・デイ)で測定し, その翌日に残余量を測定して 1 日あたりの摂餌量を算出した。

### 4) 体重

投与開始前日に 1 回, 投与および回復期間中週 1 回および剖検日に 1 回, 全例について電子天秤(FY-3000, 株式会社エー・アンド・デイ)を用いて測定した。また, 測定時ごとの体重の増加量を求めた。

### 5) 眼科的検査

投与開始前, 投与 4 週目および回復 2 週目に各 1 回, 全例についてペンライトを用いて前眼部および中間透光体を詳細に観察した。また, 眼底カメラ(RC-2, 興和株式会社)を用いて眼底を検査した。なお, 中間透光体および眼底の検査時には散瞳剤(Mydrin<sup>®</sup>-P, ロット番号 MP0659, 参天製薬株式会社)を使用した。眼底に異常が認められなかつたため写真撮影は実施しなかつた。

## 6) 尿検査

投与 4 週(投与前)および回復 2 週に各 1 回, 全例について強制採尿法により新鮮尿を採取し, 肉眼的に尿の色を確認するとともに, 尿試験紙(マルティスティックス®, バイエル・三共株式会社)および自動尿分析器(Clinitek 200+, Miles Labs., Inc.)を用いて次の項目を測定した.

pH, 蛋白, 糖, ケトン体, ビリルビン, 潜血, ウロビリノーゲン(いずれも試験紙法)

新鮮尿の採取後, 各群の雌雄とも動物番号の小さい方から各 5 例について代謝ケージにより 4 時間の蓄尿を採取し, 尿量をメスシリンダーで, 比重を尿比重屈折計(ユリコーン-JE, 株式会社アタゴ)を用いてそれぞれ測定した. また, 遠心分離(1500 r.p.m., 5 分間, 多本架遠心機, KUBOTA KS-3000P, 株式会社久保田製作所)して得た沈渣を, Sternheimer - Malbin 染色して赤血球, 白血球, 結晶, 上皮細胞, 細菌, 尿円柱, 精子およびその他を鏡検した.

## 7) 血液学的検査

各剖検時に, 全例についてペントバルビタールナトリウム(東京化成工業株式会社)水溶液(6.48 mg/mL, 5 mL/kg)の腹腔内投与による麻酔下で, 後大静脈腹部から注射器を用いて 1 mL 採血し, EDTA-2K で抗凝固処理した. その後別途 3.8w/v%クエン酸ナトリウム溶液を入れた注射器で 1 mL 採血し, 遠心分離(3000 r.p.m., 15 分間, ユニバーサル冷却遠心機 5910, 5920, KUBOTA 5800, 株式会社久保田製作所)して血漿を得た.

EDTA-2K で抗凝固処理した血液については, 多項目自動血球計数装置(E-4000, シスメックス株式会社)を用いて次の項目を測定あるいは算出した.

赤血球数, 白血球数, 血小板数(いずれも電気抵抗検出方式)

ヘマトクリット値(パルス検出方式)

ヘモグロビン濃度(ラウリル硫酸ナトリウムヘモグロビン法)

MCV, MCH, MCHC(いずれも計算式により算出)

また, 血液細胞自動分析装置(MICROX HEG-120A, 株式会社オムロン)を用いて次の項目を測定した.

網状赤血球数(Brecher 法)

白血球百分率(Wright 染色法)

3.8 w/v%クエン酸ナトリウム溶液で抗凝固処理後遠心分離して得た血漿については、全自动血液凝固測定装置(CA-5000、システムズ株式会社)を用いて次の項目を測定した。

プロトロンビン時間、活性化部分トロンボプラスチン時間(いずれも光散乱法)

#### 8) 血液生化学的検査

各剖検時に、全例について血液学的検査用に採血後、腹大動脈から注射器を用いて可能な限り採血し、室温で40~60分間静置した後、遠心分離(3000 r.p.m., 15分間、多本架遠心機、KUBOTA KS-3000P、株式会社久保田製作所)して得た血清について、自動分析装置(Clinalyzer RX-10、日本電子株式会社)を用いて次の項目を測定した。

ASAT, ALAT(いずれもJSCC準拠処方、UV法)

ALP(p-ニトロフェニルリン酸基質法)

LDH(UV Rate法)

コリンエステラーゼ(DTNB法)

γ-GTP(包接L-γ-グルタミル-p-ニトロアニリド基質法)

総ビリルビン(アルカリアゾビリルビン法)

総蛋白(ビウレット法)

アルブミン(BCG法)

A/G比(計算式により算出)

総コレステロール(COD-HDAOS法)

トリグリセライド(GPO-HDAOS法)

糖(G1cK・G-6-PDH法)

尿素窒素(ウレアーゼ-GIDH法)

クレアチニン(Jaffé法)

無機リン(モリブデン酸直接法)

Ca(OCPC法)

Na, K(いずれも電極法)

Cl(電量滴定法)

### 9) 剖検

全例について、最終投与あるいは回復期間終了の翌日(絶食 16~18 時間後)に体重測定し、ペントバルビタールナトリウム(東京化成工業株式会社)水溶液(6.48 mg/mL, 5 mL/kg)の腹腔内投与による麻酔下で検査用の血液を採取後、放血致死させ、器官および組織を観察した。なお、被験物質投与に起因したと考えられる変化がみられなかつたため写真撮影は実施しなかつた。

### 10) 器官重量(絶対および相対重量)

全例について、脳(小脳および脳幹を含む)、心臓、肝臓、腎臓(左右)、副腎(左右)、脾臓、胸腺、精巣(左右)、精巣上体(左右)および卵巣(左右)を電子天秤(ER-60A、株式会社エー・アンド・ディ)を用いて測定するとともに、絶対重量および剖検日の体重から相対重量を算出した。

### 11) 病理組織学的検査

全例について、大脳、小脳、脳幹、下垂体、ハーダー腺\*、頸下リンパ節\*\*、甲状腺\*、上皮小体(可能な限り)\*、気管、肺(気管支を含む)\*、胸腺、心臓、骨髓および骨(大腿骨、胸骨:脱灰標本)、脊髓(胸部)、胃(前胃、腺胃)、小腸(十二指腸、空腸、回腸)、大腸(盲腸、結腸、直腸)、腸間膜リンパ節、肝臓、膀胱、脾臓、副腎\*、腎臓\*、精巣上体\*、精囊、前立腺、卵巢\*、子宮、腟および坐骨神経\*\*を 10% 中性緩衝ホルマリンで、眼球(視神経を含む)\*をホルムアルデヒド・グルタルアルデヒド混合液で、精巣\*をブアン液でそれぞれ固定し、真空パック後保存した。\*及び\*\*を付した器官および組織は左右両側を採取した。

対照群および高用量群の全例の上記器官および組織について、株式会社新日本科学安全性研究所で常法に従い切り出しされた組織を、株式会社新日本科学安全性研究所薬物代謝分析センターの毒性病理部和歌山グループに送付し、パラフィン包埋、薄切を行い、H.E.染色、封入および鏡検を行った。なお、上記器官および組織のうち、\*を付した器官および組織は左右両側を、\*\*を付した器官および組織は左側を検査した。被験物質に起因したと考えられる変化がみられなかつたため、写真撮影は実施しなかつた。

## 6. 統計学的手法

各群の摂餌量、体重、尿検査の定量データ、血液学的検査、血液生化学的検査、器官重量(絶対および相対重量)のデータについては、まず、Bartlett 法により等分散性の検定を行い、等分散の場合は、一元配置法により分散分析を行った。その結果、群間に有意性が認められた場合、Dunnett 法により対照群に対する被験物質各群の平均値の一対比較検定を行った。Bartlett 法により等分散性が認められない場合は順位変換を行い、Kruskal-Wallis の H 検定を行った。その結果、有意性が認められた場合、Dunnett 型の平均順位の一対比較検定を行った。定量データ以外の尿検査、眼科的検査、剖検および病理組織学的検査については、評価段階付きのデータは Exact rank sum test、評価段階なしのデータは Fisher 検定を対照群と被験物質各群の間で実施した。これらの検定および計算には COMPUTER (AlphaServer 1000, DEC) を用い、有意水準は 5%とした。なお、一般状態および行動薬理学的側面からの行動観察のデータについては検定は実施しなかった。

## 7. 試験成績の信頼性に影響を及ぼしたと思われる環境要因および試験計画書に従わなかったこと

試験計画書では、行動薬理学的側面からの行動観察は検疫馴化期間中にも 1 回行うと記載されていたが、投与 0 日目の投与前および投与後 2~4 時間、投与 27 日目の投与後 2~4 時間および回復 2 週に各 1 回行い、検疫馴化期間中には行わなかった。検疫馴化期間中の検査は投与開始前の状態を確認することが目的であり、また、2000 年 11 月 22 日付試験計画書変更確認書(No.1)に従い、投与 0 日目の投与前に実施していることから試験成績への影響はないものと判断した。

なお、試験成績の信頼性に影響を及ぼしたと思われる環境要因および上述以外の試験計画書に従わなかったことはなかった。

## 結 果

**1. 一般状態(Tables 1-1～1-4, Appendices 1-1, 1-2)**

投与および回復期間中、いずれの群においても死亡はみられず、一般状態観察においても全例で異常はみられなかった。

**2. 行動薬理学的側面からの行動観察(Tables 2-1～2-16, Appendices 2-1～2-16)**

投与 0 日の投与前および投与後 2～4 時間、投与 27 日の投与後 2～4 時間、ならびに回復 2 週の観察では、いずれの群においても全例で異常はみられなかった。

**3. 摂餌量(Fig. 1, Tables 3-1, 3-2, Appendices 3-1, 3-2)**

1000 mg/kg 群では、回復 2 週に雌で摂餌量の低値がみられたが、個別値は対照群の個別値の範囲内であった。投与期間中は雌雄とともに異常はみられなかった。

200 mg/kg 群では、投与 2 週に雄で摂餌量の低値がみられた。

20 mg/kg 群では、雌雄ともに異常はみられなかった。

**4. 体重(Fig. 2, Tables 4-1～4-4, Appendices 4-1～4-4)**

投与および回復期間中、いずれの群においても異常はみられなかった。

**5. 眼科的検査(Tables 5-1～5-4, Appendices 5-1～5-4)**

投与 4 週および回復 2 週の検査では、いずれの群においても全例で異常はみられなかつた。

**6. 尿検査(Tables 6-1～6-16, Appendices 6-1～6-12)**

1000 および 200 mg/kg 群では、投与 4 週および回復 2 週の検査において雌雄とともに異常はみられなかった。

20 mg/kg 群では、投与 4 週の検査において雌で蛋白の高値がみられたが、個別値は背景値<sup>1)</sup>の範囲内であった。

## 7. 血液学的検査(Tables 7-1～7-4, Appendices 7-1～7-8)

1000 mg/kg 群では、回復期間終了時の検査において雄でプロトロンビン時間の延長がみられたが、個別値は 1 例を除き、背景値<sup>1)</sup>の範囲内であった。投与期間終了時の検査においては雌雄ともに異常はみられなかつた。

200 および 20 mg/kg 群では、投与期間終了時の検査において雌雄ともに異常はみられなかつた。

## 8. 血液生化学的検査(Tables 8-1～8-4, Appendices 8-1～8-8)

1000 mg/kg 群では、回復期間終了時の検査において雄で Na の高値がみられたが、個別値は背景値<sup>1)</sup>の範囲内であった。投与期間終了時の検査においては雌雄ともに異常はみられなかつた。

200 mg/kg 群では、投与期間終了時の検査において雌雄ともに異常はみられなかつた。

20 mg/kg 群では、投与期間終了時の検査において雌で糖の低値がみられたが、個別値は背景値<sup>1)</sup>の範囲内であった。

## 9. 剖検(Tables 9-1～9-4, Appendices 9-1～9-4)

1000 mg/kg 群では、投与期間終了時の剖検において肺の赤色巣あるいは黒色巣が雄 2 例、肝臓の白色巣が雌 2 例、回復期間終了時の剖検において肺の黒色巣が雌 1 例、肝臓の白色巣が雄 1 例および雌 2 例、副腎の左右不対称が雄 1 例でみられた。

200 mg/kg 群では、投与期間終了時の剖検において肺の赤色巣が雄 1 例、肝臓の白色巣が雌雄各 1 例、腎臓の囊胞が雌 1 例でみられた。

20 mg/kg 群では、投与期間終了時の剖検において肺の赤色巣が雄 1 例、肝臓の白色巣が雄 1 例、腎臓の囊胞が雄 1 例でみられた。

対照群では、投与期間終了時の剖検において肺の赤色巣あるいは黒色巣が雄 2 例および雌 1 例、肝臓の白色巣が雌 2 例、回復期間終了時の剖検において肺の黒色巣が雄 1 例、肝臓の白色巣が雄 2 例および雌 1 例でみられた。

## 10. 器官重量(Tables 10-1～10-8, Appendices 10-1～10-12)

1000 mg/kg 群では、回復期間終了時の測定において雌で副腎の絶対および相対重量の高値、脾臓および腎臓の絶対重量の低値がみられたが、これらの個別値はいずれも背景値<sup>1)</sup>の範囲内であった。投与期間終了時の測定においては雌雄ともに異常はみられなかった。

200 mg/kg 群では、投与期間終了時の測定において雄で胸腺の相対重量の低値がみられたが、個別値は背景値<sup>1)</sup>の範囲内であった。

20 mg/kg 群では、投与期間終了時の測定において雌雄ともに異常はみられなかった。

## 11. 病理組織学的検査(Tables 11-1～11-9, Appendices 11-1～11-9)

1000 mg/kg 群では、投与期間終了時の検査において脾臓の髄外造血が雄 4 例および雌 1 例、頸下リンパ節の形質細胞過形成が雌雄各 1 例、肺の肺胞泡沫細胞集簇が雄 2 例、肝臓の門脈領域の肝細胞微細空胞が雌 1 例、単核細胞浸潤が雄 5 例および雌 4 例、腎臓の尿細管鉱質沈着が雌 3 例、尿細管好酸性小体が雄 4 例、尿細管の塩基性変化が雄 2 例および雌 3 例、拡張尿細管の尿円柱が雄 1 例、卵巣の単核細胞浸潤が雌 1 例、子宮の内腔拡張が雌 1 例、副腎の皮質囊胞が雄 1 例、副腎の皮質細胞の限局性過形成が雄 2 例および雌 1 例、甲状腺の鰓囊遺残が雄 2 例、大腿骨の骨膜への褐色色素が雄 2 例、回復期間終了時の検査において脾臓の髄外造血が雄 2 例、肺の骨化生が雌 1 例、肺胞泡沫細胞集簇が雌 2 例、限局性出血が雄 1 例、肺動脈鉱質沈着が雌雄各 1 例、肝臓の単核細胞浸潤が雄 3 例および雌 4 例、限局性壞死が雄 1 例、腎臓の尿細管好酸性小体が雄 5 例、尿細管の塩基性変化が雄 2 例、副腎の皮質細胞の限局性過形成が雌 1 例、前立腺の単核細胞浸潤が雄 1 例、甲状腺の異所性胸腺が雄 1 例、鰓囊遺残が雄 1 例および雌 3 例、大腿骨の骨膜への褐色色素が雄 5 例および雌 4 例、骨膜の出血が雄 2 例でみられた。

対照群では、投与期間終了時の検査において心臓の限局性心筋変性が雌雄各 1 例、脾臓の髄外造血が雄 2 例、頸下リンパ節の形質細胞過形成が雄 1 例、肺の肺胞泡沫細胞集簇が雄 1 例、気管の粘膜単核細胞浸潤が雄 1 例、肝臓の門脈領域の肝細胞微細空胞が雌 3 例、単核細胞浸潤が雄 3 例、腎臓の尿細管鉱質沈着が雌雄各 2 例、尿細管の塩基性変化が雌 3 例、単核細胞浸潤が雄 2 例、精巣の萎縮が雄 1 例、精巣上体の片側性精子不在が雄 1 例、副腎の皮質細胞の限局性過形成が雌雄各 2 例、甲状腺の鰓囊遺残が雄 2 例および雌 3 例、

大腿骨の骨膜への褐色色素が雄 1 例、回復期間終了時の検査において心臓の単核細胞浸潤が雌 1 例、脾臓の髓外造血が雄 1 例および雌 3 例、肺の骨化生が雄 1 例、肺胞泡沫細胞集簇が雄 2 例、肺動脈鉱質沈着が雄 1 例、肝臓の門脈領域の肝細胞微細空胞が雄 1 例、単核細胞浸潤が雄 4 例および雌 5 例、限局性壊死が雌 1 例、腎臓の尿細管好酸性小体が雄 3 例、尿細管の塩基性変化が雄 1 例、尿細管鉱質沈着が雌 1 例、副腎の皮質細胞の限局性過形成が雌 1 例、甲状腺の異所性胸腺が雌 1 例、鰓囊遺残が雄 3 例、大腿骨の骨膜への褐色色素が雄 4 例および雌 5 例、骨膜の出血が雄 2 例でみられた。

## 考 察

ポリオキシエチレン p-ノニルフェニルエーテルの 0(対照), 20, 200 および 1000 mg/kg を各群雌雄各 5 例の Crj:CD (SD) IGS ラットに 1 日 1 回 28 日間反復経口投与し, さらに, 0(対照) および 1000 mg/kg 群にそれぞれ雌雄各 5 例の 2 週間回復試験例を設けて, その毒性と回復性を調べるとともに NOEL (no-observed-effect level) を求めた. 対照群には媒体の注射用水を被験物質群と同様の方法で投与した.

投与および回復期間中, いずれの群においても死亡はみられず, 一般状態観察および行動薬理学的側面からの行動観察においても全例で異常はみられなかった.

摂餌量では, 投与 2 週に 200 mg/kg 群の雄で摂餌量の低値がみられたが, 一過性の用量に依存しない変化であることから, 被験物質投与に起因した変化ではないと判断した. また, 回復 2 週に 1000 mg/kg 群の雌でみられた摂餌量の低値は, 個別値が対照群の個別値の範囲内であり, 投与および回復期間を通して一定の傾向がみられないことから偶発的変化と判断した.

体重および眼科的検査では, いずれの群においても異常はみられなかった.

尿検査では, 投与 4 週の検査において 20 mg/kg 群の雌で蛋白の高値がみられたが, 個別値は背景値<sup>1)</sup>の範囲内であり, 用量に依存しない変化であることから, 被験物質投与に起因した変化ではないと判断した. 回復 2 週の検査においては異常はみられなかった.

血液学的検査では, 投与期間終了時の検査においていずれの群においても異常はみられなかった. 回復期間終了時の検査において 1000 mg/kg 群の雄でみられたプロトロンビン時間の延長は, 個別値が 1 例を除き背景値<sup>1)</sup>の範囲内であり, 投与期間終了時の検査でみられていない変化であることから, 偶発的変化と判断した.

血液生化学的検査では, 投与期間終了時の検査において 20 mg/kg 群の雌で糖の低値がみられたが, 個別値は背景値<sup>1)</sup>の範囲内であり, 用量に依存しない変化であることから, 被験物質投与に起因した変化ではないと判断した. 回復期間終了時の検査において 1000 mg/kg 群の雄でみられた Na の高値は, 個別値が背景値<sup>1)</sup>の範囲内であり, 投与期間終了時の検査でみられていない変化であることから, 偶発的変化と判断した.

剖検では, 投与あるいは回復期間終了時において被験物質群で肺の赤色巢あるいは黒色

巣, 肝臓の白色巣, 脾臓の囊胞, 副腎の左右不対称がみられたが, 当該器官の病理組織学的検査で被験物質投与に起因した変化がみられず, 対照群にもみられる変化, 用量に依存しない変化, あるいは, 投与期間終了時にみられていない 1 例のみの変化であることから, いずれも偶発的変化と判断した。

器官重量では, 投与期間終了時の測定において 200 mg/kg 群の雄で胸腺の相対重量の低値がみられたが, 当該器官の病理組織学的検査で被験物質投与に起因した変化がみられず, 個別値は背景値<sup>1)</sup>の範囲内であり, 相対重量のみの変化であることから, 被験物質投与に起因した変化ではないと判断した。回復期間終了時の測定において 1000 mg/kg 群の雌でみられた副腎の絶対および相対重量の高値, 脾臓および腎臓の絶対重量の低値は, 当該器官の病理組織学的検査で被験物質投与に起因した変化がみられず, 個別値が背景値<sup>1)</sup>の範囲内であり, 投与期間終了時の検査でみられていない変化であること, あるいは, 絶対重量のみの変化であることから, いずれも偶発的変化と判断した。

病理組織学的検査では, 投与あるいは回復期間終了時において 1000 mg/kg 群で脾臓の髓外造血, 頸下リンパ節の形質細胞過形成, 肺の骨化生, 肺胞泡沫細胞集簇, 限局性出血, 肺動脈鉱質沈着, 肝臓の門脈領域の肝細胞微細空胞, 単核細胞浸潤, 限局性壊死, 腎臓の尿細管鉱質沈着, 尿細管好酸性小体, 尿細管の塩基性変化, 拡張尿細管の尿円柱, 前立腺の単核細胞浸潤, 卵巣の単核細胞浸潤, 子宮の内腔拡張, 副腎の皮質囊胞, 皮質細胞の限局性過形成, 甲状腺の異所性胸腺, 鰓囊遺残, 大腿骨の骨膜への褐色色素, 骨膜の出血がみられたが, 対照群あるいは背景データ<sup>1)</sup>にみられる変化, あるいは, 1 例のみの変化であることから, いずれも偶発的変化と判断した。

以上の結果, 本試験条件下では一般に反復投与毒性試験の投与量の上限とされる 1000 mg/kg を投与しても被験物質投与に起因する変化がみられなかったことから, ポリオキシエチレン p-ノルフェニルエーテルの NOEL は雌雄ともに 1000 mg/kg/日を超える量と結論した。

## 文 献

1. SNBL Control Background Data(Crj:CD(SD)IGS), Vol. 47, 株式会社新日本科学社内資料(2000)

## Stability of the Test Article

## (1) Experimental

Test Article (Lot No.) : Polyoxyethylene *p*-nonylphenyl ether [REDACTED]  
Appearance : White solid  
Sampling Size : 20 mg  
Storage Conditions : Airtight container at room temperature under light protected conditions

## (2) Results

Container	Time Point	Assay * (%)
Glass bottle	Initial	99.26
(amber)	End of Study	99.14

\* % of total area (mean of 2 values).

Dates of analysis : October 10, 2000 and February 9, 2001

## Stability of the Test Article in the Dosing Preparation

## (1) Experimental

Test Article (Lot No.) : Polyoxyethylene *p*-nonylphenyl ether [REDACTED]  
 Vehicle : Water for injection  
 Form : Solution  
 Sampling Size : 2.5 mL

## (2) Results

Container	Storage Conditions	Temperature and Duration	Stability*	
			Conc. of Analyte (mg/mL)	
	Initial		0.1	200
Glass bottle (amber)		After 24 hours at room temperature	101.1	97.5
		After 7 days at room temperature	102.4	99.9

Remaining % (mean of 2 values). Acceptable range: 100 ± 5 %

Data of analysis : October 10, 2000 - October 17, 2000

AnalystAnalystSuperv.  
(Respo.)

(Shin Nippon Biomedical Laboratories, Ltd.)

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

## Concentration of the Test Article in the Dosing Preparation

## (1) Experimental

Test Article (Lot No.) : Polyoxyethylene *p*-nonylphenyl ether [REDACTED]  
 Vehicle : Water for injection  
 Form : Solution  
 Sampling Size : 1 mL

## (2) Results

Date of Preparation	Date of Analysis	Target Conc. (mg/mL)	Found Conc. (mg/mL)	Found/Target* (%)
		2	2.008	100.4
November 23, 2000	November 24, 2000	20	19.756	98.8
		100	98.720	98.7

Data are the mean values of 2 injections of 1 determination.

\*Acceptable range : 100 ± 5 %.

Analysis [REDACTED]

Supervisor [REDACTED]

(Responsible) [REDACTED]

## Concentration of the Test Article in the Dosing Preparation

## (1) Experimental

Test Article (Lot No.) : Polyoxyethylene *p*-nonylphenyl ether [REDACTED]  
Vehicle : Water for injection  
Form : Solution  
Sampling Size : 1 mL

## (2) Results

Date of Preparation	Date of Analysis	Target Conc. (mg/mL)	Found Conc. (mg/mL)	Found/Target* (%)
		2	2.006	100.3
December 19, 2000	December 20, 2000	20	20.530	102.7
		100	100.955	101.0

Data are the mean values of 2 injections of 1 determination.

\*Acceptable range : 100 ± 5 %.

(Shin Nippon Biomedical Laboratories,Ltd.)

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

〔様式 1〕

## ば乳類を用いる 28 日間の反復投与毒性試験結果報告書

## 1. 一般的事項

新規化学物質の名称 (IUPAC 命名法による)	ポリオキシエチレンp-ノニルフェニルエーテル		
別 名	—	物理化 的 性 状	分子式 分子量
構造式又は示性式	C <sub>9</sub> H <sub>19</sub> (C <sub>6</sub> H <sub>4</sub> )O(CH <sub>2</sub> CH <sub>2</sub> O) <sub>n</sub> H (n=28.8)		常温における性状 白色固体
試験に供した新規化学物質の純度	100 wt% (ロット番号 ■■■)		安定性 常温, 遮光下で安定
不純物の名称及び濃度	—		融点 29.0°C
			沸点 —
			蒸気圧 —
			分配係数 —
			溶解性 —
			水 可溶
			DMSO —
		溶解度	アセトン —
			その他 イソプロパノール 可溶

## 2. 急性毒性試験

試験 No.	試験の種類 及び期間	動物種	1 群当たりの 動物数	投与経路	投与量 (mg/kg)	LD50 値又は NOEL (mg/kg)	実験場所
1	急性毒性試験 2000 年 10 月 12 日 ～ 2000 年 10 月 26 日	ラット Crj:CD(SD)IGS	雄 5 匹 雌 5 匹	経口	2000 1414 1000 707 500	雄 LD50 2000< 雌 LD50 2000<	株式会社 新日本科学
2	投与量設定試験 (14 日間) 2000 年 10 月 31 日 ～ 2000 年 11 月 14 日	ラット Crj:CD(SD)IGS	雄 3 匹 雌 3 匹	経口	1000 300 100 30 媒体对照群*	血液生化学的検査: トリグリセライド ↓ ♂ 血液生化学的検査: トリグリセライド ↓ ♂ 血液生化学的検査: トリグリセライド ↓ ♂ — — 雄 NOEL 30 雌 NOEL 1000<  【観察項目】 一般状態, 体重, 眼科的検査, 血液学的検査, 血液生化学的検査, 剖検, 器官重量	株式会社 新日本科学

\* 媒体: 注射用水

## 3. 28 日間反復投与毒性試験

被験物質投与期間	自平成 12 年 11 月 25 日				至平成 12 年 12 月 22 日			
使用動物種・系統	ラット, Crj:CD(SD)IGS				1 群当たりの動物数			
投与経路	強制経口投与(媒体:注射用水)				雄: 5 匹 雌: 5 匹 (対照群および高用量群には回復例の雌雄各 5 匹を加えた)			
被験物質の純度 100 wt%	投与量	(mg/kg)	対照群	低用量群	中用量群	高用量群	回復群	
			0 ♂ ♀	20 ♂ ♀	200 ♂ ♀	1000 ♂ ♀	0 ♂ ♀	1000 ♂ ♀
死亡			—	—	—	—	—	—
体重			—	—	—	—	—	—
体重増加量			—	—	—	—	—	—
摂餌量			—	—	▽	—	—	▽
一般症状			—	—	—	—	—	—
行動観察			—	—	—	—	—	—
眼科学的検査			—	—	—	—	—	—
血液形態学的検査			—	—	—	—	—	—
生化学的検査	糖		—	▼	—	—	—	—
	Na		—	—	—	—	△	—
血液凝固系検査	PT		—	—	—	—	—	△
尿検査	蛋白		—	△	—	—	—	—
臓器重量(絶対重量)	副腎(両側)		—	—	—	—	—	△
	脾臓		—	—	—	—	—	▽
	腎臓(左, 両側)		—	—	—	—	—	▽
臓器重量(相対重量)	胸腺		—	—	▽	—	—	—
	副腎(左右)		—	—	—	—	—	△
	副腎(両側)		—	—	—	—	—	▲
剖検所見								
肺	赤色巣あるいは黒色巣	2 —	1 2	1 1	— 1	1 1	2 2	— 2
肝臓	白色巣						1 —	1 —
腎臓	囊胞						—	—
副腎	左右不対称						—	—
組織学的所見								
心臓	限局性心筋変性	1 —	1 —	*	*	*	— —	— —
	単核細胞浸潤			*	*	*	— —	— —
脾臓	髓外造血	2 —	— —	*	*	*	4 —	1 —
頸下リンパ節	形質細胞過形成	1 —	— —	*	*	*	1 —	3 —
肺	肺胞泡沫細胞集簇	1 —	— —	*	*	*	2 —	— —
	限局性出血			*	*	*	— —	— —
	骨化生			*	*	*	— —	1 —
	肺動脈鉱質沈着			*	*	*	— —	1 —
気管	粘膜単核細胞浸潤	1 —	— —	*	*	*	— —	— —
肝臓	単核細胞浸潤	3 —	— —	*	*	*	5 —	4 —
	門脈領域の肝細胞微細空胞			*	*	*	1 —	1 —
	限局性壊死			*	*	*	— —	— —
腎臓	尿細管好酸性小体	— —	— —	*	*	*	— —	— —
	尿細管鉱質沈着	2 —	2 —	*	*	*	4 —	3 —
	尿細管の塩基性変化	— —	3 —	*	*	*	2 —	1 —
	拡張尿細管の尿円柱	— —	— —	*	*	*	1 —	— —
	単核細胞浸潤	2 —	— —	*	*	*	— —	— —
精巣	萎縮	1 —	* —	*	*	*	— —	* —
精巣上体	片側性精子不在	1 —	* —	*	*	*	— —	* —
前立腺	単核細胞浸潤	— —	* —	*	*	*	— —	* —
卵巢	単核細胞浸潤	*	— —	*	*	*	* —	* —
子宫	内腔拡張	*	— —	*	*	*	* —	* —
副腎	皮質囊胞	— —	— —	*	*	*	1 —	— —
甲状腺	皮質細胞の限局性過形成	2 —	2 —	*	*	*	2 —	1 —
	鰓囊遺残	2 —	3 —	*	*	*	2 —	3 —
	異所性胸腺	— —	— —	*	*	*	— —	— —
大腿骨	骨膜への褐色色素	1 —	— —	*	*	*	2 —	4 —
	骨膜の出血	— —	— —	*	*	*	— —	5 —
NOEL(mg/kg)	>1000							
NOEL の推定根拠とした変化	反復投与毒性試験の投与量の上限とされる 1000 mg/kg を投与しても被験物質投与に起因する変化がみられなかったことから、ボリオキシエチレン p-ノニルフェニルエーテルの NOEL は雌雄ともに 1000 mg/kg/日 を超える量と推定した。							

\*: 検査せず

—: 異常(変化)なし

△: 対照群に比べ有意に増加(p &lt; 0.05) ▲: 対照群に比べ有意に増加(p &lt; 0.01)

▽: 対照群に比べ有意に減少(p &lt; 0.05) ▼: 対照群に比べ有意に減少(p &lt; 0.01)

4. その他

反復投与 毒性試験 実施機関	名 称	株式会社 新日本科学
	所 在 地	〒 891-1394 鹿児島県鹿児島郡吉田町宮之浦 2438 番地
試験責任者	職 氏 名	[REDACTED]
試験実施年月日	平成 12 年 11 月 14 日	[REDACTED]

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

## REPEATED DOSE TOXICITY

### TEST SUBSTANCE

- **Identity:** Polyoxyethylene p-nonylphenylether (CAS No. 9016-45-9)
- **Remarks:** Source: Chemical Substances Safety Management Center National Institute of Technology and Evaluation Ministry of Economy, Trade and Industry. Purity: 100 wt%. Stability during use confirmed by high performance liquid chromatography.

### METHOD

- **Method/guideline:** OECD Guidelines for Testing of Chemicals 407
- **Test type:** Repeated Dose 28-day Oral Toxicity Study in Rodents
- **GLP:** Yes
- **Year:** 2000 to 2001
- **Species:** Rat
- **Strain:** Crj: CD (SD) IGS
- **Route of administration:** Oral (by gavage)
- **Doses/ concentration levels:** 0, 20, 200, 1000 mg/kg/day (in water for injection)
- **Sex:** Male & Female
- **Exposure period:** November 25, 2000 to December 22, 2000
- **Frequency of treatment:** Once daily, seven times weekly, for 28 consecutive days
- **Control group and treatment:** Concurrent vehicle
- **Post exposure observation period:** 14 Days
- **Statistical methods:** Food consumption, body weight, quantitative data from

urinalysis, hematology, blood chemistry and organ weight (absolute and relative) data were first analyzed for homogeneity of variance by Bartlett's test. When homogeneity of variance existed, a one way analysis of variance was applied. When significance was achieved, Dunnett's test was applied to compare the means between the treatment and control groups. When no homogeneity of variance existed by Bartlett's test, the order of the data was converted and analyzed by the Kruskal-Wallis H test. When the result was significant, a non-parametric Dunnett's test was applied to compare the mean ranks.

For non-quantitative data from urinalysis, ophthalmology, gross pathology and histopathology, gradeable data was analyzed by the Exact rank sum test, and non-gradeable values was analyzed by Fisher's exact test between the treatment and control groups.

The level of significance was set at 5%.

## REMARKS FIELD FOR TEST CONDITIONS

### • Test Subjects:

**Age at study initiation:** Five weeks

**Weight at study initiation:** Male; 132 to 169 g, female; 121 to 138 g

**No. of animals per sex per dose:**

Group	Number of Animals	
	Male	Female
Control	5+5 *	5+5 *
20 mg/kg/day	5	5
200 mg/kg/day	5	5
<u>1000 mg/kg/day</u>	<u>5+5 *</u>	<u>5+5 *</u>

\*: Recovery animal

### • Study Design:

**Vehicle:** Water for injection

**Satellite groups and reasons they were added:**

1 control group and 1 test article group

In order to evaluate the reversibility of the toxicity followed by a 14-day recovery period.

**Clinical observations performed and frequency:**

The first day of dosing was designated as Day 0 of the dosing period. The day following the end of the dosing period was designated as Day 0 of the recovery period. The first week of dosing or recovery periods were designated as Week 1 of the dosing and recovery periods, respectively.

Clinical signs; All animals were observed for mortality and clinical signs 3 times daily, once daily during the recovery period and once on the days of autopsy.

General behavioral observations; General behavior, neurologic and autonomic profile were observed according to the Irwin method once on Days 0 and 27 of the dosing period, and once Week 2 of the recovery period in five males and five females in each group.

Food consumption; Food consumption was weighed once prior to the initiation of dosing and once weekly during the dosing and recovery periods in all animals.

Body weight; All animals were weighed once prior to the initiation of dosing, once weekly during the dosing and recovery periods. Body weight gain was calculated at each measurement.

Ophthalmology; Gross observation and fundus examination were observed once prior to the initiation of dosing, once at Week 4 of the dosing period and Week 2 of the recovery period in all animals.

Urinalysis; All animals were examined at Week 4 of the dosing period and Week 2 the recovery period.

Hematology and biochemistry; All animals were examined at each gross pathology.

**Organs examines at necropsy:**

Organ Weight; Brain, heart, liver, kidneys, adrenals,

spleen, thymus, testes, epididymis and ovaries in all animals

Microscopic; Cerebrum, cerebellum, brain stem, pituitary, eye balls, harderian glands, submandibular lymph node, thyroids, parathyroids, trachea, lungs, thymus, heart, bone and bone marrow, spinal cord, stomach, small intestine, large intestine, mesenteric lymph node, liver, urinary bladder, spleen, adrenals, kidneys, testes, epididymides, seminal vesicles, prostate, ovaries, uterus, vagina and sciatic nerve in all animals in the control and 500 mg/kg groups

## RESULTS

- NOAEL (NOEL):  
Male; >1000 mg/kg/day  
Female; >1000 mg/kg/day
- LOAEL (LOEL):  
Male; >1000 mg/kg/day  
Female; >1000 mg/kg/day

## REMARKS FIELD FOR RESULTS

- Clinical signs (description, severity, time of onset and duration):  
No animals died in any group during the dosing or recovery period. No abnormalities were observed in any animal during the dosing or recovery period.
- General behavioral observations:  
No abnormalities were observed in any animal during the dosing or recovery period.
- Food consumption:  
Low food consumption was noted in males in the 200 mg/kg group at Week 2 of the dosing period and in females in the 1000 mg/kg group at Week 2 of the recovery period. However, they were judged not to be test article related changes.
- Body weight:  
No abnormalities were noted in any group during the dosing or recovery period.
- Ophthalmology:  
No abnormalities were observed in any animal during the dosing or recovery period.

• **Urinalysis:**

High protein in females in the 20 mg/kg group was noted at Week 4 of the dosing period. However, it was judged not to be test article related changes. No abnormalities were noted at Week 2 of the recovery period.

• **Hematology:**

No abnormalities were noted at the end of the dosing period. The prolongation of APTT in males in the 1000 mg/kg group was noted at the end of the recovery period. However, it was judged to be incidental.

• **Biochemistry:**

Low glucose was noted in females in the 20 mg/kg group at the end of the dosing period. High Na was noted in males in the 1000 mg/kg at the end of the recovery period. However, they were judged not to be test article related changes.

• **Mortality and time to death:**

None

• **Gross pathology incidence and severity:**

The following changes were observed in the test article groups at the end of dosing or recovery period: red or black focus in the lung, white foci in the liver, cysts in the kidneys and asymmetry in the size of the adrenals. However, they were judged to be incidental.

• **Organ weight changes:**

Low relative thymic weight was noted in males in the 200 mg/kg group at the end of the dosing period. High absolute and relative weights of the adrenal and low absolute weight of the spleen and kidney were noted in females in the 1000 mg/kg group at the end of the recovery period. However, they were judged not to be test article related changes.

• **Histopathology (incidence and severity):**

The following changes were observed in the 1000 mg/kg group at the end of the dosing or recovery period: extramedullary hematopoiesis, hyperplasia in the plasma cells of the submandibular lymph nodes, osseous metaplasia in the lung, foamy cell aggregation in the alveoli of the lungs, focal hemorrhage of the lung, mineralization in the pulmonary artery, microvacuolization in hepatocytes of the periportal liver, mononuclear cell infiltration in the liver, focal necrosis in the liver, mineralization of the renal tubules, eosinophilic bodies in the renal tubules, basophilic change in the renal tubules, hyaline casts in the dilated tubules of the kidney, mononuclear cell infiltration in the prostate, mononuclear cell infiltration in the ovary, dilatation in the lumen of the uterus, cysts in the cortex of the adrenal, focal hypertrophy in the cortical cells of the adrenal, ectopic thymus in the thyroid, ultimobranchial bodies in the

thyroid, brown pigment and hemorrhage in the periosteum of the femur. However, they were judged to be incidental.

## **CONCLUTIONS**

During the dosing and recovery period, no animals died in any group. No abnormalities were observed in clinical signs or in general behavioral observations.

No test article related changes were noted in food consumption, body weight, ophthalmology, urinalysis, hematology, blood biochemistry, gross pathology, organ weight or histopathology.

It was concluded from these results that under the conditions of this study, the no-observed-effect level (NOEL) of polyoxyethylene p-nonylphenyl ether was greater than 1000 mg/kg/day in both males and females.

## **DATA QUALITY**

- **Reliabilities:** Valid without restriction

### **Remarks field for Data Reliability**

Well conducted study, carried out by Shin Nippon Biomedical Laboratories, Ltd.  
(Kagoshima, Japan)

## **REFERENCES (Free Text)**

1. SNBL Control Background Data - Crj: CD (SD) IGS, Vol. 47, Shin Nippon Biomedical Laboratories, Ltd. In-house data, 2000

## **GENERAL REMAERKS**

None.

ポリオキシエチレン p-ノニルフェニルエーテルのラットにおける28日間反復経口投与毒性試験および14日間回復性試験

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。




Fig. 1 Changes of food consumption in rats

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

Study No. : SBL79-02




Fig. 2 Changes of body weight in rats

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

**Clinical Sign**

**Grade**

- 0 : No abnormal signs
- 1 : Slight
- 2 : Moderate
- 3 : Severe
- + : Non-graded clinical signs

Table 1-1 Clinical signs in male rats

Study No. : SBL79-02

Group	Dose(mg/kg/day)	Grade	Control		Polyoxyethylene p-nonylphenyl ether												
					20			200			1000						
			0	1	2	3	+	0	1	2	3	+	0	1	2	3	+
<b>Day</b>		<b>Item</b>															
0	No abnormal signs		10		5			5		5		10					
1	No abnormal signs		10		5			5		5		10					
2	No abnormal signs		10		5			5		5		10					
3	No abnormal signs		10		5			5		5		10					
4	No abnormal signs		10		5			5		5		10					
5	No abnormal signs		10		5			5		5		10					
6	No abnormal signs		10		5			5		5		10					
7	No abnormal signs		10		5			5		5		10					
8	No abnormal signs		10		5			5		5		10					
9	No abnormal signs		10		5			5		5		10					
10	No abnormal signs		10		5			5		5		10					
11	No abnormal signs		10		5			5		5		10					
12	No abnormal signs		10		5			5		5		10					
13	No abnormal signs		10		5			5		5		10					
14	No abnormal signs		10		5			5		5		10					
15	No abnormal signs		10		5			5		5		10					
16	No abnormal signs		10		5			5		5		10					
17	No abnormal signs		10		5			5		5		10					
18	No abnormal signs		10		5			5		5		10					
19	No abnormal signs		10		5			5		5		10					
20	No abnormal signs		10		5			5		5		10					
21	No abnormal signs		10		5			5		5		10					
22	No abnormal signs		10		5			5		5		10					
23	No abnormal signs		10		5			5		5		10					

Numerals represent the number of animals.

Table 1-2 Clinical signs in male rats

Study No. : SBL79-02

Group Dose(mg/kg/day)	Grade	Control		Polyoxyethylene p-nonylphenyl ether								
				20			200			1000		
		0	1	2	3	+	0	1	2	3	+	
Day	Item											
24	No abnormal signs	10		5			5		10			
25	No abnormal signs	10		5			5		10			
26	No abnormal signs	10		5			5		10			
27	No abnormal signs	10		5			5		10			
28	No abnormal signs	5		5			5		5			
R:0	No abnormal signs	5							5			
R:1	No abnormal signs	5							5			
R:2	No abnormal signs	5							5			
R:3	No abnormal signs	5							5			
R:4	No abnormal signs	5							5			
R:5	No abnormal signs	5							5			
R:6	No abnormal signs	5							5			
R:7	No abnormal signs	5							5			
R:8	No abnormal signs	5							5			
R:9	No abnormal signs	5							5			
R:10	No abnormal signs	5							5			
R:11	No abnormal signs	5							5			
R:12	No abnormal signs	5							5			
R:13	No abnormal signs	5							5			
R:14	No abnormal signs	5							5			

Numerals represent the number of animals.

Table 1-3 Clinical signs in female rats

Study No. : SBL79-02

Group Dose(mg/kg/day)	Grade	Control					Polyoxyethylene p-nonylphenyl ether									
							20			200			1000			
		0	1	2	3	+	0	1	2	3	+	0	1	2	3	+
Day	Item															
0	No abnormal signs	10					5				5				10	
1	No abnormal signs	10					5				5				10	
2	No abnormal signs	10					5				5				10	
3	No abnormal signs	10					5				5				10	
4	No abnormal signs	10					5				5				10	
5	No abnormal signs	10					5				5				10	
6	No abnormal signs	10					5				5				10	
7	No abnormal signs	10					5				5				10	
8	No abnormal signs	10					5				5				10	
9	No abnormal signs	10					5				5				10	
10	No abnormal signs	10					5				5				10	
11	No abnormal signs	10					5				5				10	
12	No abnormal signs	10					5				5				10	
13	No abnormal signs	10					5				5				10	
14	No abnormal signs	10					5				5				10	
15	No abnormal signs	10					5				5				10	
16	No abnormal signs	10					5				5				10	
17	No abnormal signs	10					5				5				10	
18	No abnormal signs	10					5				5				10	
19	No abnormal signs	10					5				5				10	
20	No abnormal signs	10					5				5				10	
21	No abnormal signs	10					5				5				10	
22	No abnormal signs	10					5				5				10	
23	No abnormal signs	10					5				5				10	

Numerals represent the number of animals.

Table 1-4 Clinical signs in female rats

Study No. : SBL79-02

Group Dose(mg/kg/day)	Grade	Control		Polyoxyethylene p-nonylphenyl ether					
				20			200		
		0	1	2	3	+	0	1	2
Day Item									
24	No abnormal signs	10	5	5	5	10			
25	No abnormal signs	10	5	5	5	10			
26	No abnormal signs	10	5	5	5	10			
27	No abnormal signs	10	5	5	5	10			
28	No abnormal signs	5	5	5	5	5			
R:0	No abnormal signs	5				5			
R:1	No abnormal signs	5				5			
R:2	No abnormal signs	5				5			
R:3	No abnormal signs	5				5			
R:4	No abnormal signs	5				5			
R:5	No abnormal signs	5				5			
R:6	No abnormal signs	5				5			
R:7	No abnormal signs	5				5			
R:8	No abnormal signs	5				5			
R:9	No abnormal signs	5				5			
R:10	No abnormal signs	5				5			
R:11	No abnormal signs	5				5			
R:12	No abnormal signs	5				5			
R:13	No abnormal signs	5				5			
R:14	No abnormal signs	5				5			

Numerals represent the number of animals.

Table 2-1 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (Prior to administration on Day 0)

Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Awareness</b>						
Alertness	N		5	5	5	5
Visual Placing	N		5	5	5	5
Stereotypy	N		5	5	5	5
Passivity	N		5	5	5	5
<b>Mood</b>						
Grooming	N		5	5	5	5
Vocalization	N		5	5	5	5
Restlessness	N		5	5	5	5
Irritability	N		5	5	5	5
Fearfulness	N		5	5	5	5
<b>Motor Activity</b>						
Reactivity	N		5	5	5	5
Spontaneous Activity	N		5	5	5	5
Touch Response	N		5	5	5	5
Pain Response	N		5	5	5	5
<b>CNS Excitation</b>						
Startle Response	N		5	5	5	5
Straub Tail	N		5	5	5	5
Tremors	N		5	5	5	5
Twitches	N		5	5	5	5
Convulsions	N		5	5	5	5
<b>Posture</b>						
Body Posture	N		5	5	5	5
Limb Posture	N		5	5	5	5
<b>Motor Incoordination</b>						
Staggering Gait	N		5	5	5	5
Abnormal Gait	N		5	5	5	5
Righting Reflex	N		5	5	5	5

Notes) N : Normal sign

Numerals represent the number of animals.

Table 2-2 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (Prior to administration on Day 0)

Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Muscle Tone</b>						
Limb Tone	N		5	5	5	5
Grip Strength	N		5	5	5	5
Body Tone	N		5	5	5	5
Abdominal Tone	N		5	5	5	5
<b>Reflex</b>						
Pinna Reflex	N		5	5	5	5
Corneal Reflex	N		5	5	5	5
IFR	N		5	5	5	5
<b>Autonomic Profile</b>						
Writhing	N		5	5	5	5
Palpebral Opening	N		5	5	5	5
Exophthalmos	N		5	5	5	5
Urination	N		5	5	5	5
Salivation	N		5	5	5	5
Piloerection	N		5	5	5	5
Hypothermia	N		5	5	5	5
Skin Color	N		5	5	5	5
Heart Rate	N		5	5	5	5
Respiratory Rate	N		5	5	5	5
Pupil Size	N		5	5	5	5
Rearing*	0		5	5	5	5

Notes) N : Normal sign

\* : Numerals represent the count of rearing

Numerals represent the number of animals.

Table 2-3 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (2 - 4 hours after administration on Day 0)

Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Awareness</b>						
Alertness	N		5	5	5	5
Visual Placing	N		5	5	5	5
Stereotypy	N		5	5	5	5
Passivity	N		5	5	5	5
<b>Mood</b>						
Grooming	N		5	5	5	5
Vocalization	N		5	5	5	5
Restlessness	N		5	5	5	5
Irritability	N		5	5	5	5
Fearfulness	N		5	5	5	5
<b>Motor Activity</b>						
Reactivity	N		5	5	5	5
Spontaneous Activity	N		5	5	5	5
Touch Response	N		5	5	5	5
Pain Response	N		5	5	5	5
<b>CNS Excitation</b>						
Startle Response	N		5	5	5	5
Straub Tail	N		5	5	5	5
Tremors	N		5	5	5	5
Twitches	N		5	5	5	5
Convulsions	N		5	5	5	5
<b>Posture</b>						
Body Posture	N		5	5	5	5
Limb Posture	N		5	5	5	5
<b>Motor Incoordination</b>						
Staggering Gait	N		5	5	5	5
Abnormal Gait	N		5	5	5	5
Righting Reflex	N		5	5	5	5

Notes) N : Normal sign

Numerals represent the number of animals.

Table 2-4 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (2 - 4 hours after administration on Day 0)

Study No. : SBL79-02

General behavior	Group		Control	Poloxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Muscle Tone</b>						
Limb Tone	N		5	5	5	5
Grip Strength	N		5	5	5	5
Body Tone	N		5	5	5	5
Abdominal Tone	N		5	5	5	5
<b>Reflex</b>						
Pinna Reflex	N		5	5	5	5
Corneal Reflex	N		5	5	5	5
IFR	N		5	5	5	5
<b>Autonomic Profile</b>						
Writhing	N		5	5	5	5
Palpebral Opening	N		5	5	5	5
Exophthalmos	N		5	5	5	5
Urination	N		5	5	5	5
Salivation	N		5	5	5	5
Piloerection	N		5	5	5	5
Hypothermia	N		5	5	5	5
Skin Color	N		5	5	5	5
Heart Rate	N		5	5	5	5
Respiratory Rate	N		5	5	5	5
Pupil Size	N		5	5	5	5
<b>Rearing*</b>						
	0		4	5	5	5
	1		1	0	0	0

Notes) N : Normal sign

\* : Numerals represent the count of rearing

Numerals represent the number of animals.

Table 2-5 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (2 - 4 hours after administration on Day 27)

Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Awareness</b>						
Alertness	N		5	5	5	5
Visual Placing	N		5	5	5	5
Stereotypy	N		5	5	5	5
Passivity	N		5	5	5	5
<b>Mood</b>						
Grooming	N		5	5	5	5
Vocalization	N		5	5	5	5
Restlessness	N		5	5	5	5
Irritability	N		5	5	5	5
Fearfulness	N		5	5	5	5
<b>Motor Activity</b>						
Reactivity	N		5	5	5	5
Spontaneous Activity	N		5	5	5	5
Touch Response	N		5	5	5	5
Pain Response	N		5	5	5	5
<b>CNS Excitation</b>						
Startle Response	N		5	5	5	5
Straub Tail	N		5	5	5	5
Tremors	N		5	5	5	5
Twitches	N		5	5	5	5
Convulsions	N		5	5	5	5
<b>Posture</b>						
Body Posture	N		5	5	5	5
Limb Posture	N		5	5	5	5
<b>Motor Incoordination</b>						
Staggering Gait	N		5	5	5	5
Abnormal Gait	N		5	5	5	5
Righting Reflex	N		5	5	5	5

Notes) N : Normal sign

Numerals represent the number of animals.

Table 2-6 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (2 - 4 hours after administration on Day 27)

Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Muscle Tone</b>						
Limb Tone	N		5	5	5	5
Grip Strength	N		5	5	5	5
Body Tone	N		5	5	5	5
Abdominal Tone	N		5	5	5	5
<b>Reflex</b>						
Pinna Reflex	N		5	5	5	5
Corneal Reflex	N		5	5	5	5
IFR	N		5	5	5	5
<b>Autonomic Profile</b>						
Writhing	N		5	5	5	5
Palpebral Opening	N		5	5	5	5
Exophthalmos	N		5	5	5	5
Urination	N		5	5	5	5
Salivation	N		5	5	5	5
Filocretion	N		5	5	5	5
Hypothermia	N		5	5	5	5
Skin Color	N		5	5	5	5
Heart Rate	N		5	5	5	5
Respiratory Rate	N		5	5	5	5
Pupil Size	N		5	5	5	5
Rearing*	O		5	5	5	5

Notes) N : Normal sign

\* : Numerals represent the count of rearing

Numerals represent the number of animals.

Table 2-7 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (Week 2 of recovery period)

Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Awareness</b>						
Alertness	N		5			5
Visual Placing	N		5			5
Stereotypy	N		5			5
Passivity	N		5			5
<b>Mood</b>						
Grooming	N		5			5
Vocalization	N		5			5
Restlessness	N		5			5
Irritability	N		5			5
Fearfulness	N		5			5
<b>Motor Activity</b>						
Reactivity	N		5			5
Spontaneous Activity	N		5			5
Touch Response	N		5			5
Pain Response	N		5			5
<b>CNS Excitation</b>						
Startle Response	N		5			5
Straub Tail	N		5			5
Tremors	N		5			5
Twitches	N		5			5
Convulsions	N		5			5
<b>Posture</b>						
Body Posture	N		5			5
Limb Posture	N		5			5
<b>Motor Incoordination</b>						
Staggering Gait	N		5			5
Abnormal Gait	N		5			5
Righting Reflex	N		5			5

Notes) N : Normal sign

Numerals represent the number of animals.

Table 2-8 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (Week 2 of recovery period)

Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Muscle Tone</b>						
Limb Tone	N		5		5	
Grip Strength	N		5		5	
Body Tone	N		5		5	
Abdominal Tone	N		5		5	
<b>Reflex</b>						
Pinna Reflex	N		5		5	
Corneal Reflex	N		5		5	
IFR	N		5		5	
<b>Autonomic Profile</b>						
Writhing	N		5		5	
Palpebral Opening	N		5		5	
Exophthalmos	N		5		5	
Urination	N		5		5	
Salivation	N		5		5	
Piloerection	N		5		5	
Hypothermia	N		5		5	
Skin Color	N		5		5	
Heart Rate	N		5		5	
Respiratory Rate	N		5		5	
Pupil Size	N		5		5	
Rearing*	O		5		5	

Notes) N : Normal sign

\* : Numerals represent the count of rearing

Numerals represent the number of animals.

Table 2-9 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (Prior to administration on Day 0)

Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Awareness</b>						
Alertness	N		5	5	5	5
Visual Placing	N		5	5	5	5
Stereotypy	N		5	5	5	5
Passivity	N		5	5	5	5
<b>Mood</b>						
Grooming	N		5	5	5	5
Vocalization	N		5	5	5	5
Restlessness	N		5	5	5	5
Irritability	N		5	5	5	5
Fearfulness	N		5	5	5	5
<b>Motor Activity</b>						
Reactivity	N		5	5	5	5
Spontaneous Activity	N		5	5	5	5
Touch Response	N		5	5	5	5
Pain Response	N		5	5	5	5
<b>CNS Excitation</b>						
Startle Response	N		5	5	5	5
Straub Tail	N		5	5	5	5
Tremors	N		5	5	5	5
Twitches	N		5	5	5	5
Convulsions	N		5	5	5	5
<b>Posture</b>						
Body Posture	N		5	5	5	5
Limb Posture	N		5	5	5	5
<b>Motor Incoordination</b>						
Staggering Gait	N		5	5	5	5
Abnormal Gait	N		5	5	5	5
Righting Reflex	N		5	5	5	5

Notes) N : Normal sign

Numerals represent the number of animals.

Table 2-10 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (Prior to administration on Day 0)

Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Muscle Tone</b>						
Limb Tone	N		5	5	5	5
Grip Strength	N		5	5	5	5
Body Tone	N		5	5	5	5
Abdominal Tone	N		5	5	5	5
<b>Reflex</b>						
Pinna Reflex	N		5	5	5	5
Corneal Reflex	N		5	5	5	5
IFR	N		5	5	5	5
<b>Autonomic Profile</b>						
Writhing	N		5	5	5	5
Palpebral Opening	N		5	5	5	5
Exophthalmos	N		5	5	5	5
Urination	N		5	5	5	5
Salivation	N		5	5	5	5
Piloerection	N		5	5	5	5
Hypothermia	N		5	5	5	5
Skin Color	N		5	5	5	5
Heart Rate	N		5	5	5	5
Respiratory Rate	N		5	5	5	5
Pupil Size	N		5	5	5	5
<b>Rearing*</b>						
	0		4	5	4	5
	1		1	0	1	0

Notes) N : Normal sign

\* : Numerals represent the count of rearing

Numerals represent the number of animals.

Table 2-11 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (2 - 4 hours after administration on Day 0)

Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Awareness</b>						
Alertness	N		5	5	5	5
Visual Placing	N		5	5	5	5
Stereotypy	N		5	5	5	5
Passivity	N		5	5	5	5
<b>Mood</b>						
Grooming	N		5	5	5	5
Vocalization	N		5	5	5	5
Restlessness	N		5	5	5	5
Irritability	N		5	5	5	5
Fearfulness	N		5	5	5	5
<b>Motor Activity</b>						
Reactivity	N		5	5	5	5
Spontaneous Activity	N		5	5	5	5
Touch Response	N		5	5	5	5
Pain Response	N		5	5	5	5
<b>CNS Excitation</b>						
Startle Response	N		5	5	5	5
Straub Tail	N		5	5	5	5
Tremors	N		5	5	5	5
Twitches	N		5	5	5	5
Convulsions	N		5	5	5	5
<b>Posture</b>						
Body Posture	N		5	5	5	5
Limb Posture	N		5	5	5	5
<b>Motor Incoordination</b>						
Staggering Gait	N		5	5	5	5
Abnormal Gait	N		5	5	5	5
Righting Reflex	N		5	5	5	5

Notes) N : Normal sign

Numerals represent the number of animals.

Table 2-12 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (2 - 4 hours after administration on Day 0)

Study No. : SBL79-02

General behavior	Group		Control	Poloxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Muscle Tone</b>						
Limb Tone	N		5	5	5	5
Grip Strength	N		5	5	5	5
Body Tone	N		5	5	5	5
Abdominal Tone	N		5	5	5	5
<b>Reflex</b>						
Pinna Reflex	N		5	5	5	5
Corneal Reflex	N		5	5	5	5
IFR	N		5	5	5	5
<b>Autonomic Profile</b>						
Writhing	N		5	5	5	5
Palpebral Opening	N		5	5	5	5
Exophthalmos	N		5	5	5	5
Urination	N		5	5	5	5
Salivation	N		5	5	5	5
Piloerection	N		5	5	5	5
Hypothermia	N		5	5	5	5
Skin Color	N		5	5	5	5
Heart Rate	N		5	5	5	5
Respiratory Rate	N		5	5	5	5
Pupil Size	N		5	5	5	5
<b>Rearing*</b>						
	0		5	5	5	4
	1		0	0	0	1

Notes) N : Normal sign

\* : Numerals represent the count of rearing

Numerals represent the number of animals.

Table 2-13 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (2 - 4 hours after administration on Day 27)

Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Awareness</b>						
Alertness	N		5	5	5	5
Visual Placing	N		5	5	5	5
Stereotypy	N		5	5	5	5
Passivity	N		5	5	5	5
<b>Mood</b>						
Grooming	N		5	5	5	5
Vocalization	N		5	5	5	5
Restlessness	N		5	5	5	5
Irritability	N		5	5	5	5
Fearfulness	N		5	5	5	5
<b>Motor Activity</b>						
Reactivity	N		5	5	5	5
Spontaneous Activity	N		5	5	5	5
Touch Response	N		5	5	5	5
Pain Response	N		5	5	5	5
<b>CNS Excitation</b>						
Startle Response	N		5	5	5	5
Straub Tail	N		5	5	5	5
Tremors	N		5	5	5	5
Twitches	N		5	5	5	5
Convulsions	N		5	5	5	5
<b>Posture</b>						
Body Posture	N		5	5	5	5
Limb Posture	N		5	5	5	5
<b>Motor Incoordination</b>						
Staggering Gait	N		5	5	5	5
Abnormal Gait	N		5	5	5	5
Righting Reflex	N		5	5	5	5

Notes) N : Normal sign

Numerals represent the number of animals.

Table 2-14 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (2 - 4 hours after administration on Day 27) Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Muscle Tone</b>						
Limb Tone	N		5	5	5	5
Grip Strength	N		5	5	5	5
Body Tone	N		5	5	5	5
Abdominal Tone	N		5	5	5	5
<b>Reflex</b>						
Pinna Reflex	N		5	5	5	5
Corneal Reflex	N		5	5	5	5
IPR	N		5	5	5	5
<b>Autonomic Profile</b>						
Writhing	N		5	5	5	5
Palpebral Opening	N		5	5	5	5
Exophthalmos	N		5	5	5	5
Urination	N		5	5	5	5
Salivation	N		5	5	5	5
Piloerection	N		5	5	5	5
Hypothermia	N		5	5	5	5
Skin Color	N		5	5	5	5
Heart Rate	N		5	5	5	5
Respiratory Rate	N		5	5	5	5
Pupil Size	N		5	5	5	5
<b>Rearing*</b>						
	0		3	5	5	3
	1		1	0	0	2
	2		1	0	0	0

Notes) N : Normal sign

\* : Numerals represent the count of rearing

Numerals represent the number of animals.

Table 2-15 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (Week 2 of recovery period)

Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Awareness</b>						
Alertness	N		5			5
Visual Placing	N		5			5
Stereotypy	N		5			5
Passivity	N		5			5
<b>Mood</b>						
Grooming	N		5			5
Vocalization	N		5			5
Restlessness	N		5			5
Irritability	N		5			5
Fearfulness	N		5			5
<b>Motor Activity</b>						
Reactivity	N		5			5
Spontaneous Activity	N		5			5
Touch Response	N		5			5
Pain Response	N		5			5
<b>CNS Excitation</b>						
Startle Response	N		5			5
Straub Tail	N		5			5
Tremors	N		5			5
Twitches	N		5			5
Convulsions	N		5			5
<b>Posture</b>						
Body Posture	N		5			5
Limb Posture	N		5			5
<b>Motor Incoordination</b>						
Staggering Gait	N		5			5
Abnormal Gait	N		5			5
Righting Reflex	N		5			5

Notes) N : Normal sign

Numerals represent the number of animals.

Table 2-16 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (Week 2 of recovery period)

Study No. : SBL79-02

General behavior	Group		Control	Polyoxyethylene p-nonylphenyl ether		
	Grade	Dose (mg/kg/day)		20	200	1000
<b>Muscle Tone</b>						
Limb Tone	N		5			5
Grip Strength	N		5			5
Body Tone	N		5			5
Abdominal Tone	N		5			5
<b>Reflex</b>						
Pinna Reflex	N		5			5
Corneal Reflex	N		5			5
IFR	N		5			5
<b>Autonomic Profile</b>						
Writhing	N		5			5
Palpebral Opening	N		5			5
Exophthalmos	N		5			5
Urination	N		5			5
Salivation	N		5			5
Piloerection	N		5			5
Hypothermia	N		5			5
Skin Color	N		5			5
Heart Rate	N		5			5
Respiratory Rate	N		5			5
Pupil Size	N		5			5
Rearing*	0		5			3
	1		0			2

Notes) N : Normal sign

\* : Numerals represent the count of rearing

Numerals represent the number of animals.

Table 3-1 Food consumption ( g/day ) in male rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Pre	23.4 ± 1.3(10)	23.2 ± 1.9( 5)	23.4 ± 3.2( 5)	23.5 ± 1.9(10)
1w	26.6 ± 2.9(10)	27.2 ± 3.0( 5)	26.2 ± 3.1( 5)	28.4 ± 1.6(10)
2w	30.2 ± 2.5(10)	27.4 ± 2.3( 5)	26.4 ± 3.4( 5)*	29.8 ± 2.8(10)
3w	28.0 ± 3.1(10)	26.6 ± 2.6( 5)	26.6 ± 2.7( 5)	28.1 ± 3.3(10)
4w	30.9 ± 3.0(10)	29.4 ± 3.4( 5)	28.0 ± 2.7( 5)	31.6 ± 4.2(10)
R:1w	29.2 ± 4.3( 5)			30.0 ± 2.1( 5)
R:2w	32.4 ± 3.1( 5)			31.8 ± 4.1( 5)

Values are expressed as the mean ± S.D. (N).

\* P&lt;0.05 : Significantly different from control.

Table 3-2 Food consumption ( g/day ) in female rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Pre	20.4± 1.6(10)	20.0± 1.4( 5)	21.0± 1.6( 5)	21.0± 1.2(10)
1w	21.3± 2.1(10)	21.6± 2.2( 5)	23.2± 2.8( 5)	21.7± 1.9(10)
2w	21.0± 2.8(10)	20.2± 1.9( 5)	21.8± 2.6( 5)	21.1± 2.3(10)
3w	19.4± 3.0(10)	19.4± 2.1( 5)	20.4± 2.6( 5)	19.8± 3.2(10)
4w	23.1± 3.2(10)	26.0± 2.3( 5)	23.2± 3.5( 5)	24.1± 5.0(10)
R:1w	21.6± 3.2( 5)			20.0± 5.7( 5)
R:2w	25.0± 1.7( 5)			21.8± 1.3( 5)*

Values are expressed as the mean ± S.D. (N).

\* P&lt;0.05 : Significantly different from control.

Table 4-1 Body weight ( g ) in male rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Pre	156.5±7.3(10)	155.6±7.3( 5)	151.8±12.9( 5)	156.1±10.1(10)
1w	213.0±14.8(10)	210.6±14.4( 5)	204.0±23.3( 5)	213.7±13.3(10)
2w	270.0±23.6(10)	263.2±17.0( 5)	251.4±29.6( 5)	268.1±17.3(10)
3w	318.5±32.3(10)	308.2±17.6( 5)	294.2±33.7( 5)	316.4±25.4(10)
4w	354.3±37.7(10)	339.2±23.0( 5)	324.4±36.4( 5)	352.0±34.2(10)
R:1w	383.2±34.2( 5)			378.6±31.6( 5)
R:2w	407.4±38.9( 5)			406.0±35.6( 5)

Values are expressed as the mean ± S.D. (N).  
 Not significantly different from control.

Table 4-2 Body weight ( g ) in female rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Pre	130.4± 4.4(10)	130.2± 6.1( 5)	130.2± 6.8( 5)	130.0± 4.8(10)
1w	163.5± 5.9(10)	165.2±10.1( 5)	168.2±10.8( 5)	164.8± 6.2(10)
2w	189.3±10.9(10)	184.8±12.5( 5)	193.0±14.8( 5)	185.9±10.3(10)
3w	212.7±18.8(10)	207.2±13.8( 5)	211.4±22.3( 5)	207.4±14.5(10)
4w	230.5±19.4(10)	231.2±14.2( 5)	229.8±24.4( 5)	224.7±19.1(10)
R:1w	238.0±12.2( 5)			222.4±10.5( 5)
R:2w	251.4±13.2( 5)			233.8±15.1( 5)

Values are expressed as the mean ± S.D. (N).  
 Not significantly different from control.

Table 4-3 Body weight gain ( g ) in male rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
1w	56.5± 8.9(10)	55.0± 7.3( 5)	52.2±10.8( 5)	57.6± 4.7(10)
2w	57.0± 9.6(10)	52.6± 4.2( 5)	47.4± 7.2( 5)	54.4± 5.5(10)
3w	48.5±10.0(10)	45.0± 2.9( 5)	42.8± 7.6( 5)	48.3± 9.5(10)
4w	35.8± 7.3(10)	31.0± 6.2( 5)	30.2± 5.8( 5)	35.6±10.1(10)
R:1w	34.6± 5.6( 5)			35.0± 4.3( 5)
R:2w	24.2± 9.2( 5)			27.4± 5.1( 5)

Values are expressed as the mean ± S.D. (N).  
 Not significantly different from Control.

Table 4-4 Body weight gain ( g ) in female rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
1w	33.1± 5.0(10)	35.0± 5.1( 5)	38.0± 4.7( 5)	34.8± 3.2(10)
2w	25.8± 7.0(10)	19.6± 4.5( 5)	24.8± 11.6( 5)	21.1± 5.2(10)
3w	23.4± 9.1(10)	22.4± 4.6( 5)	18.4± 8.1( 5)	21.5± 5.9(10)
4w	17.8± 6.2(10)	24.0± 4.0( 5)	18.4± 3.7( 5)	17.3± 8.5(10)
R:1w	18.4± 4.8( 5)			13.4± 4.0( 5)
R:2w	13.4± 1.1( 5)			11.4± 8.1( 5)

Values are expressed as the mean ± S.D. (N).  
Not significantly different from control.

Gross ophthalmological examination

Grade

0 : No abnormal changes

1 : Slight

2 : Moderate

3 : Severe

P : Non-graded change

U : Unexamined

Table 5-1 Gross ophthalmological examination in male rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose (mg/kg/day)	Item	Grade		
Week				
Pre	No abnormal changes	10	5	5
4w	No abnormal changes	10	5	10
R:2w	No abnormal changes	5		5

Numerals represent the number of animals.

Table 5-2 Gross ophthalmological examination in female rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	Item	Grade		
Week				
Pre	No abnormal changes	10	5	5
4w	No abnormal changes	10	5	5
R:2w	No abnormal changes	5		5

Numerals represent the number of animals.

**Funduscopic examination**

**Grade**

**0 : No abnormal changes**

**1 : Slight**

**2 : Moderate**

**3 : Severe**

**P : Non-graded change**

**U : Unexamined**

Table 5-3 Funduscopic examination in male rats

Study No. : SBL79-02

Group	Dose(mg/kg/day)	Week	Item	Grade	Control Polyoxyethylene p-nonylphenyl ether		
					20	200	1000
Pre	No abnormal changes			10	5	5	10
4w	No abnormal changes			10	5	5	10
R:2w	No abnormal changes			5		5	

Numerals represent the number of animals.

Table 5-4 Funduscopic examination in female rats

Study No. : SBL79-02

Group	Dose(mg/kg/day)	Week	Item	Grade	Control	Polyoxyethylene p-nonylphenyl ether		
					20	200	1000	
Pre	No abnormal changes			10	5	5	10	
4w	No abnormal changes			10	5	5	10	
R:2w	No abnormal changes			5		5		

Numerals represent the number of animals.

Number of Animals

Study No. : SBL79-02

Item : Urinalysis

Sex : Male

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose (mg/kg/day)				
4w	10	5	5	10
R:2w	5		5	
Urine volume & Specific gravity				
4w	5	5	5	
R:2w	5		5	

Number of Animals

Study No. : SBL79-02

Item : Urinalysis

Sex : Female

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)				
4w	10	5	5	10
R:2w	5		5	
Urine volume & Specific gravity				
4w	5	5	5	5
R:2w	5		5	

Standard Urinalysis

Color 0 : Normal color  
1 : Abnormal color

Protein 0 : -  
1 : +  
2 : ++ 30  
3 : +++ 100  
4 : +++++ 300  
5 : ++++++ 1000

(mg/dl)  
Glucose 0 : -  
1 : + 0.1  
2 : ++ 0.25  
3 : +++ 0.5  
4 : +++++ 1  
5 : ++++++ 2

Ketone body 0 : -  
1 : + 5  
2 : ++ 15  
3 : +++ 40  
4 : +++++ 80  
5 : ++++++ 160

Bilirubin 0 : -  
1 : +  
2 : ++  
3 : +++

Occult blood 0 : -  
1 : +  
2 : ++  
3 : +++  
4 : +++++

Urobilinogen 0 : + 0.1  
1 : ++ 1  
2 : +++ 2  
3 : +++++ 4  
4 : ++++++ 8  
5 : +++++++ 12

Urine volume (U.Volume)

Specific gravity (S.Gravity)

Table 6-1 Urinalysis in male rats

Study No. : SBL79-02

Group	Control		Polyoxyethylene p-nonylphenyl ether		
	Dose(mg/kg/day)	Grade	20	200	1000
Color	4w	0 1	10	5	5 10
	R:2w	0 1		5	
pH	4w	5 5.5 6 6.5 7 7.5 8 8.5 9	1 2 4 1 2 2 2	1 2 2 1 2 2 3	1 2 4 3
	R:2w	5 5.5 6 6.5 7 7.5 8 8.5 9		2 3	

Numerals represent the number of animals.  
 Not significantly different from control.

Table 6-2 Urinalysis in male rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	Grade			
Protein	4w	0	1	
		1	1	
		2	2	
		3	3	5
		4		
		5		
	R:2w	0	1	
		1		
		2	1	
		3	3	4
		4		1
		5		
Glucose	4w	0	10	5
		1		5
		2		
		3		
		4		
		5		
	R:2w	0	5	5
		1		
		2		
		3		
		4		
		5		

Numerals represent the number of animals.  
Not significantly different from control.

Table 6-3 Urinalysis in male rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether			
		20	200	1000	
Dose(mg/kg/day)	Grade				
Ketone body	4w	0      1 1      7 2      2 3 4 5	1 3 1	1 4 7 3	
	R:2w	0      1 1      5 2 3 4 5		1 2 2	
Bilirubin	4w	0      10 1 2 3	4 1	5 10	
	R:2w	0      5 1 2 3		5	

Numerals represent the number of animals.  
 Not significantly different from control.

Table 6-4 Urinalysis in male rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	Grade			
Occult blood	4w	0      6 1      2 2      2 3 4	5	4      9 1      1
	R:2w	0      4 1 2      1 3 4		5
Urobilinogen	4w	0      10 1 2 3 4 5	5	4      9 1
	R:2w	0      4 1      1 2 3 4 5		5

Numerals represent the number of animals.  
 Not significantly different from control.

Table 6-5 Urinalysis in male rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)				
U.Volume (mL)	4w	2.44±0.97	3.68±1.37	3.14±1.28
	R:2w	2.40±1.15		2.58±0.84
S.Gravity	4w	1.0338±0.0137	1.0268±0.0060	1.0322±0.0149
	R:2w	1.0426±0.0184		1.0360±0.0115

Values are expressed as the mean ± S.D.  
 Not significantly different from Control.

Table 6-6 Urinalysis in female rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	Grade			
Color	4w	0 1	10	5 5 1 3 2 1 1 4 1
	R:2w	0 1		5
pH	4w	5 5.5 6 6.5 7 7.5 8 8.5 9	1 3 2 1 2 3 1 7 1	
	R:2w	5 5.5 6 6.5 7 7.5 8 8.5 9	1 2 1 1 2 1 2	

Numerals represent the number of animals.  
 Not significantly different from control.

Table 6-7 Urinalysis in female rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether			
		20	200	1000	
Dose(mg/kg/day)	Grade				
Protein	4w	0      6	*	3	4
	1	2	1		
	2	2	4	2	5
	3				1
	4				
	5				
	R:2w	0      3			3
	1			2	
	2	2			
	3				
	4				
	5				
Glucose	4w	0      10	5	5	10
	1				
	2				
	3				
	4				
	5				
	R:2w	0      5		5	
	1				
	2				
	3				
	4				
	5				

Numerals represent the number of animals.

\* P&lt;0.05 : Significantly different from control.

Table 6-8 Urinalysis in female rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	Grade			
Ketone body	4w	0      9 1      1 2 3 4 5	4 1	5 4 1
	R:2w	0      4 1      1 2 3 4 5		4 1
Bilirubin	4w	0      10 1 2 3	5 5	10
	R:2w	0      5 1 2 3		5

Numerals represent the number of animals.  
 Not significantly different from control.

Table 6-9 Urinalysis in female rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	Grade			
Occult blood	4w	0      10	4      5	8
		1		1
		2	1	
		3		1
		4		
<hr/>				
	R:2w	0      4		5
		1		
		2	1	
		3		
		4		
<hr/>				
Urobilinogen	4w	0      8	5	7
		1      2		3
		2		
		3		
		4		
		5		
<hr/>				
	R:2w	0      3		5
		1      2		
		2		
		3		
		4		
		5		

Numerals represent the number of animals.  
Not significantly different from control.

Table 6-10 Urinalysis in female rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)				
U.Volume (mL)	4w	2.68±1.45	3.94±1.29	2.94±1.55
	R:2w	2.50±0.79		2.26±0.91
S.Gravity	4w	1.0242±0.0159	1.0160±0.0019	1.0300±0.0193
	R:2w	1.0262±0.0110		1.0214±0.0040

Values are expressed as the mean ± S.D.  
 Not significantly different from Control.

Urinary Sediment

RBC      0 : -  
           1 : 1 ~ 4 /HPF  
           2 : 5 ~10 /HPF  
           3 :10 < /HPF

WBC      0 : -  
           1 : 1 ~ 5 /HPF  
           2 : 6 ~20 /HPF  
           3 :20 < /HPF

Phosphate crystal  
 (Phosphate) 0 : -  
           1 : 1 ~10 /HPF  
           2 :11 ~20 /HPF  
           3 :20 < /HPF

Urate crystal  
 (Urate) 0 : -  
           1 : 1 ~10 /HPF  
           2 :11 ~20 /HPF  
           3 :20 < /HPF

Oxalate crystal  
 (Oxalate) 0 : -  
           1 : 1 ~10 /HPF  
           2 :11 ~20 /HPF  
           3 :20 < /HPF

Other crystal  
 (Other c.) 0 : -  
           1 : 1 ~10 /HPF  
           2 :11 ~20 /HPF  
           3 :20 < /HPF

Epithelial cell  
 (Epith.) 0 : -  
           1 : 1 ~ 5 /HPF  
           2 : 6 ~20 /HPF  
           3 :20 < /HPF

Bacteria 0 : -  
           1 : +

Cast      0 : -  
           1 : Hyaline Cast  
           2 : Waxy Cast  
           3 : Erythrocytic Cast

Sperm      0 : -  
           1 : +

Others      0 : -  
           1 : +

HPF : High power field

Table 6-11 Urinary sediments in male rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether			
		20	200	1000	
Dose (mg/kg/day)	Grade				
RBC					
	4w	0	5	5	5
		1			
		2			
		3			
	R:2w	0	5		5
		1			
		2			
		3			
WBC					
	4w	0	5	5	5
		1			
		2			
		3			
	R:2w	0	5		5
		1			
		2			
		3			
Phosphate					
	4w	0	3	2	1
		1	2		
		2	2	1	1
		3		2	3
	R:2w	0	1		1
		1	4		4
		2			
		3			
Urate					
	4w	0	5	5	5
		1			
		2			
		3			
	R:2w	0	5		5
		1			
		2			
		3			

Numerals represent the number of animals.  
Not significantly different from control.

Table 6-12 Urinary sediments in male rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether			
		20	200	1000	
Dose(mg/kg/day)	Grade				
Oxalate					
	4w	0 1 2 3	5 5 5 5	5 5 5 5	5 5 5 5
	R:2w	0 1 2 3	5		5
Other c.					
	4w	0 1 2 3	5 5 5 5	5 5 5 5	5 5 5 5
	R:2w	0 1 2 3	5		5
Epith.					
	4w	0 1 2 3	5 5 5 5	5 5 5 5	5 5 5 5
	R:2w	0 1 2 3	5		5
Bacteria					
	4w	0 1	5 5	5 5	5 5
	R:2w	0 1	5		5

Numerals represent the number of animals.  
 Not significantly different from control.

Table 6-13 Urinary sediments in male rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether			
		20	200	1000	
Dose (mg/kg/day)	Grade				
Cast					
	4w	0 1 2 3	5	5	5
	R:2w	0 1 2 3	5		5
Sperm					
	4w	0 1	3 2	3 2	5 4 1
	R:2w	0 1	3 2		3 2
Others					
	4w	0 1	5	5	5
	R:2w	0 1	5		5

Numerals represent the number of animals.  
 Not significantly different from control.

Table 6-14 Urinary sediments in female rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether			
		20	200	1000	
Dose(mg/kg/day)	Grade				
RBC					
	4w	0	5	5	5
		1			
		2			
		3			
	R:2w	0	5		5
		1			
		2			
		3			
WBC					
	4w	0	5	5	5
		1			
		2			
		3			
	R:2w	0	5		5
		1			
		2			
		3			
Phosphate					
	4w	0	5	5	2
		1			2
		2			1
		3			
	R:2w	0	3		4
		1	2		1
		2			
		3			
Urate					
	4w	0	5	5	5
		1			
		2			
		3			
	R:2w	0	5		5
		1			
		2			
		3			

Numerals represent the number of animals.  
Not significantly different from control.

Table 6-15 Urinary sediments in female rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether			
		20	200	1000	
Dose(mg/kg/day)	Grade				
Oxalate					
	4w	0	5	5	5
		1			
		2			
		3			
	R:2w	0	5		5
		1			
		2			
		3			
Other c.					
	4w	0	5	5	5
		1			
		2			
		3			
	R:2w	0	5		5
		1			
		2			
		3			
Epith.					
	4w	0	5	5	5
		1			
		2			
		3			
	R:2w	0	5		5
		1			
		2			
		3			
Bacteria					
	4w	0	5	5	5
		1			
	R:2w	0	5		5
		1			

Numerals represent the number of animals.  
Not significantly different from control.

Table 6-16 Urinary sediments in female rats

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether			
		20	200	1000	
Dose(mg/kg/day)	Grade				
Cast					
	4w	0	5	5	5
		1			
		2			
		3			
	R:2w	0	5		5
		1			
		2			
		3			
Sperm					
	4w	0	5	5	5
		1			
	R:2w	0	5		5
		1			
Others					
	4w	0	5	5	5
		1			
	R:2w	0	5		5
		1			

Numerals represent the number of animals.  
Not significantly different from control.

## Hematology

RBC	( $10^4/\text{mm}^3$ )	Number of red blood cells
WBC	( $10^2/\text{mm}^3$ )	Number of white blood cells
Ht	(%)	Hematocrit value
Hb	(g/dL)	Hemoglobin concentration
Plat.	( $10^4/\text{mm}^3$ )	Number of blood platelets
MCV	(fl)	Mean corpuscular volume
MCH	(pg)	Mean corpuscular hemoglobin
MCHC	(%)	Mean corpuscular hemoglobin concentration
Ret.	( $10^{-1}\%$ )	Number of reticulocytes

### Hemogram

N-Stab	( $10^2/\text{mm}^3$ )	Number of stab-form neutrophilic leukocytes
N-Stab	(%)	Stab-form neutrophilic leukocyte ratio
N-Seg.	( $10^2/\text{mm}^3$ )	Number of segmented neutrophilic leukocytes
N-Seg.	(%)	Segmented neutrophilic leukocyte ratio
Eosino.	( $10^2/\text{mm}^3$ )	Number of eosinophilic leukocytes
Eosino.	(%)	Eosinophilic leukocyte ratio
Baso.	( $10^2/\text{mm}^3$ )	Number of basophilic leukocytes
Baso.	(%)	Basophilic leukocyte ratio
Mono.	( $10^2/\text{mm}^3$ )	Number of monocytes
Mono.	(%)	Monocyte ratio
Lymph.	( $10^2/\text{mm}^3$ )	Number of lymphocytes
Lymph.	(%)	Lymphocyte ratio

### Blood coagulation test

PT	(Sec)	Prothrombin time
APTT	(Sec)	Activated partial thromboplastin time

Table 7-1 Hematology in male rats (End of drug administration)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose (mg/kg/day)	N	5	5	5
RBC	( $10^4/\text{mm}^3$ )	776.8 $\pm$ 38.8	773.4 $\pm$ 45.3	800.0 $\pm$ 38.0
WBC	( $10^2/\text{mm}^3$ )	105.8 $\pm$ 45.5	64.0 $\pm$ 23.6	78.6 $\pm$ 23.3
Ht	(%)	44.26 $\pm$ 1.89	43.84 $\pm$ 2.45	44.80 $\pm$ 1.90
Hb	(g/dL)	15.66 $\pm$ 1.07	15.20 $\pm$ 0.64	15.70 $\pm$ 0.64
Plat.	( $10^4/\text{mm}^3$ )	131.62 $\pm$ 8.54	105.64 $\pm$ 20.12	120.30 $\pm$ 7.02
MCV	(fl)	57.0 $\pm$ 3.2	56.8 $\pm$ 1.1	56.0 $\pm$ 1.2
MCH	(pg)	20.20 $\pm$ 1.66	19.68 $\pm$ 0.51	19.64 $\pm$ 0.44
MCHC	(%)	35.36 $\pm$ 1.22	34.70 $\pm$ 0.89	35.08 $\pm$ 1.16
Ret.	( $10^{-1}\%$ )	15.2 $\pm$ 3.7	18.8 $\pm$ 2.6	14.6 $\pm$ 3.2
N-Stab	( $10^2/\text{mm}^3$ )	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00
N-Stab	(%)	0.0 $\pm$ 0.0	0.0 $\pm$ 0.0	0.0 $\pm$ 0.0
N-Seg.	( $10^2/\text{mm}^3$ )	5.32 $\pm$ 2.76	2.28 $\pm$ 0.43	8.52 $\pm$ 6.68
N-Seg.	(%)	5.0 $\pm$ 2.2	4.0 $\pm$ 1.6	11.4 $\pm$ 7.0
Eosino.	( $10^2/\text{mm}^3$ )	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.18 $\pm$ 0.40
Eosino.	(%)	0.0 $\pm$ 0.0	0.0 $\pm$ 0.0	0.2 $\pm$ 0.4
Baso.	( $10^2/\text{mm}^3$ )	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00
Baso.	(%)	0.0 $\pm$ 0.0	0.0 $\pm$ 0.0	0.0 $\pm$ 0.0
Mono.	( $10^2/\text{mm}^3$ )	2.30 $\pm$ 2.85	0.82 $\pm$ 0.95	0.56 $\pm$ 0.82
Mono.	(%)	1.8 $\pm$ 1.6	1.4 $\pm$ 1.3	0.8 $\pm$ 1.1
Lymph.	( $10^2/\text{mm}^3$ )	98.22 $\pm$ 41.16	60.92 $\pm$ 23.72	63.56 $\pm$ 12.94
Lymph.	(%)	93.2 $\pm$ 1.8	94.6 $\pm$ 2.2	87.6 $\pm$ 8.4
PT	(Sec)	11.84 $\pm$ 2.25	15.14 $\pm$ 2.02	15.24 $\pm$ 2.97
APTT	(Sec)	22.40 $\pm$ 1.68	23.94 $\pm$ 1.80	22.36 $\pm$ 2.22
				23.64 $\pm$ 1.97

Values are expressed as the mean  $\pm$  S.D.  
Not significantly different from control.

Table 7-2 Hematology in female rats (End of drug administration)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose (mg/kg/day)	N	5	5	5
RBC	( $10^4/\text{mm}^3$ )	747.8 $\pm$ 52.1	768.0 $\pm$ 25.2	778.0 $\pm$ 46.7
WBC	( $10^2/\text{mm}^3$ )	43.8 $\pm$ 7.3	48.0 $\pm$ 6.3	53.4 $\pm$ 12.3
Ht	(%)	42.32 $\pm$ 2.75	43.64 $\pm$ 1.79	44.58 $\pm$ 2.40
Hb	(g/dL)	14.88 $\pm$ 0.81	15.24 $\pm$ 0.67	15.26 $\pm$ 0.61
Plat.	( $10^4/\text{mm}^3$ )	102.96 $\pm$ 21.76	124.82 $\pm$ 11.63	98.84 $\pm$ 20.47
MCV	(fl)	56.8 $\pm$ 1.3	56.8 $\pm$ 1.3	57.2 $\pm$ 4.4
MCH	(pg)	19.94 $\pm$ 0.46	19.86 $\pm$ 0.51	19.64 $\pm$ 0.60
MCHC	(%)	35.18 $\pm$ 0.54	34.94 $\pm$ 0.38	34.28 $\pm$ 1.56
Ret.	( $10^{-1}\%$ )	12.4 $\pm$ 2.3	12.8 $\pm$ 5.3	15.8 $\pm$ 5.9
N-Stab	( $10^2/\text{mm}^3$ )	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00
N-Stab	(%)	0.0 $\pm$ 0.0	0.0 $\pm$ 0.0	0.0 $\pm$ 0.0
N-Seg.	( $10^2/\text{mm}^3$ )	2.12 $\pm$ 1.45	1.76 $\pm$ 0.98	3.02 $\pm$ 0.95
N-Seg.	(%)	4.8 $\pm$ 3.1	3.6 $\pm$ 1.8	6.0 $\pm$ 2.3
Eosino.	( $10^2/\text{mm}^3$ )	0.40 $\pm$ 0.28	0.10 $\pm$ 0.22	0.32 $\pm$ 0.31
Eosino.	(%)	1.0 $\pm$ 0.7	0.2 $\pm$ 0.4	0.6 $\pm$ 0.5
Baso.	( $10^2/\text{mm}^3$ )	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00
Baso.	(%)	0.0 $\pm$ 0.0	0.0 $\pm$ 0.0	0.0 $\pm$ 0.0
Mono.	( $10^2/\text{mm}^3$ )	0.34 $\pm$ 0.33	0.60 $\pm$ 0.28	0.38 $\pm$ 0.65
Mono.	(%)	0.8 $\pm$ 0.8	1.2 $\pm$ 0.4	0.8 $\pm$ 1.3
Lymph.	( $10^2/\text{mm}^3$ )	40.92 $\pm$ 6.97	45.58 $\pm$ 5.64	49.68 $\pm$ 12.95
Lymph.	(%)	93.4 $\pm$ 3.2	95.0 $\pm$ 2.1	92.6 $\pm$ 3.0
PT	(Sec)	7.66 $\pm$ 0.15	7.40 $\pm$ 0.25	7.44 $\pm$ 0.43
APTT	(Sec)	17.38 $\pm$ 0.24	16.90 $\pm$ 1.65	16.36 $\pm$ 1.58
				16.54 $\pm$ 1.39

Values are expressed as the mean  $\pm$  S.D.  
Not significantly different from Control.

Table 7-3 Hematology in male rats (End of recovery test)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20 N	200 0	1000 5
RBC	( $10^4/\text{mm}^3$ )	848.2 $\pm$ 21.4		823.4 $\pm$ 33.2
WBC	( $10^2/\text{mm}^3$ )	85.2 $\pm$ 27.3		93.4 $\pm$ 25.8
Ht	(%)	45.92 $\pm$ 1.66		44.32 $\pm$ 1.41
Hb	(g/dL)	16.24 $\pm$ 0.58		15.72 $\pm$ 0.36
Plat.	( $10^4/\text{mm}^3$ )	117.90 $\pm$ 10.84		126.72 $\pm$ 18.20
MCV	(fl)	54.0 $\pm$ 1.2		53.8 $\pm$ 1.5
MCH	(pg)	19.14 $\pm$ 0.40		19.10 $\pm$ 0.61
MCHC	(%)	35.38 $\pm$ 0.16		35.50 $\pm$ 1.29
Ret.	( $10^{-1}\%$ )	15.6 $\pm$ 5.0		18.4 $\pm$ 4.9
N-Stab	( $10^2/\text{mm}^3$ )	0.00 $\pm$ 0.00		0.00 $\pm$ 0.00
N-Stab	(%)	0.0 $\pm$ 0.0		0.0 $\pm$ 0.0
N-Seg.	( $10^2/\text{mm}^3$ )	2.30 $\pm$ 2.36		5.72 $\pm$ 5.64
N-Seg.	(%)	2.4 $\pm$ 1.5		6.0 $\pm$ 5.1
Eosino.	( $10^2/\text{mm}^3$ )	0.18 $\pm$ 0.40		0.84 $\pm$ 1.17
Eosino.	(%)	0.2 $\pm$ 0.4		0.8 $\pm$ 1.1
Baso.	( $10^2/\text{mm}^3$ )	0.00 $\pm$ 0.00		0.00 $\pm$ 0.00
Baso.	(%)	0.0 $\pm$ 0.0		0.0 $\pm$ 0.0
Mono.	( $10^2/\text{mm}^3$ )	1.22 $\pm$ 1.11		1.14 $\pm$ 1.13
Mono.	(%)	1.8 $\pm$ 1.9		1.4 $\pm$ 1.5
Lymph.	( $10^2/\text{mm}^3$ )	81.52 $\pm$ 26.15		85.72 $\pm$ 24.47
Lymph.	(%)	95.6 $\pm$ 1.7		91.8 $\pm$ 6.3
PT	(sec)	12.66 $\pm$ 2.00		16.00 $\pm$ 2.28*
APTT	(sec)	20.52 $\pm$ 1.40		21.44 $\pm$ 1.37

Values are expressed as the mean  $\pm$  S.D.\*  $p < 0.05$  : Significantly different from control.

Table 7-4 Hematology in female rats (End of recovery test)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose (mg/kg/day)	N			N
RBC	( $10^4/\text{mm}^3$ )	772.2 $\pm$ 20.8		764.0 $\pm$ 40.8
WBC	( $10^2/\text{mm}^3$ )	41.6 $\pm$ 3.3		36.6 $\pm$ 12.3
Ht	(%)	42.86 $\pm$ 1.04		42.10 $\pm$ 2.15
Hb	(g/dL)	15.24 $\pm$ 0.58		15.08 $\pm$ 0.85
Plat.	( $10^4/\text{mm}^3$ )	117.26 $\pm$ 16.83		90.82 $\pm$ 21.91
MCV	(fl)	55.4 $\pm$ 1.1		55.0 $\pm$ 1.9
MCH	(pg)	19.72 $\pm$ 0.48		19.76 $\pm$ 0.59
MCHC	(%)	35.54 $\pm$ 0.75		35.82 $\pm$ 0.47
Ret.	( $10^{-1}\%$ )	11.2 $\pm$ 6.1		17.6 $\pm$ 5.5
N-Stab	( $10^2/\text{mm}^3$ )	0.00 $\pm$ 0.00		0.00 $\pm$ 0.00
N-Stab	(%)	0.0 $\pm$ 0.0		0.0 $\pm$ 0.0
N-Seg.	( $10^2/\text{mm}^3$ )	3.26 $\pm$ 2.74		3.18 $\pm$ 1.31
N-Seg.	(%)	8.2 $\pm$ 7.3		8.8 $\pm$ 2.9
Eosino.	( $10^2/\text{mm}^3$ )	0.24 $\pm$ 0.36		0.20 $\pm$ 0.19
Eosino.	(%)	0.6 $\pm$ 0.9		0.6 $\pm$ 0.5
Baso.	( $10^2/\text{mm}^3$ )	0.00 $\pm$ 0.00		0.00 $\pm$ 0.00
Baso.	(%)	0.0 $\pm$ 0.0		0.0 $\pm$ 0.0
Mono.	( $10^2/\text{mm}^3$ )	0.72 $\pm$ 0.90		0.54 $\pm$ 0.23
Mono.	(%)	1.6 $\pm$ 1.9		1.6 $\pm$ 0.9
Lymph.	( $10^2/\text{mm}^3$ )	37.46 $\pm$ 5.56		32.70 $\pm$ 11.42
Lymph.	(%)	89.6 $\pm$ 6.7		89.0 $\pm$ 2.9
PT	(Sec)	7.80 $\pm$ 0.10		7.70 $\pm$ 0.25
APTT	(Sec)	16.98 $\pm$ 0.93		17.34 $\pm$ 1.13

Values are expressed as the mean  $\pm$  S.D.  
Not significantly different from Control.

Blood Chemistry

ASAT	(IU/L)	Aspartate aminotransferase
ALAT	(IU/L)	Alanine aminotransferase
ALP	(IU/L)	Alkaline phosphatase
LDH	(IU/L)	Lactate dehydrogenase
G-GTP	(IU/L)	Gamma - glutamyl transpeptidase
T.Bil.	(mg/dL)	Total bilirubin
T.Prot.	(g/dL)	Total protein
Albumin	(g/dL)	Albumin
A/G		Albumin / Globulin
T.Chol.	(mg/dL)	Total cholesterol
TGL	(mg/dL)	Triglyceride
Glucose	(mg/dL)	Glucose
BUN	(mg/dL)	Blood urea nitrogen
Creat.	(mg/dL)	Creatinine
ChE	(IU/L)	Cholinesterase
IP	(mg/dL)	Inorganic phosphorus
Ca	(mg/dL)	Calcium
Na	(mEq/L)	Sodium
K	(mEq/L)	Potassium
Cl	(mEq/L)	Chloride

Table 8-1 Blood chemistry in male rats (End of drug administration)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20 N 5	200 5	1000 5
ASAT (IU/L)	81.0±15.3	80.6±7.7	85.0±7.2	87.6±20.2
ALAT (IU/L)	30.0±3.7	31.2±5.1	31.2±2.8	32.0±5.5
ALP (IU/L)	311.2±38.3	329.6±59.9	327.4±50.9	296.8±43.0
LDH (IU/L)	882.8±493.8	747.0±209.2	1375.0±357.7	961.8±431.1
G-GTP (IU/L)	0.72±0.38	0.36±0.21	0.46±0.11	0.58±0.31
T.Bil. (mg/dL)	0.102±0.015	0.098±0.016	0.084±0.005	0.094±0.011
T.Prot. (g/dL)	5.84±0.25	5.68±0.22	5.76±0.29	5.74±0.26
Albumin (g/dL)	4.22±0.13	4.14±0.09	4.28±0.19	4.12±0.13
A/G	2.570±0.232	2.706±0.258	2.904±0.340	2.568±0.246
T.Chol. (mg/dL)	53.6±4.7	46.0±6.4	56.0±4.1	44.2±10.9
TGL (mg/dL)	33.4±13.5	24.6±7.1	33.8±12.1	23.0±6.1
Glucose (mg/dL)	150.6±10.2	149.0±17.1	135.6±6.7	138.2±25.4
BUN (mg/dL)	19.48±1.55	17.50±2.08	19.28±1.41	18.70±3.97
Creat. (mg/dL)	0.514±0.094	0.474±0.056	0.448±0.027	0.456±0.039
ChE (IU/L)	476.2±126.0	351.2±65.8	414.4±86.1	406.6±28.8
IP (mg/dL)	8.944±0.447	9.420±0.392	9.590±0.647	9.618±0.220
Ca (mg/dL)	10.40±0.28	10.26±0.32	10.14±0.58	10.58±0.30
Na (mEq/L)	142.8±2.2	144.8±0.8	145.0±1.2	144.2±1.5
K (mEq/L)	3.90±0.33	3.86±0.21	4.10±0.24	4.02±0.31
Cl (mEq/L)	101.4±1.5	103.8±1.8	104.0±1.4	103.4±2.3

Values are expressed as the mean ± S.D.  
 Not significantly different from Control.

Table 8-2 Blood chemistry in female rats (End of drug administration)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	N	5	5	5
ASAT (IU/L)	96.6±24.7	105.6±14.1	100.6±9.3	81.2±13.1
ALAT (IU/L)	20.8±4.6	22.0±5.0	25.2±3.8	19.6±1.1
ALP (IU/L)	215.0±50.1	220.4±31.0	241.4±62.5	189.2±35.4
LDH (IU/L)	2009.4±808.2	2425.8±647.3	1625.4±524.0	1355.4±685.8
G-GTP (IU/L)	0.86±0.13	0.90±0.50	1.06±0.47	0.72±0.36
T.Bil. (mg/dL)	0.100±0.010	0.102±0.013	0.082±0.018	0.086±0.023
T.Prot. (g/dL)	5.74±0.19	5.96±0.42	5.84±0.57	6.00±0.30
Albumin (g/dL)	4.28±0.13	4.38±0.27	4.30±0.34	4.50±0.19
A/G	3.010±0.209	2.854±0.202	2.914±0.419	3.058±0.375
T.Chol. (mg/dL)	55.4±10.3	60.2±7.5	62.0±11.8	70.8±10.0
TGL (mg/dL)	13.2±4.5	10.6±4.2	12.2±1.8	15.2±1.9
Glucose (mg/dL)	148.0±11.8	124.8±4.4**	147.6±6.9	137.8±9.7
BUN (mg/dL)	22.94±2.35	20.96±1.68	22.46±3.08	25.08±4.69
Creat. (mg/dL)	0.526±0.051	0.476±0.034	0.548±0.050	0.546±0.097
ChE (IU/L)	1517.8±289.5	1781.4±466.8	1406.8±466.0	1533.4±338.0
IP (mg/dL)	7.858±0.491	8.490±0.793	7.796±0.584	8.912±0.813
Ca (mg/dL)	9.92±0.31	10.22±0.31	10.32±0.36	10.46±0.23
Na (mEq/L)	144.0±0.7	145.4±1.1	144.6±1.1	145.0±2.5
K (mEq/L)	3.82±0.19	3.74±0.25	3.80±0.20	3.84±0.17
Cl (mEq/L)	105.4±0.9	106.6±1.1	106.8±1.3	107.8±1.9

Values are expressed as the mean ± S.D.

\*\* P&lt;0.01 : Significantly different from control.

Table 8-3 Blood chemistry in male rats (End of recovery test)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	N	5	0	5
ASAT (IU/L)	86.4±24.0			78.2±9.9
ALAT (IU/L)	33.6±4.1			30.6±6.9
ALP (IU/L)	243.0±48.5			278.0±60.7
LDH (IU/L)	1502.6±1353.2			915.2±379.9
G-GTP (IU/L)	0.36±0.15			0.46±0.40
T.Bil. (mg/dL)	0.154±0.021			0.160±0.012
T.Prot. (g/dL)	5.70±0.12			5.72±0.36
Albumin (g/dL)	4.14±0.11			4.00±0.20
A/G	2.632±0.264			2.330±0.146
T.Chol. (mg/dL)	47.2±8.6			50.6±14.4
TGL (mg/dL)	38.4±13.1			26.2±8.1
Glucose (mg/dL)	168.0±15.2			162.2±9.7
BUN (mg/dL)	17.38±2.41			19.42±4.33
Creat. (mg/dL)	0.508±0.034			0.558±0.074
ChE (IU/L)	367.8±43.8			382.0±106.7
IP (mg/dL)	7.522±0.542			8.064±0.536
Ca (mg/dL)	9.82±0.26			9.98±0.29
Na (mEq/L)	141.2±1.1			143.2±0.8*
K (mEq/L)	3.86±0.09			3.82±0.22
Cl (mEq/L)	102.0±1.0			101.2±0.4

Values are expressed as the mean ± S.D.

\* P&lt;0.05 : Significantly different from control.

Table 8-4 Blood chemistry in female rats (End of recovery test)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	N	5	0	5
ASAT (IU/L)	80.6±18.1		96.0±15.3	
ALAT (IU/L)	25.0±2.7		30.2±10.2	
ALP (IU/L)	173.4±49.2		201.8±35.1	
LDH (IU/L)	1560.2±858.4		1335.6±764.2	
G-GTP (IU/L)	0.92±0.50		0.82±0.46	
T.Bil. (mg/dL)	0.174±0.019		0.178±0.019	
T.Prot. (g/dL)	5.96±0.42		6.24±0.32	
Albumin (g/dL)	4.32±0.26		4.36±0.13	
A/G	2.632±0.268		2.324±0.233	
T.Chol. (mg/dL)	57.4±12.2		63.2±10.7	
TGL (mg/dL)	11.0±9.1		7.2±3.3	
Glucose (mg/dL)	137.2±22.8		130.4±15.3	
BUN (mg/dL)	17.38±2.39		18.98±1.55	
Creat. (mg/dL)	0.534±0.053		0.590±0.058	
ChE (IU/L)	1551.8±567.7		1600.8±266.9	
IP (mg/dL)	5.896±1.277		6.244±0.553	
Ca (mg/dL)	9.90±0.20		9.80±0.19	
Na (mEq/L)	142.4±1.5		143.0±1.4	
K (mEq/L)	3.80±0.25		3.52±0.34	
Cl (mEq/L)	105.0±1.9		105.6±1.3	

Values are expressed as the mean ± S.D.  
Not significantly different from control.

**Gross Autopsy Findings**

**Grade**

0 : No abnormal changes

1 : Slight

2 : Moderate

3 : Marked

P : Non-graded changes

Table 9-1 Gross autopsy findings in male rats (End of drug administration)

Study No. : SBL79-02

Findings	Group Dose(mg/kg/day) Grade	Control					Polyoxyethylene p-nonylphenyl ether									
							20		200			1000				
		0	1	2	3	P	0	1	2	3	P	0	1	2	3	P
Lung																
Black focus, single		4			1	5		0	5		0	5		0		
Black focus, several		5			0	5		0	5		0	4		1		
Red focus, several		4			1	5		0	5		0	5		0		
Red focus, single		5			0	4		1	4		1	4		1		
Liver																
White focus, single		5			0	4		1	4		1	5		0		
Kidney																
Cyst, single, right		5			0	4		1	5		0	5		0		

Numerals represent the number of animals.  
Not significantly different from control.

Table 9-2 Gross autopsy findings in female rats (End of drug administration)

Study No. : SBL79-02

Findings	Group Dose(mg/kg/day) Grade	Control					Polyoxyethylene p-nonylphenyl ether									
							20		200			1000				
		0	1	2	3	P	0	1	2	3	P	0	1	2	3	P
Lung Red focus, single		4		1	5		0	5		0	5		0			
Liver White focus, single		3		2	5		0	4		1	3		2			
Kidney Cyst, single, right		5		0	5		0	4		1	5		0			

Numerals represent the number of animals.  
Not significantly different from control.

Table 9-3

Gross autopsy findings in male rats (End of recovery test)

Study No. : SBL79-02

Findings	Group Dose(mg/kg/day) Grade	Control					Polyoxyethylene p-nonylphenyl ether									
							20		200			1000				
		0	1	2	3	P	0	1	2	3	P	0	1	2	3	P
Lung																
Black focus, several		4		1								5		0		
Liver																
White focus, single		3		2								4		1		
Adrenal																
Asymmetry, size		5		0								4		1		

Numerals represent the number of animals.  
Not significantly different from control.

Table 9-4

Gross autopsy findings in female rats (End of recovery test)

Study No. : SBL79-02

Findings	Group Dose(mg/kg/day) Grade	Control					Polyoxyethylene p-nonylphenyl ether									
							20		200			1000				
		0	1	2	3	P	0	1	2	3	P	0	1	2	3	P
Lung																
Black focus, several		5		0								4		1		
Liver																
White focus, single		4		1								3		2		

Numerals represent the number of animals.  
Not significantly different from control.

Organ weight

Epididy.	Epididymis
-R	(Right)
-L	(Left)
-R&L	(Right and Left)

Table 10-1 Organ weight in male rats (End of drug administration)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20 N 5	200 5	1000 5
Adrenal-R (mg)	29.32±6.70	25.96±2.52	27.60±1.63	31.98±6.91
Adrenal-L (mg)	29.44±6.08	28.14±3.84	30.46±2.33	32.32±5.51
Adrenal-R&L (mg)	58.76±12.71	54.10±5.89	58.06±3.03	64.30±12.03
Testis-R (mg)	1359.6±244.4	1460.8±108.0	1268.8±376.9	1387.4±174.8
Testis-L (mg)	1435.8±124.0	1443.2±92.7	1273.0±360.2	1406.6±139.6
Testis-R&L (mg)	2795.4±348.9	2904.0±198.5	2541.8±737.0	2794.0±313.9
Thymus (mg)	554.4±108.4	497.2±88.0	396.0±32.9	593.6±170.2
Spleen (mg)	672.2±170.5	652.0±63.5	629.8±116.6	734.0±137.0
Brain (mg)	1959.0±118.4	1941.4±83.1	1951.6±70.9	1908.2±122.0
Heart (mg)	1142.6±197.6	1106.4±20.5	1133.0±104.5	1103.6±92.5
Liver (g)	10.786±2.096	9.642±0.723	9.550±1.404	11.190±1.886
Kidney-R (mg)	1400.4±226.9	1330.2±58.8	1231.2±154.3	1436.8±166.2
Kidney-L (mg)	1351.0±203.7	1315.6±90.6	1217.2±181.5	1443.2±150.8
Kidney-R&L (mg)	2751.4±428.0	2645.8±132.4	2448.4±335.6	2880.0±313.7
Epididy.-R (mg)	339.2±80.6	399.0±15.2	370.8±45.3	371.8±40.6
Epididy.-L (mg)	353.6±54.5	380.8±26.0	370.6±48.2	368.0±42.5
Epididy.-R&L(mg)	692.8±133.3	779.8±39.5	741.4±91.9	739.8±80.7

Values are expressed as the mean ± S.D.  
 Not significantly different from Control.

Table 10-2 Organ weight in female rats (End of drug administration)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20 N 5	200 5	1000 5
Adrenal-R (mg)	29.48±4.84	32.80±4.49	34.96±2.59	33.36±4.81
Adrenal-L (mg)	32.34±4.68	35.14±6.67	39.00±2.63	34.94±6.32
Adrenal-R&L (mg)	61.82±9.34	67.94±10.52	73.96±3.25	68.30±10.84
Ovary-R (mg)	45.48±8.45	45.34±11.30	42.76±9.84	39.90±9.16
Ovary-L (mg)	42.96±4.19	43.30±7.20	45.32±7.11	42.82±11.02
Ovary-R&L (mg)	88.44±12.38	88.64±18.11	88.08±12.07	82.72±17.25
Thymus (mg)	522.6±112.9	518.2±44.1	387.0±76.2	522.6±100.6
Spleen (mg)	512.0±81.0	477.4±62.0	457.0±56.6	444.4±27.4
Brain (mg)	1852.0±79.7	1858.8±67.7	1842.8±138.8	1781.2±55.2
Heart (mg)	824.4±92.6	748.0±55.4	837.6±75.8	816.8±44.4
Liver (g)	7.040±0.925	6.632±0.646	6.740±0.874	7.044±0.377
Kidney-R (mg)	939.4±99.2	918.2±103.9	923.2±130.4	882.0±60.7
Kidney-L (mg)	923.4±108.7	904.4±126.4	909.6±152.5	879.4±63.2
Kidney-R&L (mg)	1862.8±197.3	1822.6±229.4	1832.8±282.1	1761.4±120.7

Values are expressed as the mean ± S.D.  
 Not significantly different from control.

Table 10-3 Organ weight in male rats (End of recovery test)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	N	0	0	5
Adrenal-R (mg)	30.26±3.76			26.68±8.31
Adrenal-L (mg)	32.66±4.39			31.86±5.84
Adrenal-R&L (mg)	62.92±8.13			58.54±12.14
Testis-R (mg)	1429.0±93.3			1525.0±162.4
Testis-L (mg)	1436.6±95.1			1529.8±160.8
Testis-R&L (mg)	2865.6±187.1			3054.8±322.5
Thymus (mg)	534.4±93.8			464.0±62.1
Spleen (mg)	708.8±119.6			711.2±109.6
Brain (mg)	1967.4±57.1			2004.2±108.7
Heart (mg)	1325.4±156.7			1304.4±69.7
Liver (g)	12.114±2.147			11.650±1.656
Kidney-R (mg)	1502.6±169.2			1474.6±231.9
Kidney-L (mg)	1484.8±156.1			1521.4±255.3
Kidney-R&L (mg)	2987.4±321.5			2996.0±486.6
Epididy.-R (mg)	529.6±14.9			507.2±66.2
Epididy.-L (mg)	520.0±29.8			511.0±74.7
Epididy.-R&L(mg)	1049.6±43.0			1018.2±138.4

Values are expressed as the mean ± S.D.  
Not significantly different from control.

Table 10-4 Organ weight in female rats (End of recovery test)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	N	5	0	5
Adrenal-R (mg)	28.68±5.07			33.40±2.05
Adrenal-L (mg)	30.26±3.71			35.34±3.40
Adrenal-R&L (mg)	58.94±8.09			68.74±3.71*
Ovary-R (mg)	43.38±12.18			49.18±12.32
Ovary-L (mg)	46.06±8.09			41.00±6.84
Ovary-R&L (mg)	89.44±18.46			90.18±18.87
Thymus (mg)	405.0±72.0			406.8±87.0
Spleen (mg)	540.8±46.1			448.0±75.6*
Brain (mg)	1876.0±69.8			1845.2±25.5
Heart (mg)	821.0±73.2			814.8±30.6
Liver (g)	6.856±0.993			6.366±0.596
Kidney-R (mg)	968.4±60.6			893.4±59.9
Kidney-L (mg)	972.4±71.9			862.2±60.6*
Kidney-R&L (mg)	1940.8±131.0			1755.6±117.8*

Values are expressed as the mean ± S.D.

\* P&lt;0.05 : Significantly different from control.

Table 10-5 Relative organ weight in male rats (End of drug administration)

Study No. : SBL79-02

Group Dose(mg/kg/day) N	Control 5	Polyoxyethylene p-nonylphenyl ether		
		20 5	200 5	1000 5
Body weight (g)	330.4±42.1	312.8±20.7	298.2±35.8	327.0±37.5
Adrenal-R (mg/100gBW)	8.78±1.08	8.32±0.69	9.38±1.39	9.98±2.99
Adrenal-L (mg/100gBW)	8.82±0.87	9.02±1.34	10.34±1.48	10.14±2.98
Adrenal-R&L (mg/100gBW)	17.60±1.89	17.34±1.94	19.72±2.76	20.12±5.89
Testis-R (mg/100gBW)	419.4±98.0	468.4±43.3	437.6±155.3	431.0±86.2
Testis-L (mg/100gBW)	440.0±63.4	462.4±36.2	438.6±150.0	436.4±76.3
Testis-R&L (mg/100gBW)	859.4±158.3	930.8±78.6	876.4±304.8	867.4±162.5
Thymus (mg/100gBW)	167.2±22.8	158.0±17.6	133.4±6.3*	180.0±45.3
Spleen (mg/100gBW)	202.2±30.9	209.4±28.3	210.0±21.0	223.4±19.1
Brain (mg/100gBW)	597.6±48.5	622.0±30.7	660.8±69.3	589.4±69.4
Heart (mg/100gBW)	344.8±26.5	354.6±21.3	382.4±38.5	339.0±22.1
Liver (g/100gBW)	3.242±0.296	3.080±0.072	3.196±0.162	3.406±0.230
Kidney-R (mg/100gBW)	422.6±21.0	426.2±26.2	412.8±12.9	441.2±42.1
Kidney-L (mg/100gBW)	407.8±15.5	421.4±34.2	407.0±22.5	443.4±38.5
Kidney-R&L (mg/100gBW)	830.4±33.9	847.8±55.7	819.8±34.8	884.6±79.3
Epididy.-R (mg/100gBW)	104.4±27.5	127.8±8.8	125.8±19.8	115.8±23.3
Epididy.-L (mg/100gBW)	108.6±20.5	122.0±11.9	126.2±22.7	114.2±20.5
Epididy.-R&L (mg/100gBW)	213.0±48.2	250.2±20.6	251.6±42.4	229.8±43.2

Values are expressed as the mean ± S.D.

\* p&lt;0.05 : Significantly different from control.

Table 10-6 Relative organ weight in female rats (End of drug administration)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	N	5	5	5
Body weight (g)		221.4±19.4	210.4±12.6	210.8±22.8
Adrenal-R (mg/100gBW)		13.26±1.22	15.56±1.60	16.76±2.44
Adrenal-L (mg/100gBW)		14.56±1.21	16.62±2.37	18.58±0.90
Adrenal-R&L (mg/100gBW)		27.84±2.30	32.20±3.59	35.36±3.17
Ovary-R (mg/100gBW)		20.48±2.95	21.52±4.84	20.24±4.35
Ovary-L (mg/100gBW)		19.44±1.38	20.62±3.46	21.62±3.34
Ovary-R&L (mg/100gBW)		39.90±4.02	42.12±7.93	41.88±4.61
Thymus (mg/100gBW)		235.0±39.4	246.4±18.0	182.4±19.1
Spleen (mg/100gBW)		231.2±29.4	227.0±27.5	218.6±34.9
Brain (mg/100gBW)		843.0±96.8	885.2±43.9	881.2±104.3
Heart (mg/100gBW)		372.0±17.9	355.4±8.8	398.4±21.5
Liver (g/100gBW)		3.170±0.161	3.146±0.139	3.192±0.083
Kidney-R (mg/100gBW)		424.4±22.4	435.4±27.1	437.4±31.1
Kidney-L (mg/100gBW)		416.4±20.7	428.4±39.6	430.0±39.8
Kidney-R&L (mg/100gBW)		840.6±29.6	864.2±66.3	867.6±70.1
				803.4±55.6

Values are expressed as the mean ± S.D.  
Not significantly different from control.

Table 10-7 Relative organ weight in male rats (End of recovery test)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	N	5	0	5
Body weight (g)		379.8±38.8		378.2±33.5
Adrenal-R (mg/100gBW)		8.08±1.45		7.16±2.35
Adrenal-L (mg/100gBW)		8.72±1.66		8.44±1.48
Adrenal-R&L (mg/100gBW)		16.72±3.11		15.62±3.45
Testis-R (mg/100gBW)		380.6±58.1		402.8±12.3
Testis-L (mg/100gBW)		382.6±58.8		404.0±14.9
Testis-R&L (mg/100gBW)		763.6±116.7		807.0±26.4
Thymus (mg/100gBW)		140.6±18.9		122.4±9.6
Spleen (mg/100gBW)		185.8±14.9		187.6±19.3
Brain (mg/100gBW)		521.2±39.6		532.4±45.3
Heart (mg/100gBW)		349.8±37.6		346.2±24.3
Liver (g/100gBW)		3.170±0.236		3.070±0.189
Kidney-R (mg/100gBW)		395.4±12.5		388.6±37.3
Kidney-L (mg/100gBW)		391.2±13.1		400.4±43.9
Kidney-R&L (mg/100gBW)		786.4±21.5		788.8±81.3
Epididy.-R (mg/100gBW)		140.8±15.8		134.0±8.2
Epididy.-L (mg/100gBW)		138.2±16.8		134.8±8.9
Epididy.-R&L(mg/100gBW)		278.8±32.8		268.8±15.5

Values are expressed as the mean ± S.D.  
Not significantly different from Control.

Table 10-8 Relative organ weight in female rats (End of recovery test)

Study No. : SBL79-02

Group	Control	Polyoxyethylene p-nonylphenyl ether		
		20	200	1000
Dose(mg/kg/day)	N	5	0	5
Body weight (g)		231.8±13.8		216.2±12.0
Adrenal-R (mg/100gBW)		12.32±1.65		15.48±1.37*
Adrenal-L (mg/100gBW)		13.02±0.96		16.44±2.34*
Adrenal-R&L (mg/100gBW)		25.36±2.10		31.94±3.29**
Ovary-R (mg/100gBW)		18.70±5.15		22.72±5.34
Ovary-L (mg/100gBW)		19.84±3.20		19.00±3.17
Ovary-R&L (mg/100gBW)		38.54±7.49		41.70±8.29
Thymus (mg/100gBW)		174.0±20.5		187.6±36.0
Spleen (mg/100gBW)		233.4±17.4		207.4±33.2
Brain (mg/100gBW)		811.2±54.9		855.8±49.7
Heart (mg/100gBW)		354.0±23.7		377.4±16.5
Liver (g/100gBW)		2.948±0.244		2.938±0.138
Kidney-R (mg/100gBW)		418.0±17.7		413.2±12.3
Kidney-L (mg/100gBW)		419.4±18.5		398.8±20.5
Kidney-R&L (mg/100gBW)		837.6±35.0		812.0±32.1

Values are expressed as the mean ± S.D.

\* P&lt;0.05 , \*\* P&lt;0.01 : Significantly different from control.

**Histopathological Findings**

**Grade**

0 : No abnormal changes  
1 : Very slight  
2 : Slight  
3 : Moderate  
4 : Marked  
P : Non-graded change  
U : Unexamined

Table 11-1 Histopathological findings in male rats (End of drug administration) - [H.E STAINING]

Study No. : SBL79-02

Findings	Group Dose(mg/kg/day) Grade	Control						Polyoxyethylene p-nonylphenyl ether																	
								20			200			1000											
		0	1	2	3	4	P	U	0	1	2	3	4	P	U	0	1	2	3	4	P	U			
Heart																									
Myocardial degeneration, focal		4	1	0	0	0											5	0	0	0	0				
Spleen																		1	4	0	0	0			
Extramedullary hematopoiesis		3	2	0	0	0																			
Thymus		5																5							
Femoral bone marrow		5																5							
Sternal bone marrow		5																5							
Lymph node (Mesenteric)		5																5							
Lymph node (Submandibular)																									
Hyperplasia, plasma cell		4	1	0	0	0												4	1	0	0	0			
Lung																									
Foamy cell aggregation, alveolus		4	1	0	0	0												3	2	0	0	0			
Trachea																		5	0	0	0	0			
Mononuclear cell infiltration, mucosa		4	1	0	0	0																			
Bronchus/Bronchiole		5																5							
Stomach		5																5							
Duodenum		5																5							
Jejunum		5																5							
Ileum		5																5							
Cecum		5																5							
Colon		5																5							
Rectum		5																5							
Liver																			0	5	0	0	0		
Mononuclear cell infiltration		2	3	0	0	0																			
Kidney																			1	3	1	0	0		
Eosinophilic body, renal tubule		2	2	1	0	0																			
Mineralization, renal tubule		3	2	0	0	0												5	0	0	0	0			
Basophilic change, renal tubule		5	0	0	0	0												3	2	0	0	0			

Numerals represent the number of animals.  
Not significantly different from control.

Table 11-2 Histopathological findings in male rats (End of drug administration) - [H.E STAINING]

Study No. : SBL79-02

Findings	Group Dose(mg/kg/day) Grade	Control						Polyoxyethylene p-nonylphenyl ether																							
								20						200						1000											
		0	1	2	3	4	P	0	1	2	3	4	P	U	0	1	2	3	4	P	U	0	1	2	3	4	P	U			
Kidney																															
Hyaline cast, dilated tubule		5	0	0	0	0																				4	1	0	0	0	
Mononuclear cell infiltration		3	2	0	0	0																				5	0	0	0	0	
Urinary bladder		5																									5				
Testis																															
Atrophy, seminiferous tubule, bilateral		4	0	0	1	0																				5	0	0	0	0	
Epididymis																															
Absence, sperm, unilateral		4					1																			5				0	
Seminal vesicle		5																								5					
Prostate		5																								5					
Pituitary		5																								5					
Adrenal																															
Cyst, cortex		5	0	0	0	0																			4	1	0	0	0		
Hypertrophy, cortical cell, focal		3	2	0	0	0																			3	2	0	0	0		
Thyroid																										3				2	
Ultimobranchial body		3					2																			3					
Parathyroid		5																								5					
Cerebrum		5																								5					
Cerebellum		5																								5					
Sciatic nerve		5																								5					
Brain stem		5																								5					
Spinal cord (Thoracic)		5																								5					
Eyeball (Optic n.)		5																								5					
Harderian gland		5																								5					
Femur																															
Brown pigment, periosteum		4	1	0	0	0																			3	2	0	0	0		
Sternum		5																								5					

Numerals represent the number of animals.  
Not significantly different from control.

Table 11-3 Histopathological findings in female rats (End of drug administration) - [H.E STAINING]

Study No. : SBL79-02

Findings	Group Dose(mg/kg/day) Grade	Control						Polyoxyethylene p-nonylphenyl ether																												
								20				200				1000																				
		0	1	2	3	4	P	0	1	2	3	4	P	U	0	1	2	3	4	P	U	0	1	2	3	4	P	U								
Heart																																				
Myocardial degeneration, focal		4	1	0	0	0																				5	0	0	0	0	0					
Spleen																											4	1	0	0	0	0				
Extramedullary hematopoiesis		4	1	0	0	0																														
Thymus		5																									5									
Femoral bone marrow		5																									5									
Sternal bone marrow		5																									5									
Lymph node (Mesenteric)		5																									5									
Lymph node (Submandibular)																											4	1	0	0	0	0				
Hyperplasia, plasma cell		5	0	0	0	0																														
Lung		5																									5									
Trachea		5																									5									
Bronchus/Bronchiole		5																									5									
Stomach		5																									5									
Duodenum		5																									5									
Jejunum		5																									5									
Ileum		5																									5									
Cecum		5																									5									
Colon		5																									5									
Rectum		5																									5									
Liver																																				
Microvacuolization, hepatocyte, periportal		2	3	0	0	0																				4	1	0	0	0	0					
Mononuclear cell infiltration		1	4	0	0	0																				1	4	0	0	0	0					
Kidney																																				
Mineralization, renal tubule		3	2	0	0	0																				2	3	0	0	0	0					
Basophilic change, renal tubule		2	3	0	0	0																				2	3	0	0	0	0					

Numerals represent the number of animals.  
Not significantly different from control.

Table 11-4 Histopathological findings in female rats (End of drug administration) - [H.E STAINING]

Study No. : SBL79-02

Findings	Group Dose(mg/kg/day) Grade	Control						Polyoxyethylene p-nonylphenyl ether														
								20				200				1000						
		0	1	2	3	4	P	U	0	1	2	3	4	P	U	0	1	2	3	4	P	U
Kidney																						
Mononuclear cell infiltration		5	0	0	0	0										3	2	0	0	0		
Urinary bladder		5														5						
Ovary																						
Mononuclear cell infiltration		5	0	0	0	0										4	1	0	0	0		
Uterus																						
Dilatation, lumen		5	0	0	0	0										4	1	0	0	0		
Vagina		5														5						
Pituitary		5														5						
Adrenal																						
Hypertrophy, cortical cell, focal		3	2	0	0	0										4	1	0	0	0		
Thyroid									2		3					5				0		
Ultimobranchial body																5						
Parathyroid		5														5						
Cerebrum		5														5						
Cerebellum		5														5						
Sciatic nerve		5														5						
Brain stem		5														5						
Spinal cord (Thoracic)		5														5						
Eyeball (Optic n.)		5														5						
Harderian gland		5														5						
Femur																						
Brown pigment, periosteum		5	0	0	0	0										4	1	0	0	0		
Sternum		5														5						

Numerals represent the number of animals.  
Not significantly different from control.

Table 11-5 Histopathological findings in male rats (End of recovery test) - [H.E STAINING]

Study No. : SBL79-02

Findings	Group Dose(mg/kg/day) Grade	Control						Polyoxyethylene p-nonylphenyl ether																					
								20						200						1000									
		0	1	2	3	4	P	U	0	1	2	3	4	P	U	0	1	2	3	4	P	U	0	1	2	3	4	P	U
Heart		5																											
Spleen																													
Extramedullary hematopoiesis		4	1	0	0	0																							
Thymus		5																											
Femoral bone marrow		5																											
Sternal bone marrow		5																											
Lymph node (Mesenteric)		5																											
Lymph node (Submandibular)		5																											
Lung																													
Hemorrhage, focal		5	0	0	0	0																							
Osseous metaplasia		4	1	0	0	0																							
Foamy cell aggregation, alveolus		3	2	0	0	0																							
Mineralization, pulmonary artery		4	1	0	0	0																							
Trachea		5																											
Bronchus/Bronchiole		5																											
Stomach		5																											
Duodenum		5																											
Jejunum		5																											
Ileum		5																											
Cecum		5																											
Colon		5																											
Rectum		5																											
Liver																													
Microvacuolization, hepatocyte, periportal		4	1	0	0	0																							
Mononuclear cell infiltration		1	4	0	0	0																							

Numerals represent the number of animals.  
Not significantly different from control.

Table 11-6 Histopathological findings in male rats (End of recovery test) - [H.E STAINING]

Study No. : SBL79-02

Findings	Group Dose(mg/kg/day) Grade	Control						Polyoxyethylene p-nonylphenyl ether																					
								20				200				1000													
		0	1	2	3	4	P	U	0	1	2	3	4	P	U	0	1	2	3	4	P	U							
Liver																													
Necrosis, focal		5	0	0	0	0																							
Kidney																													
Eosinophilic body, renal tubule		2	3	0	0	0																							
Basophilic change, renal tubule		4	1	0	0	0																							
Urinary bladder		5																											
Testis		5																											
Epididymis		5																											
Seminal vesicle		5																											
Prostate																													
Mononuclear cell infiltration		5	0	0	0	0																							
Pituitary		5																											
Adrenal		5																											
Thyroid																													
Ectopic thymus		5				0																							
Ultimobranchial body		2				3																							
Parathyroid		5	0	0	0	0																							
Cerebrum		5																											
Cerebellum		5																											
Sciatic nerve		5																											
Brain stem		5																											
Spinal cord (Thoracic)		5																											
Eyeball (Optic n.)		5																											
Harderian gland		5																											
Femur																													
Brown pigment, periosteum		1	4	0	0	0																							
Hemorrhage, periosteum		3	2	0	0	0																							

Numerals represent the number of animals.  
Not significantly different from control.

Table 11-7 Histopathological findings in male rats (End of recovery test) - [H.E STAINING]

Study No. : SBL79-02

Findings	Group Dose(mg/kg/day) Grade	Control						Polyoxyethylene p-nonylphenyl ether																				
								20				200				1000												
		0	1	2	3	4	P	U	0	1	2	3	4	P	U	0	1	2	3	4	P	U	0	1	2	3	4	P
Sternum		5																										5

Numerals represent the number of animals.  
 Not significantly different from control.

Table 11-8 Histopathological findings in female rats (End of recovery test) - [H.E STAINING]

Study No. : SBL79-02

Findings	Group Dose(mg/kg/day) Grade	Control						Polyoxyethylene p-nonylphenyl ether																											
								20				200				1000																			
		0	1	2	3	4	P	U	0	1	2	3	4	P	U	0	1	2	3	4	P	U	0	1	2	3	4	P	U						
Heart																																			
Mononuclear cell infiltration		4	1	0	0	0																					5	0	0	0	0	0	0		
Spleen																												5	0	0	0	0	0	0	
Extramedullary hematopoiesis		2	3	0	0	0																					5	0	0	0	0	0	0		
Thymus		5																										5							
Femoral bone marrow		5																										5							
Sternal bone marrow		5																										5							
Lymph node (Mesenteric)		5																										5							
Lymph node (Submandibular)		5																										5							
Lung																																			
Osseous metaplasia		5	0	0	0	0	0																				4	1	0	0	0	0	0		
Foamy cell aggregation, alveolus		5	0	0	0	0	0																			3	2	0	0	0	0	0			
Mineralization, pulmonary artery		5	0	0	0	0	0																			4	1	0	0	0	0	0			
Inflammation, perivascular		5	0	0	0	0	0																			4	0	1	0	0	0	0			
Trachea		5																										5							
Bronchus/Bronchiole		5																										5							
Stomach		5																										5							
Duodenum		5																										5							
Jejunum		5																										5							
Ileum		5																										5							
Cecum		5																										5							
Colon		5																										5							
Rectum		5																										5							
Liver																																			
Mononuclear cell infiltration		0	5	0	0	0	0																			1	4	0	0	0	0	0			
Necrosis, focal		4	1	0	0	0	0																			5	0	0	0	0	0	0			

Numerals represent the number of animals.  
Not significantly different from control.

Table 11-9 Histopathological findings in female rats (End of recovery test) - [H.E STAINING]

Study No. : SBL79-02

Findings	Group Dose(mg/kg/day) Grade	Control						Polyoxyethylene p-nonylphenyl ether																				
								20				200				1000												
		0	1	2	3	4	P	U	0	1	2	3	4	P	U	0	1	2	3	4	P	U						
Kidney Mineralization, renal tubule		4	1	0	0	0																		5	0	0	0	0
Urinary bladder		5																						5				
Ovary		5																						5				
Uterus		5																						5				
Vagina		5																						5				
Pituitary		5																						5				
Adrenal																												
Hypertrophy, cortical cell, focal		4	1	0	0	0																		4	1	0	0	0
Thyroid Ectopic thymus		4				1																		5				0
Ultimobranchial body		5				0																		2				3
Parathyroid		4	0	0	0	0	0	1															5	0	0	0	0	
Cerebrum		5																						5				
Cerebellum		5																						5				
Sciatic nerve		5																						5				
Brain stem		5																						5				
Spinal cord (Thoracic)		5																						5				
Eyeball (Optic n.)		5																						5				
Harderian gland		5																						5				
Femur Brown pigment, periosteum		0	5	0	0	0																	1	4	0	0	0	
Sternum		5																						5				

Numerals represent the number of animals.  
Not significantly different from control.

**Clinical Sign**

**Grade**

1 : Slight  
2 : Moderate  
3 : Severe  
+ : Non-graded clinical signs

**Time**

Pre: Before administration  
S1 : 1-2 hours after administration  
S2 : 4-6 hours after administration

## Appendix 1-1 Clinical signs in male rats

Study No. : SBL79-02

Group	Anim.No.	Item	Grade	Time	Day
<b>Control</b>					
	1	No abnormal signs			
	2	No abnormal signs			
	3	No abnormal signs			
	4	No abnormal signs			
	5	No abnormal signs			
	6	No abnormal signs			
	7	No abnormal signs			
	8	No abnormal signs			
	9	No abnormal signs			
	10	No abnormal signs			
<b>Polyoxyethylene p-nonylphenyl ether</b>					
	20 (mg/kg/day)				
	21	No abnormal signs			
	22	No abnormal signs			
	23	No abnormal signs			
	24	No abnormal signs			
	25	No abnormal signs			
<b>Polyoxyethylene p-nonylphenyl ether</b>					
	200 (mg/kg/day)				
	31	No abnormal signs			
	32	No abnormal signs			
	33	No abnormal signs			
	34	No abnormal signs			
	35	No abnormal signs			
<b>Polyoxyethylene p-nonylphenyl ether</b>					
	1000 (mg/kg/day)				
	41	No abnormal signs			
	42	No abnormal signs			
	43	No abnormal signs			
	44	No abnormal signs			
	45	No abnormal signs			
	46	No abnormal signs			
	47	No abnormal signs			
	48	No abnormal signs			
	49	No abnormal signs			
	50	No abnormal signs			

## Appendix 1-2 Clinical signs in female rats

Study No. : SBL79-02

Group	Anim.No.	Item	Grade	Time	Day
<b>Control</b>					
	11	No abnormal signs			
	12	No abnormal signs			
	13	No abnormal signs			
	14	No abnormal signs			
	15	No abnormal signs			
	16	No abnormal signs			
	17	No abnormal signs			
	18	No abnormal signs			
	19	No abnormal signs			
	20	No abnormal signs			
<b>Polyoxyethylene p-nonylphenyl ether</b>					
	20	(mg/kg/day)			
	26	No abnormal signs			
	27	No abnormal signs			
	28	No abnormal signs			
	29	No abnormal signs			
	30	No abnormal signs			
<b>Polyoxyethylene p-nonylphenyl ether</b>					
	200	(mg/kg/day)			
	36	No abnormal signs			
	37	No abnormal signs			
	38	No abnormal signs			
	39	No abnormal signs			
	40	No abnormal signs			
<b>Polyoxyethylene p-nonylphenyl ether</b>					
	1000	(mg/kg/day)			
	51	No abnormal signs			
	52	No abnormal signs			
	53	No abnormal signs			
	54	No abnormal signs			
	55	No abnormal signs			
	56	No abnormal signs			
	57	No abnormal signs			
	58	No abnormal signs			
	59	No abnormal signs			
	60	No abnormal signs			

## Appendix 2-1 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (Prior to administration on Day 0)

Study No. : SBL79-02

General behavior	Group Dose(mg/kg/day)	Control					Polyoxyethylene p-nonylphenyl ether															
							20					200					1000					
		Animal No.	1	2	3	4	5	21	22	23	24	25	31	32	33	34	35	41	42	43	44	45
Awareness																						
Alertness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Visual Placing		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stereotypy		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Passivity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mood																						
Grooming		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Vocalization		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restlessness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Irritability		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fearfulness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Motor Activity																						
Reactivity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Spontaneous Activity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Touch Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
CNS Excitation																						
Startle Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Straub Tail		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tremors		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Twitches		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convulsions		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Posture																						
Body Posture		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Limb Posture		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Motor Incoordination																						
Staggering Gait		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Abnormal Gait		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Righting Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Note) - : Normal sign

## Appendix 2-2 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (Prior to administration on Day 0)

Study No. : SBL79-02

General behavior	Group Dose(mg/kg/day)	Control					Polyoxyethylene p-nonylphenyl ether															
							20					200					1000					
		Animal No.	1	2	3	4	5	21	22	23	24	25	31	32	33	34	35	41	42	43	44	45
Muscle Tone																						
Limb Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grip Strength		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Body Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Abdominal Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reflex																						
Pinna Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Corneal Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
IFR		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Autonomic Profile																						
Writhing		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Palpebral Opening		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exophthalmos		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Urination		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Salivation		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Piloerection		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hypothermia		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Skin Color		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Heart Rate		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Respiratory Rate		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pupil Size		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Rearing*		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Notes) - : Normal sign

\*: Numerals represent the count of rearing

Appendix 2-3 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (2 - 4 hours after administration on Day 0)

Study No. : SBL79-02

General behavior	Group Dose(mg/kg/day)	Control					Polyoxyethylene p-nonylphenyl ether															
							20					200					1000					
		Animal No.	1	2	3	4	5	21	22	23	24	25	31	32	33	34	35	41	42	43	44	45
Awareness																						
Alertness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Visual Placing		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stereotypy		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Passivity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mood																						
Grooming		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Vocalization		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restlessness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Irritability		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fearfulness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Motor Activity																						
Reactivity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Spontaneous Activity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Touch Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
CNS Excitation																						
Startle Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Straub Tail		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Trémors		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Twitches		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convulsions		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Posture																						
Body Posture		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Limb Posture		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Motor Incoordination																						
Staggering Gait		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Abnormal Gait		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Righting Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Note) - : Normal sign

Appendix 2-4 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (2 - 4 hours after administration on Day 0)

Study No. : SBL79-02

General behavior	Group	Control					Polyoxyethylene p-nonylphenyl ether															
							20					200					1000					
	Dose(mg/kg/day)	Animal No.	1	2	3	4	5	21	22	23	24	25	31	32	33	34	35	41	42	43	44	45
Muscle Tone																						
Limb Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grip Strength		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Body Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Abdominal Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reflex																						
Pinna Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Corneal Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
IFR		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Autonomic Profile																						
Writhing		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Palpebral Opening		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exophthalmos		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Urination		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Salivation		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Piloerection		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hypothermia		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Skin Color		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Heart Rate		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Respiratory Rate		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pupil Size		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Rearing*		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Notes) - : Normal sign

\* : Numerals represent the count of rearing

Appendix 2-5 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (2 - 4 hours after administration on Day 27)

Study No. : SBL79-02

General behavior	Group Dose(mg/kg/day)	Control					Polyoxyethylene p-nonylphenyl ether															
							20					200					1000					
		Animal No.	1	2	3	4	5	21	22	23	24	25	31	32	33	34	35	41	42	43	44	45
Awareness																						
Alertness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Visual Placing		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stereotypy		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Passivity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mood																						
Grooming		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Vocalization		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restlessness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Irritability		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fearfulness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Motor Activity																						
Reactivity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Spontaneous Activity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Touch Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
CNS Excitation																						
Startle Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Straub Tail		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tremors		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Twitches		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convulsions		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Posture																						
Body Posture		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Limb Posture		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Motor Incoordination																						
Staggering Gait		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Abnormal Gait		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Righting Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Note) - : Normal sign

Appendix 2-6 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (2 - 4 hours after administration on Day 27)

Study No. : SBL79-02

General behavior	Group	Control					Polyoxyethylene p-nonylphenyl ether															
							20					200					1000					
	Dose(mg/kg/day)	Animal No.	1	2	3	4	5	21	22	23	24	25	31	32	33	34	35	41	42	43	44	45
Muscle Tone																						
Limb Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grip Strength		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Body Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Abdominal Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reflex																						
Finnex Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Corneal Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
IFR		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Autonomic Profile																						
Writhing		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Palpebral Opening		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exophthalmos		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Urination		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Salivation		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Piloerection		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hypothermia		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Skin Color		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Heart Rate		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Respiratory Rate		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pupil Size		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Rearing*		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Notes) - : Normal sign

\* : Numerals represent the count of rearing

## Appendix 2-7 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (Week 2 of recovery period)

Study No. : SBL79-02

General behavior	Group	Control					Polyoxyethylene p-nonylphenyl ether										
							20	200					1000				
		Dose(mg/kg/day)					Animal No.	1	2	3	4	5	41	42	43	44	45
Awareness																	
Alertness		-	-	-	-	-							-	-	-	-	-
Visual Placing		-	-	-	-	-							-	-	-	-	-
Stereotypy		-	-	-	-	-							-	-	-	-	-
Passivity		-	-	-	-	-							-	-	-	-	-
Mood																	
Grooming		-	-	-	-	-							-	-	-	-	-
Vocalization		-	-	-	-	-							-	-	-	-	-
Restlessness		-	-	-	-	-							-	-	-	-	-
Irritability		-	-	-	-	-							-	-	-	-	-
Fearfulness		-	-	-	-	-							-	-	-	-	-
Motor Activity																	
Reactivity		-	-	-	-	-							-	-	-	-	-
Spontaneous Activity		-	-	-	-	-							-	-	-	-	-
Touch Response		-	-	-	-	-							-	-	-	-	-
Pain Response		-	-	-	-	-							-	-	-	-	-
CNS Excitation																	
Startle Response		-	-	-	-	-							-	-	-	-	-
Straub Tail		-	-	-	-	-							-	-	-	-	-
Tremors		-	-	-	-	-							-	-	-	-	-
Twitches		-	-	-	-	-							-	-	-	-	-
Convulsions		-	-	-	-	-							-	-	-	-	-
Posture																	
Body Posture		-	-	-	-	-							-	-	-	-	-
Limb Posture		-	-	-	-	-							-	-	-	-	-
Motor Incoordination																	
Staggering Gait		-	-	-	-	-							-	-	-	-	-
Abnormal Gait		-	-	-	-	-							-	-	-	-	-
Righting Reflex		-	-	-	-	-							-	-	-	-	-

Note) - : Normal sign

## Appendix 2-8 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in male rats (Week 2 of recovery period)

Study No. : SBL79-02

General behavior	Group Dose(mg/kg/day)	Control					Polyoxyethylene p-nonylphenyl ether							
							20	200		1000				
		Animal No.	1	2	3	4	5			41	42	43	44	45
Muscle Tone														
Limb Tone	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grip Strength	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Body Tone	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Abdominal Tone	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reflex														
Pinna Reflex	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Corneal Reflex	-	-	-	-	-	-	-	-	-	-	-	-	-	-
IFR	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Autonomic Profile														
Writhing	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Palpebral Opening	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exophthalmos	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Urination	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Salivation	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Piloerection	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hypothermia	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Skin Color	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Heart Rate	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Respiratory Rate	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pupil Size	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Rearing*		0	0	0	0	0	0			0	0	0	0	0

Notes) - : Normal sign

\* : Numerals represent the count of rearing

## Appendix 2-9 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (Prior to administration on Day 0)

Study No. : SBL79-02

General behavior	Group	Control					Polyoxyethylene p-nonylphenyl ether														
							20				200				1000						
	Animal No.	11	12	13	14	15	26	27	28	29	30	36	37	38	39	40	51	52	53	54	55
Awareness																					
Alertness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Visual Placing		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stereotypy		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Passivity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mood																					
Grooming		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Vocalization		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restlessness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Irritability		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fearfulness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Motor Activity																					
Reactivity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Spontaneous Activity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Touch Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
CNS Excitation																					
Startle Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Straub Tail		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tremors		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Twitches		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convulsions		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Posture																					
Body Posture		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Limb Posture		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Motor Incoordination																					
Staggering Gait		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Abnormal Gait		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Righting Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Note) - : Normal sign

## Appendix 2-10 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (Prior to administration on Day 0)

Study No. : SBL79-02

General behavior	Group	Control					Polyoxyethylene p-nonylphenyl ether														
							20				200				1000						
	Animal No.	11	12	13	14	15	26	27	28	29	30	36	37	38	39	40	51	52	53	54	55
Muscle Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Limb Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grip Strength		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Body Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Abdominal Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pinna Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Corneal Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
IFR		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Autonomic Profile		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Writhing		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Palpebral Opening		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exophthalmos		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Urination		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Salivation		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Piloerection		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hypothermia		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Skin Color		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Heart Rate		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Respiratory Rate		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pupil Size		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Rearing*		0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0

Notes) - : Normal sign

\* : Numerals represent the count of rearing

Appendix 2-11 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (2 - 4 hours after administration on Day 0)

Study No. : SBL79-02

General behavior	Group	Control					Polyoxyethylene p-nonylphenyl ether															
							20				200				1000							
	Dose(mg/kg/day)	Animal No.	11	12	13	14	15	26	27	28	29	30	36	37	38	39	40	51	52	53	54	55
Awareness																						
Alertness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Visual Placing		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stereotypy		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Passivity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mood																						
Grooming		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Vocalization		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restlessness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Irritability		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fearfulness		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Motor Activity																						
Reactivity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Spontaneous Activity		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Touch Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
CNS Excitation																						
Startle Response		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Straub Tail		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tremors		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Twitches		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convulsions		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Posture																						
Body Posture		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Limb Posture		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Motor Incoordination																						
Staggering Gait		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Abnormal Gait		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Righting Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Note) - : Normal sign

Appendix 2-12 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (2 - 4 hours after administration on Day 0)

Study No. : SBL79-02

General behavior	Group Dose(mg/kg/day)	Control					Polyoxyethylene p-nonylphenyl ether															
							20					200					1000					
		Animal No.	11	12	13	14	15	26	27	28	29	30	36	37	38	39	40	51	52	53	54	55
<b>Muscle Tone</b>																						
Limb Tone	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grip Strength	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Body Tone	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Abdominal Tone	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Reflex</b>																						
Pinna Reflex	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Corneal Reflex	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
IFR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Autonomic Profile</b>																						
Writhing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Palpebral Opening	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exophthalmos	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Urination	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Salivation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Piloerection	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hypothermia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Skin Color	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Heart Rate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Respiratory Rate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pupil Size	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Rearing*	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0

Notes) - : Normal sign

\* : Numerals represent the count of rearing

Appendix 2-13 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (2 - 4 hours after administration on Day 27)

Study No. : SBL79-02

General behavior	Group Dose(mg/kg/day)	Control					Polyoxyethylene p-nonylphenyl ether																
							20				200				1000								
		Animal No.	11	12	13	14	15	26	27	28	29	30	36	37	38	39	40	51	52	53	54	55	
<b>Awareness</b>																							
Alertness	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Visual Placing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Stereotypy	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Passivity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<b>Mood</b>																							
Grooming	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Vocalization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Restlessness	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Irritability	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fearfulness	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<b>Motor Activity</b>																							
Reactivity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Spontaneous Activity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Touch Response	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Pain Response	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<b>CNS Excitation</b>																							
Startle Response	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Straub Tail	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Tremors	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Twitches	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Convulsions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<b>Posture</b>																							
Body Posture	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Limb Posture	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<b>Motor Incoordination</b>																							
Staggering Gait	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Abnormal Gait	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Righting Reflex	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

Note) - : Normal sign

Appendix 2-14 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (2 - 4 hours after administration on Day 27)

Study No. : SBL79-02

General behavior	Group Dose(mg/kg/day)	Control					Polyoxyethylene p-nonylphenyl ether															
							20				200				1000							
		Animal No.	11	12	13	14	15	26	27	28	29	30	36	37	38	39	40	51	52	53	54	55
<b>Muscle Tone</b>																						
Limb Tone	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grip Strength	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Body Tone	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Abdominal Tone	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Reflex</b>																						
Pinna Reflex	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Corneal Reflex	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
IPR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Autonomic Profile</b>																						
Writhing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Palpebral Opening	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exophthalmos	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Urination	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Salivation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Piloerection	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hypothermia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Skin Color	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Heart Rate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Respiratory Rate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pupil Size	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Rearing*	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0

Notes) - : Normal sign

\* : Numerals represent the count of rearing

## Appendix 2-15 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (Week 2 of recovery period)

Study No. : SBL79-02

General behavior	Group Dose(mg/kg/day)	Control					Polyoxyethylene p-nonylphenyl ether							
							20	200		1000				
		Animal No.	11	12	13	14	15			51	52	53	54	55
Awareness			-	-	-	-	-	-	-	-	-	-	-	-
Alertness			-	-	-	-	-	-	-	-	-	-	-	-
Visual Placing			-	-	-	-	-	-	-	-	-	-	-	-
Stereotypy			-	-	-	-	-	-	-	-	-	-	-	-
Passivity			-	-	-	-	-	-	-	-	-	-	-	-
Mood			-	-	-	-	-	-	-	-	-	-	-	-
Grooming			-	-	-	-	-	-	-	-	-	-	-	-
Vocalization			-	-	-	-	-	-	-	-	-	-	-	-
Restlessness			-	-	-	-	-	-	-	-	-	-	-	-
Irritability			-	-	-	-	-	-	-	-	-	-	-	-
Fearfulness			-	-	-	-	-	-	-	-	-	-	-	-
Motor Activity			-	-	-	-	-	-	-	-	-	-	-	-
Reactivity			-	-	-	-	-	-	-	-	-	-	-	-
Spontaneous Activity			-	-	-	-	-	-	-	-	-	-	-	-
Touch Response			-	-	-	-	-	-	-	-	-	-	-	-
Pain Response			-	-	-	-	-	-	-	-	-	-	-	-
CNS Excitation			-	-	-	-	-	-	-	-	-	-	-	-
Startle Response			-	-	-	-	-	-	-	-	-	-	-	-
Straub Tail			-	-	-	-	-	-	-	-	-	-	-	-
Tremors			-	-	-	-	-	-	-	-	-	-	-	-
Twitches			-	-	-	-	-	-	-	-	-	-	-	-
Convulsions			-	-	-	-	-	-	-	-	-	-	-	-
Posture			-	-	-	-	-	-	-	-	-	-	-	-
Body Posture			-	-	-	-	-	-	-	-	-	-	-	-
Limb Posture			-	-	-	-	-	-	-	-	-	-	-	-
Motor Incoordination			-	-	-	-	-	-	-	-	-	-	-	-
Staggering Gait			-	-	-	-	-	-	-	-	-	-	-	-
Abnormal Gait			-	-	-	-	-	-	-	-	-	-	-	-
Righting Reflex			-	-	-	-	-	-	-	-	-	-	-	-

Note) - : Normal sign

## Appendix 2-16 Effects of Polyoxyethylene p-nonylphenyl ether on the general behavior in female rats (Week 2 of recovery period)

Study No. : SBL79-02

General behavior	Group	Control					Polyoxyethylene p-nonylphenyl ether								
							20		200		1000				
	Animal No.	11	12	13	14	15					51	52	53	54	55
Muscle Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	
Limb Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	
Grip Strength		-	-	-	-	-	-	-	-	-	-	-	-	-	
Body Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	
Abdominal Tone		-	-	-	-	-	-	-	-	-	-	-	-	-	
Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	
Pinna Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	
Corneal Reflex		-	-	-	-	-	-	-	-	-	-	-	-	-	
IFR		-	-	-	-	-	-	-	-	-	-	-	-	-	
Autonomic Profile		-	-	-	-	-	-	-	-	-	-	-	-	-	
Writhing		-	-	-	-	-	-	-	-	-	-	-	-	-	
Palpebral Opening		-	-	-	-	-	-	-	-	-	-	-	-	-	
Exophthalmos		-	-	-	-	-	-	-	-	-	-	-	-	-	
Urination		-	-	-	-	-	-	-	-	-	-	-	-	-	
Salivation		-	-	-	-	-	-	-	-	-	-	-	-	-	
Piloerection		-	-	-	-	-	-	-	-	-	-	-	-	-	
Hypothermia		-	-	-	-	-	-	-	-	-	-	-	-	-	
Skin Color		-	-	-	-	-	-	-	-	-	-	-	-	-	
Heart Rate		-	-	-	-	-	-	-	-	-	-	-	-	-	
Respiratory Rate		-	-	-	-	-	-	-	-	-	-	-	-	-	
Pupil Size		-	-	-	-	-	-	-	-	-	-	-	-	-	
Rearing*		0	0	0	0	0					0	1	1	0	0

Notes) - : Normal sign

\* : Numerals represent the count of rearing

## Appendix 3-1 Food consumption ( g/day ) in male rats

Study No. : SBL79-02

Group	Anim.No.	Pre	1w	2w	3w	4w	R:1w	R:2w
<b>Control</b>								
	1	23	26	32	28	31	30	31
	2	26	26	31	26	31	28	29
	3	21	26	31	27	28	30	34
	4	24	32	33	33	36	35	37
	5	23	25	29	29	30	23	31
	6	22	22	25	22	25		
	7	24	31	31	29	33		
	8	24	26	32	27	30		
	9	23	26	31	27	33		
	10	24	26	27	32	32		
	Mean	23.4	26.6	30.2	28.0	30.9	29.2	32.4
	+S.D.	1.3	2.9	2.5	3.1	3.0	4.3	3.1
<b>Polyoxyethylene p-nonylphenyl ether 20 (mg/kg/day)</b>								
	21	22	24	24	26	27		
	22	24	30	27	26	30		
	23	21	24	27	23	25		
	24	23	30	30	30	33		
	25	26	28	29	28	32		
	Mean	23.2	27.2	27.4	26.6	29.4		
	+S.D.	1.9	3.0	2.3	2.6	3.4		
<b>Polyoxyethylene p-nonylphenyl ether 200 (mg/kg/day)</b>								
	31	22	27	25	27	25		
	32	26	29	30	31	32		
	33	27	29	30	26	29		
	34	23	24	24	25	28		
	35	19	22	23	24	26		
	Mean	23.4	26.2	26.4	26.6	28.0		
	+S.D.	3.2	3.1	3.4	2.7	2.7		
<b>Polyoxyethylene p-nonylphenyl ether 1000 (mg/kg/day)</b>								
	41	21	26	24	23	25	28	25
	42	24	29	30	29	35	33	36
	43	23	29	29	26	29	28	33
	44	24	29	30	29	30	30	33
	45	22	29	32	29	31	31	32
	46	25	27	28	28	37		
	47	23	30	32	32	34		
	48	25	28	28	27	32		
	49	27	31	34	34	37		
	50	21	26	31	24	26		
	Mean	23.5	28.4	29.8	28.1	31.6	30.0	31.8
	+S.D.	1.9	1.6	2.8	3.3	4.2	2.1	4.1

## Appendix 3-2 Food consumption ( g/day ) in female rats

Study No. : SBL79-02

Group	Anim.No.	Pre	1w	2w	3w	4w	R:1w	R:2w
<b>Control</b>								
	11	20	22	19	15	23	19	26
	12	21	17	23	20	24	23	26
	13	19	21	21	20	21	26	25
	14	23	22	20	20	21	18	26
	15	18	19	16	15	21	22	22
	16	21	21	26	24	23		
	17	22	23	23	23	30		
	18	19	21	19	18	21		
	19	19	23	20	18	20		
	20	22	24	23	21	27		
	Mean	20.4	21.3	21.0	19.4	23.1	21.6	25.0
	+S.D.	1.6	2.1	2.8	3.0	3.2	3.2	1.7
<b>Polyoxyethylene p-nonylphenyl ether 20 (mg/kg/day)</b>								
	26	19	18	18	16	24		
	27	21	22	23	21	28		
	28	18	22	20	21	25		
	29	21	24	19	19	24		
	30	21	22	21	20	29		
	Mean	20.0	21.6	20.2	19.4	26.0		
	+S.D.	1.4	2.2	1.9	2.1	2.3		
<b>Polyoxyethylene p-nonylphenyl ether 200 (mg/kg/day)</b>								
	36	20	20	19	20	21		
	37	21	27	24	22	20		
	38	22	25	21	22	27		
	39	19	22	20	16	21		
	40	23	22	25	22	27		
	Mean	21.0	23.2	21.8	20.4	23.2		
	+S.D.	1.6	2.8	2.6	2.6	3.5		
<b>Polyoxyethylene p-nonylphenyl ether 1000 (mg/kg/day)</b>								
	51	22	20	17	16	21	18	20
	52	21	22	22	18	33	11	23
	53	19	19	19	15	17	25	23
	54	22	22	24	20	19	24	21
	55	21	23	23	25	30	22	22
	56	22	20	21	22	26		
	57	19	25	23	23	26		
	58	21	23	23	19	20		
	59	21	23	20	18	25		
	60	22	20	19	22	24		
	Mean	21.0	21.7	21.1	19.8	24.1	20.0	21.8
	+S.D.	1.2	1.9	2.3	3.2	5.0	5.7	1.3

## Appendix 4-1 Body weight ( g ) in male rats

Study No. : SBL79-02

Group	Anim.No.	Pre	1w	2w	3w	4w	R:1w	R:2w
<b>Control</b>								
1	155	214	270	324	372	409	429	
2	153	207	262	306	341	371	388	
3	144	198	256	292	317	353	385	
4	166	226	294	349	387	429	465	
5	150	202	251	296	326	354	370	
6	151	189	225	257	286			
7	167	239	307	372	416			
8	158	219	283	330	360			
9	161	224	285	334	375			
10	160	212	267	325	363			
Mean	156.5	213.0	270.0	318.5	354.3	383.2	407.4	
+S.D.	7.3	14.8	23.6	32.3	37.7	34.2	38.9	
<b>Polyoxyethylene p-nonylphenyl ether</b>								
20 (mg/kg/day)								
21	151	201	248	293	323			
22	165	229	285	328	368			
23	146	192	245	289	314			
24	157	217	274	324	358			
25	159	214	264	307	333			
Mean	155.6	210.6	263.2	308.2	339.2			
+S.D.	7.3	14.4	17.0	17.6	23.0			
<b>Polyoxyethylene p-nonylphenyl ether</b>								
200 (mg/kg/day)								
31	154	213	258	298	323			
32	163	219	275	329	365			
33	163	225	279	323	353			
34	147	196	238	271	307			
35	132	167	207	250	274			
Mean	151.8	204.0	251.4	294.2	324.4			
+S.D.	12.9	23.3	29.6	33.7	36.4			
<b>Polyoxyethylene p-nonylphenyl ether</b>								
1000 (mg/kg/day)								
41	137	188	234	272	299	331	352	
42	159	222	285	334	378	419	452	
43	154	208	262	307	344	381	411	
44	160	224	278	321	345	375	405	
45	147	207	267	320	352	387	410	
46	157	210	264	314	351			
47	163	225	282	341	389			
48	168	224	276	332	376			
49	169	229	287	347	392			
50	147	200	246	276	294			
Mean	156.1	213.7	268.1	316.4	352.0	378.6	406.0	
+S.D.	10.1	13.3	17.3	25.4	34.2	31.6	35.6	

## Appendix 4-2 Body weight ( g ) in female rats

Study No. : SBL79-02

Group	Anim.No.	Pre	1w	2w	3w	4w	R:1w	R:2w
<b>Control</b>								
	11	131	162	183	195	216	235	248
	12	130	157	184	205	225	235	248
	13	129	163	192	216	237	259	274
	14	134	162	184	201	213	234	248
	15	124	155	170	183	207	227	239
	16	135	164	204	241	251		
	17	133	176	204	243	271		
	18	122	161	184	209	221		
	19	131	166	187	214	225		
	20	135	169	201	220	239		
	Mean	130.4	163.5	189.3	212.7	230.5	238.0	251.4
	+S.D.	4.4	5.9	10.9	18.8	19.4	12.2	13.2
<b>Polyoxyethylene p-nonylphenyl ether</b>								
20 (mg/kg/day)	26	121	150	168	186	207		
	27	135	166	184	213	239		
	28	127	162	182	207	236		
	29	133	172	187	206	231		
	30	135	176	203	224	243		
	Mean	130.2	165.2	184.8	207.2	231.2		
	+S.D.	6.1	10.1	12.5	13.8	14.2		
<b>Polyoxyethylene p-nonylphenyl ether</b>								
200 (mg/kg/day)	36	133	167	191	212	235		
	37	134	176	187	196	215		
	38	138	182	214	242	262		
	39	123	157	174	185	198		
	40	123	159	199	222	239		
	Mean	130.2	168.2	193.0	211.4	229.8		
	+S.D.	6.8	10.8	14.8	22.3	24.4		
<b>Polyoxyethylene p-nonylphenyl ether</b>								
1000 (mg/kg/day)	51	128	158	177	196	208	220	228
	52	129	163	180	198	208	216	233
	53	121	155	171	183	199	212	223
	54	137	174	193	209	210	225	225
	55	130	160	178	204	220	239	260
	56	135	172	201	234	260		
	57	125	165	191	214	232		
	58	134	171	201	225	244		
	59	132	166	185	204	234		
	60	129	164	182	207	232		
	Mean	130.0	164.8	185.9	207.4	224.7	222.4	233.8
	+S.D.	4.8	6.2	10.3	14.5	19.1	10.5	15.1

## Appendix 4-3 Body weight gain ( g ) in male rats

Study No. : SBL79-02

Group	Anim.No.	1w	2w	3w	4w	R:1w	R:2w
<b>Control</b>							
1	59	56	54	48	37	20	
2	54	55	44	35	30	17	
3	54	58	36	25	36	32	
4	60	68	55	38	42	36	
5	52	49	45	30	28	16	
6	38	36	32	29			
7	72	68	65	44			
8	61	64	47	30			
9	63	61	49	41			
10	52	55	58	38			
Mean	56.5	57.0	48.5	35.8	34.6	24.2	
+S.D.	8.9	9.6	10.0	7.3	5.6	9.2	
<b>Polyoxyethylene p-nonylphenyl ether</b>							
20 (mg/kg/day)							
21	50	47	45	30			
22	64	56	43	40			
23	46	53	44	25			
24	60	57	50	34			
25	55	50	43	26			
Mean	55.0	52.6	45.0	31.0			
+S.D.	7.3	4.2	2.9	6.2			
<b>Polyoxyethylene p-nonylphenyl ether</b>							
200 (mg/kg/day)							
31	59	45	40	25			
32	56	56	54	36			
33	62	54	44	30			
34	49	42	33	36			
35	35	40	43	24			
Mean	52.2	47.4	42.8	30.2			
+S.D.	10.8	7.2	7.6	5.8			
<b>Polyoxyethylene p-nonylphenyl ether</b>							
1000 (mg/kg/day)							
41	51	46	38	27	32	21	
42	63	63	49	44	41	33	
43	54	54	45	37	37	30	
44	64	54	43	24	30	30	
45	60	60	53	32	35	23	
46	53	54	50	37			
47	62	57	59	48			
48	56	52	56	44			
49	60	58	60	45			
50	53	46	30	18			
Mean	57.6	54.4	48.3	35.6	35.0	27.4	
+S.D.	4.7	5.5	9.5	10.1	4.3	5.1	

## Appendix 4-4 Body weight gain ( g ) in female rats

Study No. : SBL79-02

Group	Anim.No.	1w	2w	3w	4w	R:1w	R:2w
<b>Control</b>							
	11	31	21	12	21	19	13
	12	27	27	21	20	10	13
	13	34	29	24	21	22	15
	14	28	22	17	12	21	14
	15	31	15	13	24	20	12
	16	29	40	37	10		
	17	43	28	39	28		
	18	39	23	25	12		
	19	35	21	27	11		
	20	34	32	19	19		
	Mean	33.1	25.8	23.4	17.8	18.4	13.4
	+S.D.	5.0	7.0	9.1	6.2	4.8	1.1
<b>Polyoxyethylene p-nonylphenyl ether</b>							
20 (mg/kg/day)	26	29	18	18	21		
	27	31	18	29	26		
	28	35	20	25	29		
	29	39	15	19	25		
	30	41	27	21	19		
	Mean	35.0	19.6	22.4	24.0		
	+S.D.	5.1	4.5	4.6	4.0		
<b>Polyoxyethylene p-nonylphenyl ether</b>							
200 (mg/kg/day)	36	34	24	21	23		
	37	42	11	9	19		
	38	44	32	28	20		
	39	34	17	11	13		
	40	36	40	23	17		
	Mean	38.0	24.8	18.4	18.4		
	+S.D.	4.7	11.6	8.1	3.7		
<b>Polyoxyethylene p-nonylphenyl ether</b>							
1000 (mg/kg/day)	51	30	19	19	12	12	8
	52	34	17	18	10	8	17
	53	34	16	12	16	13	11
	54	37	19	16	1	15	0
	55	30	18	26	16	19	21
	56	37	29	33	26		
	57	40	26	23	18		
	58	37	30	24	19		
	59	34	19	19	30		
	60	35	18	25	25		
	Mean	34.8	21.1	21.5	17.3	13.4	11.4
	+S.D.	3.2	5.2	5.9	8.5	4.0	8.1

**Gross ophthalmological examination**

**Grade**

1 : Slight

2 : Moderate

3 : Severe

P : Non-graded change

N : No abnormal changes

U : Unexamined

## Appendix 5-1 Gross ophthalmological examination in male rats

Study No. : SBL79-02

Group	Anim.No.	Item	Pre	4w	R:2w
<b>Control</b>					
	1		N	N	N
	2		N	N	N
	3		N	N	N
	4		N	N	N
	5		N	N	N
	6		N	N	
	7		N	N	
	8		N	N	
	9		N	N	
	10		N	N	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
20 (mg/kg/day)	21		N	N	
	22		N	N	
	23		N	N	
	24		N	N	
	25		N	N	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
200 (mg/kg/day)	31		N	N	
	32		N	N	
	33		N	N	
	34		N	N	
	35		N	N	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
1000 (mg/kg/day)	41		N	N	N
	42		N	N	N
	43		N	N	N
	44		N	N	N
	45		N	N	N
	46		N	N	
	47		N	N	
	48		N	N	
	49		N	N	
	50		N	N	

## Appendix 5-2 Gross ophthalmological examination in female rats

Study No. : SBL79-02

Group	Anim.No.	Item	Pre	4w	R:2w
<b>Control</b>					
	11		N	N	N
	12		N	N	N
	13		N	N	N
	14		N	N	N
	15		N	N	N
	16		N	N	
	17		N	N	
	18		N	N	
	19		N	N	
	20		N	N	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
20 (mg/kg/day)	26		N	N	
	27		N	N	
	28		N	N	
	29		N	N	
	30		N	N	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
200 (mg/kg/day)	36		N	N	
	37		N	N	
	38		N	N	
	39		N	N	
	40		N	N	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
1000 (mg/kg/day)	51		N	N	N
	52		N	N	N
	53		N	N	N
	54		N	N	N
	55		N	N	N
	56		N	N	
	57		N	N	
	58		N	N	
	59		N	N	
	60		N	N	

**Funduscopic examination**

**Grade**

1 : Slight

2 : Moderate

3 : Severe

P : Non-graded change

N : No abnormal changes

U : Unexamined

## Appendix 5-3 FUNDUSCOPIIC EXAMINATION IN MALE RATS

Study No. : SBL79-02

Group	Anim.No.	Item	Pre	4w	R:2w
<b>Control</b>					
	1		N	N	N
	2		N	N	N
	3		N	N	N
	4		N	N	N
	5		N	N	N
	6		N	N	
	7		N	N	
	8		N	N	
	9		N	N	
	10		N	N	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
	20 (mg/kg/day)				
	21		N	N	
	22		N	N	
	23		N	N	
	24		N	N	
	25		N	N	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
	200 (mg/kg/day)				
	31		N	N	
	32		N	N	
	33		N	N	
	34		N	N	
	35		N	N	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
	1000 (mg/kg/day)				
	41		N	N	N
	42		N	N	N
	43		N	N	N
	44		N	N	N
	45		N	N	N
	46		N	N	
	47		N	N	
	48		N	N	
	49		N	N	
	50		N	N	

Group	Anim.No.	Item	Pre	4w	R:2w
<b>Control</b>					
	11		N	N	N
	12		N	N	N
	13		N	N	N
	14		N	N	N
	15		N	N	N
	16		N	N	
	17		N	N	
	18		N	N	
	19		N	N	
	20		N	N	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
20 (mg/kg/day)	26		N	N	
	27		N	N	
	28		N	N	
	29		N	N	
	30		N	N	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
200 (mg/kg/day)	36		N	N	
	37		N	N	
	38		N	N	
	39		N	N	
	40		N	N	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
1000 (mg/kg/day)	51		N	N	N
	52		N	N	N
	53		N	N	N
	54		N	N	N
	55		N	N	N
	56		N	N	
	57		N	N	
	58		N	N	
	59		N	N	
	60		N	N	

Standard Urinalysis

Color 0 : Normal color  
1 : Abnormal color

Protein (mg/dL)  
0 : -  
1 : +  
2 : ++ 30  
3 : +++ 100  
4 : +++++ 300  
5 : ++++++ 1000

Glucose (g/dL)  
0 : -  
1 : + 0.1  
2 : ++ 0.25  
3 : +++ 0.5  
4 : +++++ 1  
5 : ++++++ 2

Ketone body (mg/dL)  
(Ketone)  
0 : -  
1 : + 5  
2 : ++ 15  
3 : +++ 40  
4 : +++++ 80  
5 : ++++++ 160

Bilirubin (Bill.)  
0 : -  
1 : +  
2 : ++  
3 : +++

Occult blood (Oc.Bld.)  
0 : -  
1 : +  
2 : ++  
3 : +++  
4 : +++++

Urobilinogen (Ehrlich unit/dL)  
(Urobil.)  
0 : + 0.1  
1 : ++ 1  
2 : +++ 2  
3 : +++++ 4  
4 : ++++++ 8  
5 : +++++++ 12

Urine volume (U.Vol.)

Specific gravity (S.Grav.)

## Appendix 6-1 Urinalysis in male rats

Study No. : SBL79-02

Group	Anim.No.	Color		pH		Protein		Glucose		Ketone		Bil.	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
1	0	0	8	8	2	2	0	0	2	1	0	0	0
2	0	0	6.5	7.5	2	3	0	0	0	1	0	0	0
3	0	0	7	7.5	3	3	0	0	1	1	0	0	0
4	0	0	6	8	2	3	0	0	1	1	0	0	0
5	0	0	6.5	7.5	3	0	0	0	1	1	0	0	0
6	0	7.5		3			0		2			0	
7	0	8		3			0		1			0	
8	0	7		3			0		1			0	
9	0	7		3			0		1			0	
10	0	7		2			0		1			0	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
20 (mg/kg/day)													
21	0	7		3			0		0			0	
22	0	7		2			0		2			0	
23	0	6		0			0		1			1	
24	0	6.5		1			0		1			0	
25	0	7.5		2			0		1			0	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
200 (mg/kg/day)													
31	0	7.5		3			0		0			0	
32	0	7		2			0		1			0	
33	0	8		3			0		1			0	
34	0	8		2			0		1			0	
35	0	7.5		2			0		1			0	

## Appendix 6-2 Urinalysis in male rats

Study No. : SBL79-02

Group	Anim.No.	Color		pH		Protein		Glucose		Ketone		Bil.	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Polyoxyethylene p-nonylphenyl ether 1000 (mg/kg/day)</b>													
41	0	0	7.5	7	3	3	0	0	2	2	0	0	0
42	0	0	7.5	7.5	3	2	0	0	2	1	0	0	0
43	0	0	7.5	7.5	2	2	0	0	1	1	0	0	0
44	0	0	7	7.5	3	2	0	0	1	2	0	0	0
45	0	0	8	7	2	2	0	0	1	0	0	0	0
46	0		8		3		0		1		0		
47	0		6.5		2		0		1		0		
48	0		7.5		2		0		1		0		
49	0		8		3		0		1		0		
50	0		7		2		0		2		0		

## Appendix 6-3 Urinalysis in male rats

Study No. : SBL79-02

Group	Anim.No.	Oc.Bld.		Urobil.		U.Vol. (mL)		S.Grav.	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>									
1	0	0	0	1	2.6	3.2	1.034	1.035	
2	1	0	0	0	2.7	1.6	1.030	1.024	
3	2	0	0	0	1.2	0.8	1.022	1.071	
4	0	2	0	0	1.9	2.9	1.057	1.050	
5	0	0	0	0	3.8	3.5	1.026	1.033	
6	0	0	0						
7	0	0	0						
8	2	0	0						
9	0	0	0						
10	1	0	0						
Mean				2.44	2.40	1.0338	1.0426		
+S.D.				0.97	1.15	0.0137	0.0184		
<b>Polyoxyethylene p-nonylphenyl ether</b>									
20 (mg/kg/day)									
21	0	0	0	2.1		1.034			
22	0	0	0	3.4		1.032			
23	0	0	0	3.1		1.025			
24	0	0	0	4.0		1.023			
25	0	0	0	5.8		1.020			
Mean				3.68		1.0268			
+S.D.				1.37		0.0060			
<b>Polyoxyethylene p-nonylphenyl ether</b>									
200 (mg/kg/day)									
31	0	0	0	1.6		1.045			
32	1	0	1	2.4		1.050			
33	0	0	0	3.2		1.022			
34	0	0	0	3.5		1.029			
35	0	0	0	5.0		1.015			
Mean				3.14		1.0322			
+S.D.				1.28		0.0149			

## Appendix 6-4 Urinalysis in male rats

Study No. : SBL79-02

Group	Anim.No.	Oc.Bld.		Urobil.		U.vol. (mL)		S.Grav.	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Polyoxyethylene p-nonylphenyl ether 1000 (mg/kg/day)</b>									
41	0	0		1	0	2.4	1.9	1.026	1.024
42	0	0		0	0	2.2	3.2	1.045	1.035
43	0	0		0	0	1.4	1.6	1.043	1.055
44	0	0		0	0	0.3	2.6	1.070	1.034
45	0	0		0	0	0.9	3.6	1.018	1.032
46	0			0					
47	0			0					
48	1			0					
49	0			0					
50	0			0					
Mean				1.44		2.58	1.0404	1.0360	
+S.D.				0.88		0.84	0.0201	0.0115	

## Appendix 6-5 Urinalysis in female rats

Study No. : SBL79-02

Group	Anim.No.	Color		pH		Protein		Glucose		Ketone		Bil.	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
11	0	0		6.5	7	0	0	0	0	0	0	0	0
12	0	0		8	6.5	1	0	0	0	0	0	0	0
13	0	0		8	7	0	2	0	0	0	1	0	0
14	0	0		8	7.5	0	0	0	0	0	0	0	0
15	0	0		6.5	8	2	2	0	0	1	0	0	0
16	0			7.5		1		0		0		0	
17	0			7.5		0		0		0		0	
18	0			8		2		0		0		0	
19	0			6		0		0		0		0	
20	0			6.5		0		0		0		0	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
20 (mg/kg/day)													
26	0			6.5		2		0		0		0	
27	0			7		2		0		0		0	
28	0			7.5		2		0		1		0	
29	0			6.5		1		0		0		0	
30	0			7		2		0		0		0	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
200 (mg/kg/day)													
36	0			7		0		0		0		0	
37	0			7.5		2		0		0		0	
38	0			7		2		0		0		0	
39	0			7		0		0		0		0	
40	0			8		0		0		0		0	

## Appendix 6-6 Urinalysis in female rats

Study No. : SBL79-02

Group	Anim.No.	Color		pH		Protein		Glucose		Ketone		Bil.	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Polyoxyethylene p-nonylphenyl ether 1000 (mg/kg/day)</b>													
51	0	0	6.5	7	2	1	0	0	1	1	0	0	0
52	0	0	7.5	7.5	2	0	0	0	2	0	0	0	0
53	0	0	8	7	2	1	0	0	0	0	0	0	0
54	0	0	7.5	8	3	0	0	0	1	0	0	0	0
55	0	0	7.5	8	2	0	0	0	1	0	0	0	0
56	0		7.5		0		0		0				0
57	0		7.5		0		0		0				0
58	0		7.5		2		0		1				0
59	0		7.5		0		0		0				0
60	0		7		0		0		0				0

## Appendix 6-7 Urinalysis in female rats

Study No. : SBL79-02

Group	Anim.No.	Oc.Bld.		Urobil.		U.Vol. (mL)		S.Grav.	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>									
11	0	0	0	0	3.5	3.4	1.021	1.015	
12	0	2	0	0	4.2	2.0	1.013	1.018	
13	0	0	0	1	3.0	2.9	1.020	1.026	
14	0	0	0	0	2.3	2.8	1.015	1.029	
15	0	0	1	1	0.4	1.4	1.052	1.043	
16	0		0						
17	0		0						
18	0		1						
19	0		0						
20	0		0						
Mean				2.68	2.50	1.0242	1.0262		
+S.D.				1.45	0.79	0.0159	0.0110		
<b>Polyoxyethylene p-nonylphenyl ether</b>									
20 (mg/kg/day)									
26	2		0		1.9		1.016		
27	0		0		5.4		1.013		
28	0		0		4.0		1.018		
29	0		0		3.9		1.016		
30	0		0		4.5		1.017		
Mean				3.94		1.0160			
+S.D.				1.29		0.0019			
<b>Polyoxyethylene p-nonylphenyl ether</b>									
200 (mg/kg/day)									
36	0		0		3.2		1.028		
37	0		0		2.4		1.019		
38	0		0		1.2		1.063		
39	0		0		2.5		1.026		
40	0		0		5.4		1.014		
Mean				2.94		1.0300			
+S.D.				1.55		0.0193			

## Appendix 6-8 Urinalysis in female rats

Study No. : SBL79-02

Group	Anim.No.	Oc.Bld.		Urobil.		U.Vol. (mL)		S.Grav.		
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	
<b>Polyoxyethylene p-nonylphenyl ether</b>										
1000 (mg/kg/day)										
51	0	0	0	0	2.8	3.0	1.024	1.023		
52	0	0	0	0	1.1	3.1	1.037	1.021		
53	0	0	1	0	2.0	1.1	1.024	1.022		
54	0	0	1	0	1.3	1.5	1.020	1.015		
55	0	0	1	0	1.6	2.6	1.018	1.026		
56	0		0							
57	1		0							
58	0		0							
59	0		0							
60	2		0							
Mean				1.76	2.26	1.0246	1.0214			
<u>±S.D.</u>				0.67	0.91	0.0074	0.0040			

**Urinary Sediment**

RBC      0 : -  
        1 : 1 - 4 /HPF  
        2 : 5 -10 /HPF  
        3 :10 < /HPF

WBC      0 : -  
        1 : 1 - 5 /HPF  
        2 : 6 -20 /HPF  
        3 :20 < /HPF

Phosphate crystal  
(Phosphate) 0 : -  
        1 : 1 -10 /HPF  
        2 :11 -20 /HPF  
        3 :20 < /HPF

Urate crystal  
(Urate) 0 : -  
        1 : 1 -10 /HPF  
        2 :11 -20 /HPF  
        3 :20 < /HPF

Oxalate crystal  
(Oxalate) 0 : -  
        1 : 1 -10 /HPF  
        2 :11 -20 /HPF  
        3 :20 < /HPF

Other crystal  
(Other c.) 0 : -  
        1 : 1 -10 /HPF  
        2 :11 -20 /HPF  
        3 :20 < /HPF

Epithelial cell  
(Epith.) 0 : -  
        1 : 1 - 5 /HPF  
        2 : 6 -20 /HPF  
        3 :20 < /HPF

Bacteria 0 : -  
        1 : +

Cast      0 : -  
        1 : Hyaline Cast  
        2 : Waxy Cast  
        3 : Erythrocytic Cast

Sperm      0 : -  
        1 : +

Others      0 : -  
        1 : +

HPF : High power field

## Appendix 6-9 Urinary sediments in male rats

Study No. : SBL79-02

Group	Anim.No.	RBC		WBC		Phosphate		Urate		Oxalate		Other c.	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
1	0	0	0	0	0	1	0	0	0	0	0	0	0
2	0	0	0	0	0	1	0	0	0	0	0	0	0
3	0	0	0	0	0	1	0	0	0	0	0	0	0
4	0	0	0	0	1	1	0	0	0	0	0	0	0
5	0	0	0	0	1	0	0	0	0	0	0	0	0
<b>Polyoxyethylene p-nonylphenyl ether</b>													
20 (mg/kg/day)													
21	0	0	0	0	0	0	0	0	0	0	0	0	0
22	0	0	0	1	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0	0	0	0	0
25	0	0	0	1	0	0	0	0	0	0	0	0	0
<b>Polyoxyethylene p-nonylphenyl ether</b>													
200 (mg/kg/day)													
31	0	0	0	2	0	0	0	0	0	0	0	0	0
32	0	0	0	1	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0	0	0	0	0
34	0	0	0	2	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Polyoxyethylene p-nonylphenyl ether</b>													
1000 (mg/kg/day)													
41	0	0	0	0	2	0	0	0	0	0	0	0	0
42	0	0	0	0	2	1	0	0	0	0	0	0	0
43	0	0	0	0	2	1	0	0	0	0	0	0	0
44	0	0	0	0	0	1	0	0	0	0	0	0	0
45	0	0	0	0	1	1	0	0	0	0	0	0	0

Group	Anim.No.	Epith.		Bacteria		Cast		Sperm		Others	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>											
1	0	0	0	0	0	0	0	0	1	0	0
2	0	0	0	0	0	0	1	0	0	0	0
3	0	0	0	0	0	0	1	1	0	0	0
4	0	0	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0	0	0
<b>Polyoxyethylene p-nonylphenyl ether</b>											
20 (mg/kg/day)											
21	0	0	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	1	0	0	0	0
23	0	0	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	1	0	0	0	0
<b>Polyoxyethylene p-nonylphenyl ether</b>											
200 (mg/kg/day)											
31	0	0	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0	0	0
<b>Polyoxyethylene p-nonylphenyl ether</b>											
1000 (mg/kg/day)											
41	0	0	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	1	1	0	0	0
43	0	0	0	0	0	0	0	1	0	0	0
44	0	0	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0	0	0

## Appendix 6-11 Urinary sediments in female rats

Study No. : SBL79-02

Group	Anim.No.	RBC		WBC		Phosphate		Urate		Oxalate		Other c.	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
11	0	0	0	0	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	1	0	0	0	0	0	0
14	0	0	0	0	0	0	1	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Polyoxyethylene p-nonylphenyl ether</b>													
20 (mg/kg/day)													
26	0	0	0	0	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Polyoxyethylene p-nonylphenyl ether</b>													
200 (mg/kg/day)													
36	0	0	0	1	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0	0	0	0	0
38	0	0	0	1	0	0	0	0	0	0	0	0	0
39	0	0	0	2	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Polyoxyethylene p-nonylphenyl ether</b>													
1000 (mg/kg/day)													
51	0	0	0	0	0	0	0	0	0	0	0	0	0
52	0	0	0	0	1	1	0	0	0	0	0	0	0
53	0	0	0	0	0	1	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0	0	0	0	0

## Appendix 6-12 Urinary sediments in female rats

Study No. : SBL79-02

Group	Anim.No.	Epith.		Bacteria		Cast		Sperm		Others	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>											
11	0	0	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0	0	0
<b>Polyoxyethylene p-nonylphenyl ether</b>											
20 (mg/kg/day)											
26	0	0	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0	0	0
<b>Polyoxyethylene p-nonylphenyl ether</b>											
200 (mg/kg/day)											
36	0	0	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0	0	0
<b>Polyoxyethylene p-nonylphenyl ether</b>											
1000 (mg/kg/day)											
51	0	0	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0	0	0

## Hematology

RBC	( $10^4/\text{mm}^3$ )	Number of red blood cells
WBC	( $10^2/\text{mm}^3$ )	Number of white blood cells
Ht	(%)	Hematocrit value
Hb	(g/dL)	Hemoglobin concentration
Plat.	( $10^4/\text{mm}^3$ )	Number of blood platelets
MCV	(fl)	Mean corpuscular volume
MCH	(pg)	Mean corpuscular hemoglobin
MCHC	(%)	Mean corpuscular hemoglobin concentration
Ret.	( $10^{-1}\%$ )	Number of reticulocytes

Hemogram		
N-Stab	( $10^2/\text{mm}^3$ )	Number of stab-form neutrophilic leukocytes
N-Stab	(%)	Stab-form neutrophilic leukocyte ratio
N-Seg.	( $10^2/\text{mm}^3$ )	Number of segmented neutrophilic leukocytes
N-Seg.	(%)	Segmented neutrophilic leukocyte ratio
Eosino.	( $10^2/\text{mm}^3$ )	Number of eosinophilic leukocytes
Eosino.	(%)	Eosinophilic leukocyte ratio
Baso.	( $10^2/\text{mm}^3$ )	Number of basophilic leukocytes
Baso.	(%)	Basophilic leukocyte ratio
Mono.	( $10^2/\text{mm}^3$ )	Number of monocytes
Mono.	(%)	Monocyte ratio
Lymph.	( $10^2/\text{mm}^3$ )	Number of lymphocytes
Lymph.	(%)	Lymphocyte ratio

Blood coagulation test		
PT	(Sec)	Prothrombin time
APTT	(Sec)	Activated partial thromboplastin time

## Appendix 7-1 Hematology in male rats

Study No. : SBL79-02

Group	Anim.No.	RBC (10 <sup>4</sup> /mm <sup>3</sup> )		WBC (10 <sup>2</sup> /mm <sup>3</sup> )		Ht (%)		Hb (g/dL)		Plat (10 <sup>4</sup> /mm <sup>3</sup> )		MCV (fl)	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
1		824		75		45.2		16.1		124.6		55	
2		855		60		46.5		16.5		117.3		54	
3		870		69		46.9		16.5		105.2		54	
4		827		129		43.4		15.3		132.2		52	
5		865		93		47.6		16.8		110.2		55	
6		825		180		44.6		16.2		135.1		54	
7		757		113		47.1		17.3		141.0		62	
8		723		97		41.9		14.9		132.3		58	
9		783		73		44.2		15.0		131.9		56	
10		796		66		43.5		14.9		117.8		55	
Mean		776.8		848.2		105.8		85.2		44.26		45.92	
+S.D.		38.8		21.4		45.5		27.3		1.89		1.66	
Polyoxyethylene p-nonylphenyl ether										15.66		131.62	
20 (mg/kg/day)										16.24		117.90	
21		793		53		44.2		15.7		112.2		56	
22		756		59		42.6		15.1		116.6		56	
23		702		35		40.5		14.2		70.1		58	
24		811		97		47.0		15.8		118.6		58	
25		805		76		44.9		15.2		110.7		56	
Mean		773.4		64.0		43.84		15.20		105.64		56.8	
+S.D.		45.3		23.6		2.45		0.64		20.12		1.1	
Polyoxyethylene p-nonylphenyl ether													
200 (mg/kg/day)													
31		779		92		43.0		15.6		116.7		55	
32		765		49		42.8		14.9		130.3		56	
33		816		79		45.3		16.4		117.5		56	
34		781		73		45.6		15.3		124.4		58	
35		859		71		47.3		16.3		112.6		55	
Mean		800.0		72.8		44.80		15.70		120.30		56.0	
+S.D.		38.0		15.6		1.90		0.64		7.02		1.2	
Polyoxyethylene p-nonylphenyl ether													
1000 (mg/kg/day)													
41		875		120		45.5		16.2		134.4		52	
42		793		88		43.1		15.7		153.3		54	
43		816		63		45.3		15.2		107.3		56	
44		835		76		45.2		15.8		113.3		54	
45		798		120		42.5		15.7		125.3		53	
46		819		66		45.2		16.4		155.1		55	
47		680		110		38.3		14.6		83.4		56	
48		774		96		43.9		15.5		129.1		57	
49		705		55		41.2		14.4		128.4		58	
50		785		66		43.7		15.1		123.1		56	
Mean		752.6		823.4		78.6		93.4		42.46		44.32	
+S.D.		58.0		33.2		23.3		25.8		2.74		1.41	
										15.20		15.72	
										0.80		0.36	
										25.80		25.80	
										18.20		18.20	
										1.1		1.1	
										53.8		53.8	
										1.5		1.5	

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

## Appendix 7-2 Hematology in male rats

Study No. : SBL79-02

Group	Anim.No.	MCH (pg)		MCHC (%)		Ret. (10 <sup>-1</sup> %)		N-Stab (10 <sup>2</sup> /mm <sup>3</sup> )		N-Stab (%)		N-Seg. (10 <sup>2</sup> /mm <sup>3</sup> )	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
1		19.5		35.6		16		0.0		0		1.5	
2		19.3		35.5		23		0.0		0		1.2	
3		19.0		35.2		14		0.0		0		1.4	
4		18.5		35.3		16		0.0		0		6.5	
5		19.4		35.3		9		0.0		0		0.9	
6		19.6		36.3		11		0.0		0		7.2	
7		22.9		36.7		20		0.0		0		6.8	
8		20.6		35.6		14		0.0		0		7.8	
9		19.2		33.9		18		0.0		0		1.5	
10		18.7		34.3		13		0.0		0		3.3	
Mean		20.20		19.14		35.36		35.38		15.2		15.6	
+S.D.		1.66		0.40		1.22		0.16		3.7		5.0	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
20 (mg/kg/day)													
21		19.8		35.5		22		0.0		0		2.1	
22		20.0		35.4		16		0.0		0		3.0	
23		20.2		35.1		18		0.0		0		2.1	
24		19.5		33.6		17		0.0		0		1.9	
25		18.9		33.9		21		0.0		0		2.3	
Mean		19.68		34.70		18.8		0.00		0.0		2.28	
+S.D.		0.51		0.89		2.6		0.00		0.0		0.43	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
200 (mg/kg/day)													
31		20.0		36.3		11		0.0		0		20.2	
32		19.5		34.8		16		0.0		0		7.4	
33		20.1		36.2		19		0.0		0		6.3	
34		19.6		33.6		15		0.0		0		5.1	
35		19.0		34.5		12		0.0		0		3.6	
Mean		19.64		35.08		14.6		0.00		0.0		8.52	
+S.D.		0.44		1.16		3.2		0.00		0.0		6.68	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
1000 (mg/kg/day)													
41		18.5		35.6		20		0.0		0		2.4	
42		19.8		36.4		25		0.0		0		0.9	
43		18.6		33.6		13		0.0		0		2.5	
44		18.9		35.0		14		0.0		0		8.4	
45		19.7		36.9		20		0.0		0		14.4	
46		20.0		36.3		16		0.0		0		4.0	
47		21.5		38.1		19		0.0		0		12.1	
48		20.0		35.3		16		0.0		0		5.8	
49		20.4		35.0		27		0.0		0		6.6	
50		19.2		34.6		12		0.0		0		2.0	
Mean		20.22		19.10		35.86		35.50		18.0		18.4	
+S.D.		0.84		0.61		1.40		1.29		5.6		4.9	

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

## Appendix 7-3 Hematology in male rats

Study No. : SBL79-02

Group	Anim.No.	N-Seg. (%)		Eosino. (10 <sup>2</sup> /mm <sup>3</sup> )		Eosino. (%)		Baso. (10 <sup>2</sup> /mm <sup>3</sup> )		Baso. (%)		Mono. (10 <sup>2</sup> /mm <sup>3</sup> )	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
1		2		0.0		0		0.0		0		0.8	
2		2		0.0		0		0.0		0		3.0	
3		2		0.0		0		0.0		0		1.4	
4		5		0.0		0		0.0		0		0.0	
5		1		0.9		1		0.0		0		0.9	
6		4		0.0		0		0.0		0		7.2	
7		6		0.0		0		0.0		0		1.1	
8		8		0.0		0		0.0		0		1.0	
9		2		0.0		0		0.0		0		2.2	
10		5		0.0		0		0.0		0		0.0	
Mean		5.0		2.4		0.00		0.18		0.0		2.30	
+S.D.		2.2		1.5		0.00		0.40		0.0		2.85	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
20 (mg/kg/day)													
21		4		0.0		0		0.0		0		1.1	
22		5		0.0		0		0.0		0		0.0	
23		6		0.0		0		0.0		0		0.7	
24		2		0.0		0		0.0		0		0.0	
25		3		0.0		0		0.0		0		2.3	
Mean		4.0		0.00		0.0		0.00		0.0		0.82	
+S.D.		1.6		0.00		0.0		0.00		0.0		0.95	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
200 (mg/kg/day)													
31		22		0.9		1		0.0		0		1.8	
32		15		0.0		0		0.0		0		1.0	
33		8		0.0		0		0.0		0		0.0	
34		7		0.0		0		0.0		0		0.0	
35		5		0.0		0		0.0		0		0.0	
Mean		11.4		0.18		0.2		0.00		0.0		0.56	
+S.D.		7.0		0.40		0.4		0.00		0.0		0.82	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
1000 (mg/kg/day)													
41		2		0.0		0		0.0		0		0.0	
42		1		1.8		2		0.0		0		0.9	
43		4		0.0		0		0.0		0		0.6	
44		11		0.0		0		0.0		0		3.0	
45		12		2.4		2		0.0		0		1.2	
46		6		0.7		1		0.0		0		0.0	
47		11		0.0		0		0.0		0		2.2	
48		6		0.0		0		0.0		0		1.9	
49		12		0.0		0		0.0		0		0.6	
50		3		0.0		0		0.0		0		0.7	
Mean		7.6		6.0		0.14		0.84		0.2		0.8	
+S.D.		3.8		5.1		0.31		1.17		0.4		1.1	

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

Group	Anim.No.	Mono. (%)		Lymph. (10 <sup>2</sup> /mm <sup>3</sup> )		Lymph. (%)		PT (Sec)		APTT (Sec)	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>											
1		1		72.8		97		16.0		22.2	
2		5		55.8		93		12.2		20.7	
3		2		66.2		96		12.2		20.8	
4		0		122.6		95		12.3		20.6	
5		1		90.2		97		10.6		18.3	
6	4		165.6		92		8.9		20.7		
7	1		105.1		93		10.0		21.7		
8	1		88.3		91		13.2		24.1		
9	3		69.4		95		13.0		21.2		
10	0		62.7		95		14.1		24.3		
Mean		1.8	1.8	98.22	81.52	93.2	95.6	11.84	12.66	22.40	20.52
+S.D.		1.6	1.9	41.16	26.15	1.8	1.7	2.25	2.00	1.68	1.40
<b>Polyoxyethylene p-nonylphenyl ether</b>											
20 (mg/kg/day)											
21	2		49.8		94		17.9		25.2		
22	0		56.1		95		13.5		21.6		
23	2		32.2		92		13.7		22.4		
24	0		95.1		98		13.9		25.1		
25	3		71.4		94		16.7		25.4		
Mean		1.4		60.92		94.6		15.14		23.94	
+S.D.		1.3		23.72		2.2		2.02		1.80	
<b>Polyoxyethylene p-nonylphenyl ether</b>											
200 (mg/kg/day)											
31	2		69.0		75		16.6		23.2		
32	2		40.7		83		13.2		23.5		
33	0		72.7		92		19.1		23.1		
34	0		67.9		93		11.5		18.4		
35	0		67.5		95		15.8		23.6		
Mean		0.8		63.56		87.6		15.24		22.36	
+S.D.		1.1		12.94		8.4		2.97		2.22	
<b>Polyoxyethylene p-nonylphenyl ether</b>											
1000 (mg/kg/day)											
41		0		117.6		98		13.1		20.0	
42		1		84.5		96		15.7		20.7	
43		1		59.9		95		15.7		20.7	
44		4		64.6		85		16.0		23.1	
45		1		102.0		85		19.5		22.7	
46	0		61.4		93		9.2		21.7		
47	2		95.7		87		17.1		22.7		
48	2		88.3		92		10.5		22.3		
49	1		47.9		87		14.2		26.0		
50	1		63.4		96		16.1		25.5		
Mean		1.2	1.4	71.34	85.72	91.0	91.8	13.42	16.00	23.64	21.44
+S.D.		0.8	1.5	19.95	24.47	3.9	6.3	3.45	2.28	1.97	1.37

## Appendix 7-5 Hematology in female rats

Study No. : SBL79-02

Group	Anim.No.	RBC (10 <sup>4</sup> /mm <sup>3</sup> )		WBC (10 <sup>2</sup> /mm <sup>3</sup> )		Ht (%)		Hb (g/dL)		Plat. (10 <sup>4</sup> /mm <sup>3</sup> )		MCV (fl)	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
11		798		45		44.2		15.6		141.2		55	
12		791		45		43.5		16.0		97.5		55	
13		753		41		42.7		15.0		105.7		57	
14		756		38		42.4		15.1		118.9		56	
15		763		39		41.5		14.5		123.0		54	
16		763		40		41.8		15.0		114.9		55	
17		679		37		39.2		13.9		115.3		58	
18		711		42		40.3		14.2		109.6		57	
19		778		56		45.4		15.7		64.3		58	
20		808		44		44.9		15.6		110.7		56	
Mean		747.8		772.2		43.8		41.6		42.32		42.86	
+S.D.		52.1		20.8		7.3		3.3		2.75		1.04	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
20 (mg/kg/day)													
26		798		46		44.7		15.7		137.8		56	
27		779		53		43.9		15.4		113.9		56	
28		735		50		41.7		14.7		117.6		57	
29		778		38		45.9		16.0		117.7		59	
30		750		53		42.0		14.4		137.1		56	
Mean		768.0		48.0		43.64				124.82		56.8	
+S.D.		25.2		6.3		1.79				11.63		1.3	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
200 (mg/kg/day)													
36		779		68		43.0		15.4		108.9		55	
37		723		49		46.9		14.9		119.9		65	
38		793		41		44.8		15.2		97.0		56	
39		749		65		41.4		14.6		65.5		55	
40		846		44		46.8		16.2		102.9		55	
Mean		778.0		53.4		44.58		15.26		98.84		57.2	
+S.D.		46.7		12.3		2.40		0.61		20.47		4.4	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
1000 (mg/kg/day)													
51		783		30		44.2		15.6		125.5		56	
52		693		25		39.4		14.0		72.7		57	
53		777		57		41.4		14.9		71.9		53	
54		796		34		44.4		16.2		88.2		56	
55		771		37		41.1		14.7		95.8		53	
56		766		44		42.7		15.1		126.4		56	
57		743		57		43.4		15.3		63.5		58	
58		733		91		41.5		14.6		122.5		57	
59		761		44		43.7		14.9		123.2		57	
60		748		64		43.3		14.7		132.5		58	
Mean		750.2		764.0		60.0		36.6		42.92		42.10	
+S.D.		13.4		40.8		19.4		12.3		0.87		2.15	
Ht (%)													
Hb (g/dL)													
Plat. (10 <sup>4</sup> /mm <sup>3</sup> )													
MCV (fl)													

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

## Appendix 7-6 Hematology in female rats

Study No. : SBL79-02

Group	Anim.No.	MCH (pg)		MCHC (%)		Ret. (10 <sup>-1</sup> %)		N-Stab (10 <sup>2</sup> /mm <sup>3</sup> )		N-Stab (%)		N-Seg. (10 <sup>2</sup> /mm <sup>3</sup> )	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
11		19.5		35.3		8		0.0		0		0.9	
12		20.2		36.8		4		0.0		0		0.9	
13		19.9		35.1		14		0.0		0		2.1	
14		20.0		35.6		20		0.0		0		6.5	
15		19.0		34.9		10		0.0		0		5.9	
16	19.7		35.9		14		0.0		0		3.2		
17	20.5		35.5		14		0.0		0		0.7		
18	20.0		35.2		11		0.0		0		2.9		
19	20.2		34.6		9		0.0		0		3.4		
20	19.3		34.7		14		0.0		0		0.4		
Mean	19.94	19.72	35.18	35.54	12.4	11.2	0.00	0.00	0.0	0.0	2.12	3.26	
+S.D.	0.46	0.48	0.54	0.75	2.3	6.1	0.00	0.00	0.0	0.0	1.45	2.74	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
20 (mg/kg/day)													
26	19.7		35.1		17		0.0		0		0.5		
27	19.8		35.1		13		0.0		0		1.6		
28	20.0		35.3		8		0.0		0		2.0		
29	20.6		34.9		19		0.0		0		1.5		
30	19.2		34.3		7		0.0		0		3.2		
Mean	19.86		34.94		12.8		0.00		0.0		1.76		
+S.D.	0.51		0.38		5.3		0.00		0.0		0.98		
<b>Polyoxyethylene p-nonylphenyl ether</b>													
200 (mg/kg/day)													
36	19.8		35.8		11		0.0		0		1.4		
37	20.6		31.8		20		0.0		0		3.4		
38	19.2		33.9		16		0.0		0		3.3		
39	19.5		35.3		9		0.0		0		3.9		
40	19.1		34.6		23		0.0		0		3.1		
Mean	19.64		34.28		15.8		0.00		0.0		3.02		
+S.D.	0.60		1.56		5.9		0.00		0.0		0.95		
<b>Polyoxyethylene p-nonylphenyl ether</b>													
1000 (mg/kg/day)													
51	19.9		35.3		11		0.0		0		3.9		
52	20.2		35.5		13		0.0		0		2.3		
53	19.2		36.0		19		0.0		0		5.1		
54	20.4		36.5		24		0.0		0		2.7		
55	19.1		35.8		21		0.0		0		1.9		
56	19.7		35.4		22		0.0		0		2.6		
57	20.6		35.3		21		0.0		0		4.6		
58	19.9		35.2		18		0.0		0		3.6		
59	19.6		34.1		16		0.0		0		0.9		
60	19.7		33.9		11		0.0		0		1.3		
Mean	19.90	19.76	34.78	35.82	17.6	17.6	0.00	0.00	0.0	0.0	2.60	3.18	
+S.D.	0.41	0.59	0.72	0.47	4.4	5.5	0.00	0.00	0.0	0.0	1.55	1.31	

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

Group	Anim.No.	N-Seg. (%)		Eosino. (10 <sup>2</sup> /mm <sup>3</sup> )		Eosino. (%)		Baso. (10 <sup>2</sup> /mm <sup>3</sup> )		Baso. (%)		Mono. (10 <sup>2</sup> /mm <sup>3</sup> )	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
11		2		0.0		0		0.0		0		0.5	
12		2		0.0		0		0.0		0		2.3	
13		5		0.8		2		0.0		0		0.0	
14		17		0.0		0		0.0		0		0.4	
15		15		0.4		1		0.0		0		0.4	
16	8		0.4		1		0.0		0		0.4		
17	2		0.4		1		0.0		0		0.7		
18	7		0.8		2		0.0		0		0.0		
19	6		0.0		0		0.0		0		0.6		
20	1		0.4		1		0.0		0		0.0		
Mean		4.8	8.2	0.40	0.24	1.0	0.6	0.00	0.00	0.0	0.0	0.34	0.72
+S.D.		3.1	7.3	0.28	0.36	0.7	0.9	0.00	0.00	0.0	0.0	0.33	0.90
<b>Polyoxyethylene p-nonylphenyl ether</b>													
20 (mg/kg/day)													
26	1		0.0		0		0.0		0		0.5		
27	3		0.0		0		0.0		0		1.1		
28	4		0.0		0		0.0		0		0.5		
29	4		0.0		0		0.0		0		0.4		
30	6		0.5		1		0.0		0		0.5		
Mean		3.6		0.10		0.2		0.00		0.0		0.60	
+S.D.		1.8		0.22		0.4		0.00		0.0		0.28	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
200 (mg/kg/day)													
36	2		0.7		1		0.0		0		0.0		
37	7		0.5		1		0.0		0		1.5		
38	8		0.0		0		0.0		0		0.0		
39	6		0.0		0		0.0		0		0.0		
40	7		0.4		1		0.0		0		0.4		
Mean		6.0		0.32		0.6		0.00		0.0		0.38	
+S.D.		2.3		0.31		0.5		0.00		0.0		0.65	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
1000 (mg/kg/day)													
51		13		0.3		1		0.0		0		0.3	
52		9		0.3		1		0.0		0		0.8	
53		9		0.0		0		0.0		0		0.6	
54		8		0.0		0		0.0		0		0.3	
55		5		0.4		1		0.0		0		0.7	
56	6		0.0		0		0.0		0		1.3		
57	8		0.6		1		0.0		0		0.6		
58	4		0.0		0		0.0		0		0.0		
59	2		0.4		1		0.0		0		0.9		
60	2		0.6		1		0.0		0		0.6		
Mean		4.4	8.8	0.32	0.20	0.6	0.6	0.00	0.00	0.0	0.0	0.68	0.54
+S.D.		2.6	2.9	0.30	0.19	0.5	0.5	0.00	0.00	0.0	0.0	0.48	0.23

## Appendix 7-8 Hematology in female rats

Study No. : SBL79-02

Group	Anim.No.	Mono. (%)		Lymph. (10 <sup>2</sup> /mm <sup>3</sup> )		Lymph. (%)		PT (Sec)		APTT (Sec)	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>											
11		1		43.7		97		7.7		16.2	
12		5		41.9		93		7.8		15.8	
13		0		38.1		93		7.7		17.8	
14		1		31.2		82		7.9		17.8	
15		1		32.4		83		7.9		17.3	
16	1		36.0		90		7.8		17.2		
17	2		35.2		95		7.7		17.3		
18	0		38.2		91		7.7		17.3		
19	1		52.1		93		7.4		17.3		
20	0		43.1		98		7.7		17.8		
Mean		0.8	1.6	40.92	37.46	93.4	89.6	7.66	7.80	17.38	16.98
+S.D.		0.8	1.9	6.97	5.56	3.2	6.7	0.15	0.10	0.24	0.93
<b>Polyoxyethylene p-nonylphenyl ether</b>											
20 (mg/kg/day)											
26	1		45.1		98		7.6		16.5		
27	2		50.4		95		7.7		18.4		
28	1		47.5		95		7.2		14.3		
29	1		36.1		95		7.1		18.2		
30	1		48.8		92		7.4		17.1		
Mean		1.2		45.58		95.0		7.40		16.90	
+S.D.		0.4		5.64		2.1		0.25		1.65	
<b>Polyoxyethylene p-nonylphenyl ether</b>											
200 (mg/kg/day)											
36	0		66.0		97		7.2		16.4		
37	3		43.6		89		7.8		17.0		
38	0		37.7		92		8.0		18.1		
39	0		61.1		94		7.1		16.5		
40	1		40.0		91		7.1		13.8		
Mean		0.8		49.68		92.6		7.44		16.36	
+S.D.		1.3		12.95		3.0		0.43		1.58	
<b>Polyoxyethylene p-nonylphenyl ether</b>											
1000 (mg/kg/day)											
51		1		25.5		85		8.1		18.4	
52		3		21.8		87		7.6		18.3	
53		1		51.3		90		7.5		17.7	
54		1		30.9		91		7.5		16.4	
55		2		34.0		92		7.8		15.9	
56	3		40.0		91		7.3		14.7		
57	1		51.3		90		7.4		17.5		
58	0		87.4		96		7.3		15.7		
59	2		41.8		95		7.2		18.2		
60	1		61.4		96		7.1		16.6		
Mean		1.4	1.6	56.38	32.70	93.6	89.0	7.26	7.70	16.54	17.34
+S.D.		1.1	0.9	19.33	11.42	2.9	2.9	0.11	0.25	1.39	1.13

Blood Chemistry

ASAT	(IU/L)	Aspartate aminotransferase
ALAT	(IU/L)	Alanine aminotransferase
ALP	(IU/L)	Alkaline phosphatase
LDH	(IU/L)	Lactate dehydrogenase
G-GTP	(IU/L)	Gamma - glutamyl transpeptidase
T.Bil.	(mg/dL)	Total bilirubin
T.Prot.	(g/dL)	Total protein
Albumin	(g/dL)	Albumin
A/G		Albumin / Globulin
T.Chol.	(mg/dL)	Total cholesterol
TGL	(mg/dL)	Triglyceride
Glucose	(mg/dL)	Glucose
BUN	(mg/dL)	Blood urea nitrogen
Creat.	(mg/dL)	Creatinine
ChE	(IU/L)	Cholinesterase
IP	(mg/dL)	Inorganic phosphorus
Ca	(mg/dL)	Calcium
Na	(mEq/L)	Sodium
K	(mEq/L)	Potassium
Cl	(mEq/L)	Chloride

## Appendix 8-1 Blood chemistry in male rats

Study No. : SBL79-02

Group	Anim.No.	ASAT (IU/L)		ALAT (IU/L)		ALP (IU/L)		LDH (IU/L)		G-GTP (IU/L)		T.Bil. (mg/dL)	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
1		64		37		217		647		0.3		0.13	
2		127		30		242		3843		0.3		0.14	
3		86		39		309		1511		0.4		0.17	
4		77		31		266		761		0.6		0.15	
5		78		31		181		751		0.2		0.18	
6		103		36		345		1753		0.7		0.10	
7		69		27		312		636		0.9		0.12	
8		64		29		328		575		0.8		0.10	
9		85		27		325		804		1.1		0.11	
10		84		31		246		646		0.1		0.08	
Mean		81.0		86.4		30.0		33.6		311.2		243.0	
+S.D.		15.3		24.0		3.7		4.1		38.3		48.5	
Polyoxyethylene p-nonylphenyl ether										882.8		1502.6	
20 (mg/kg/day)										493.8		1353.2	
21		71		25		401		523		0.3		0.08	
22		92		37		251		978		0.2		0.09	
23		78		27		287		554		0.2		0.09	
24		83		32		359		932		0.7		0.12	
25		79		35		350		748		0.4		0.11	
Mean		80.6		31.2		329.6		747.0		0.36		0.098	
+S.D.		7.7		5.1		59.9		209.2		0.21		0.016	
Polyoxyethylene p-nonylphenyl ether													
200 (mg/kg/day)													
31		78		36		276		965		0.6		0.09	
32		81		30		271		1316		0.3		0.08	
33		81		31		382		1111		0.4		0.08	
34		90		29		346		1771		0.5		0.09	
35		95		30		362		1712		0.5		0.08	
Mean		85.0		31.2		327.4		1375.0		0.46		0.084	
+S.D.		7.2		2.8		50.9		357.7		0.11		0.005	
Polyoxyethylene p-nonylphenyl ether													
1000 (mg/kg/day)													
41		93		32		288		1356		0.5		0.16	
42		69		28		231		496		0.4		0.16	
43		83		26		363		1260		1.1		0.14	
44		71		25		299		629		0.0		0.17	
45		75		42		209		835		0.3		0.17	
46		79		32		268		939		0.4		0.10	
47		119		41		346		1446		0.9		0.09	
48		70		28		254		740		0.2		0.11	
49		74		27		340		378		0.9		0.08	
50		96		32		276		1306		0.5		0.09	
Mean		87.6		78.2		32.0		30.6		296.8		278.0	
+S.D.		20.2		9.9		5.5		6.9		43.0		60.7	
										961.8		915.2	
										431.1		379.9	
										0.58		0.46	
										0.31		0.40	
										0.11		0.011	
										0.094		0.160	
										0.012			

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

## Appendix 8-2 Blood chemistry in male rats

Study No. : SBL79-02

Group	Anim.No.	T.Prot. (g/dL)		Albumin (g/dL)		A/G		T.Chol. (mg/dL)		TGL (mg/dL)		Glucose (mg/dL)	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
1		5.7		4.1		2.54		58		41		146	
2		5.9		4.2		2.47		40		29		169	
3		5.6		4.1		2.61		41		34		164	
4		5.7		4.0		2.45		42		60		188	
5		5.6		4.3		3.09		55		28		173	
6		5.9		4.2		2.40		53		22		134	
7		5.9		4.3		2.63		52		48		149	
8		6.0		4.3		2.41		57		27		155	
9		5.4		4.0		2.95		59		22		154	
10		6.0		4.3		2.46		47		48		161	
Mean		5.84		5.70		4.22		41.4		2.570		2.632	
+S.D.		0.25		0.12		0.13		0.11		0.232		0.264	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
20 (mg/kg/day)													
21		5.7		4.1		2.61		46		32		151	
22		5.6		4.1		2.68		45		30		131	
23		5.4		4.1		3.14		36		14		132	
24		6.0		4.3		2.45		52		25		163	
25		5.7		4.1		2.65		51		22		168	
Mean		5.68		4.14		2.706				46.0		24.6	
+S.D.		0.22		0.09		0.258				6.4		7.1	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
200 (mg/kg/day)													
31		5.9		4.2		2.43		53		23		141	
32		5.4		4.1		3.17		54		27		131	
33		6.0		4.3		2.68		56		28		140	
34		5.5		4.2		3.01		54		38		140	
35		6.0		4.6		3.23		63		53		126	
Mean		5.76		4.28		2.904				56.0		33.8	
+S.D.		0.29		0.19		0.340				4.1		12.1	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
1000 (mg/kg/day)													
41		5.5		3.9		2.46		48		32		153	
42		6.0		4.1		2.13		75		37		163	
43		5.2		3.7		2.42		49		22		161	
44		5.9		4.1		2.22		44		17		156	
45		6.0		4.2		2.42		37		23		178	
46		6.0		4.3		2.54		52		24		163	
47		5.4		4.0		2.82		40		22		157	
48		6.0		4.2		2.31		57		22		147	
49		5.6		4.1		2.82		43		32		121	
50		5.7		4.0		2.35		29		15		103	
Mean		5.74		5.72		4.12		4.00		2.568		2.330	
+S.D.		0.26		0.36		0.13		0.20		0.246		0.146	

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

## Appendix 8-3 Blood chemistry in male rats

Study No. : SBL79-02

Group	Anim.No.	BUN (mg/dL)		Creat. (mg/dL)		ChE (IU/L)		IP (mg/dL)		Ca (mg/dL)		Na (mEq/L)	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
1		16.8		0.55		380		7.07		9.7		141	
2		19.3		0.52		338		7.16		9.5		143	
3		19.3		0.49		412		7.64		9.9		141	
4		18.0		0.52		308		8.41		10.2		141	
5		13.5		0.46		401		7.33		9.8		140	
6		21.7		0.62		453		9.46		10.4		141	
7		17.8		0.61		690		9.17		10.4		140	
8		18.7		0.46		434		8.57		10.0		144	
9		18.8		0.46		449		8.39		10.4		145	
10		20.4		0.42		355		9.13		10.8		144	
Mean		19.48		17.38		0.514		0.508		476.2		367.8	
+S.D.		1.55		2.41		0.094		0.034		126.0		43.8	
Polyoxyethylene p-nonylphenyl ether													
20 (mg/kg/day)													
21		16.6		0.45		311		8.99		10.3		145	
22		16.4		0.46		321		9.57		10.1		146	
23		16.4		0.40		396		9.01		10.1		145	
24		16.9		0.54		443		9.80		10.0		144	
25		21.2		0.52		285		9.73		10.8		144	
Mean		17.50		0.474		351.2		9.420		10.26		144.8	
+S.D.		2.08		0.056		65.8		0.392		0.32		0.8	
Polyoxyethylene p-nonylphenyl ether													
200 (mg/kg/day)													
31		21.1		0.46		418		8.83		9.4		144	
32		18.6		0.46		338		9.50		9.9		147	
33		19.2		0.46		402		9.13		10.5		144	
34		20.1		0.40		357		10.15		10.0		145	
35		17.4		0.46		557		10.34		10.9		145	
Mean		19.28		0.448		414.4		9.590		10.14		145.0	
+S.D.		1.41		0.027		86.1		0.647		0.58		1.2	
Polyoxyethylene p-nonylphenyl ether													
1000 (mg/kg/day)													
41		21.6		0.64		463		8.13		9.6		144	
42		15.3		0.48		510		8.26		10.3		143	
43		22.5		0.54		385		8.59		9.8		142	
44		14.2		0.50		269		7.16		10.2		144	
45		23.5		0.63		283		8.18		10.0		143	
46		25.2		0.50		385		9.61		10.2		144	
47		15.6		0.47		370		9.40		10.3		142	
48		17.3		0.48		433		9.47		10.8		145	
49		15.8		0.41		410		9.64		10.8		146	
50		19.6		0.42		435		9.97		10.8		144	
Mean		18.70		19.42		0.456		0.558		406.6		382.0	
+S.D.		3.97		4.33		0.039		0.074		28.8		106.7	

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

## Appendix 8-4 Blood chemistry in male rats

Study No. : SBL79-02

Group	Anim.No.	K (mEq/L)		Cl (mEq/L)	
		4w	R:2w	4w	R:2w
<b>Control</b>					
1		3.9		102	
2		3.8		103	
3		4.0		103	
4		3.8		101	
5		3.8		101	
6		4.4		102	
7		3.8		101	
8		3.8		103	
9		4.0		102	
10		3.5		99	
Mean		3.90	3.86	101.4	102.0
+S.D.		0.33	0.09	1.5	1.0
<b>Polyoxyethylene p-nonylphenyl ether</b>					
20 (mg/kg/day)					
21		3.6		105	
22		4.0		105	
23		3.7		105	
24		3.9		101	
25		4.1		103	
Mean		3.86		103.8	
+S.D.		0.21		1.8	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
200 (mg/kg/day)					
31		4.3		104	
32		3.8		106	
33		4.0		104	
34		4.0		104	
35		4.4		102	
Mean		4.10		104.0	
+S.D.		0.24		1.4	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
1000 (mg/kg/day)					
41		4.1		101	
42		3.7		101	
43		4.0		102	
44		3.6		101	
45		3.7		101	
46		4.3		100	
47		3.8		103	
48		4.1		103	
49		3.6		105	
50		4.3		106	
Mean		4.02	3.82	103.4	101.2
+S.D.		0.31	0.22	2.3	0.4

Group	Anim.No.	ASAT (IU/L)		ALAT (IU/L)		ALP (IU/L)		LDH (IU/L)		G-GTP (IU/L)		T.Bil. (mg/dL)	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
11		67		21		129		1096		0.2		0.17	
12		98		25		182		2283		1.6		0.18	
13		63		24		121		925		0.8		0.17	
14		73		28		195		817		1.0		0.15	
15		102		27		240		2680		1.0		0.20	
16		92		15		245		1928		0.8		0.09	
17		67		18		287		997		0.8		0.11	
18		85		23		164		1547		1.0		0.09	
19		133		27		194		3067		1.0		0.10	
20		106		21		185		2508		0.7		0.11	
Mean		96.6		80.6		20.8		215.0		173.4		2009.4	
+S.D.		24.7		18.1		4.6		50.1		49.2		808.2	
Polyoxyethylene p-nonylphenyl ether													
20 (mg/kg/day)													
26		124		19		212		3317		1.0		0.11	
27		98		23		259		1836		1.4		0.08	
28		106		26		238		2482		1.3		0.11	
29		87		15		217		1764		0.2		0.11	
30		113		27		176		2730		0.6		0.10	
Mean		105.6		22.0		220.4		2425.8				0.90	
+S.D.		14.1		5.0		31.0		647.3				0.50	
Polyoxyethylene p-nonylphenyl ether													
200 (mg/kg/day)													
36		85		23		253		1031		0.7		0.07	
37		102		21		270		1856		1.2		0.10	
38		103		31		226		1804		1.2		0.08	
39		110		26		313		1151		0.5		0.10	
40		103		25		145		2285		1.7		0.06	
Mean		100.6		25.2		241.4		1625.4				1.06	
+S.D.		9.3		3.8		62.5		524.0				0.47	
Polyoxyethylene p-nonylphenyl ether													
1000 (mg/kg/day)													
51		106		26		185		2546		1.2		0.15	
52		79		20		231		1244		0.7		0.17	
53		104		45		157		902		0.4		0.18	
54		111		36		243		1462		1.4		0.20	
55		80		24		193		524		0.4		0.19	
56		81		19		144		1200		1.2		0.07	
57		77		21		235		925		0.4		0.12	
58		77		20		177		1174		1.0		0.06	
59		68		18		213		919		0.6		0.09	
60		103		20		177		2559		0.4		0.09	
Mean		81.2		96.0		19.6		30.2		189.2		201.8	
+S.D.		13.1		15.3		1.1		10.2		35.4		35.1	
LDH													
G-GTP													
T.Bil.													

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

## Appendix 8-6 Blood chemistry in female rats

Study No. : SBL79-02

Group	Anim.No.	T.Prot. (g/dL)		Albumin (g/dL)		A/G		T.Chol. (mg/dL)		TGL (mg/dL)		Glucose (mg/dL)	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
11		5.9		4.3		2.62		44		5		167	
12		5.8		4.4		3.02		47		9		150	
13		6.7		4.7		2.40		74		27		139	
14		5.7		4.0		2.37		62		8		119	
15		5.7		4.2		2.75		60		6		111	
16		5.5		4.1		3.00		41		8		155	
17		5.8		4.4		3.19		54		20		156	
18		5.8		4.3		2.99		55		15		157	
19		6.0		4.4		2.68		70		11		130	
20		5.6		4.2		3.19		57		12		142	
Mean		5.74		5.96		4.28		4.32		3.010		2.632	
+S.D.		0.19		0.42		0.13		0.26		0.209		0.268	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
20 (mg/kg/day)													
26		5.6		4.2		3.06		48		6		124	
27		5.8		4.2		2.69		58		9		118	
28		6.3		4.5		2.62		64		12		125	
29		6.5		4.8		2.85		66		9		127	
30		5.6		4.2		3.05		65		17		130	
Mean		5.96		4.38		2.854				60.2		10.6	
+S.D.		0.42		0.27		0.202				7.5		4.2	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
200 (mg/kg/day)													
36		6.4		4.5		2.51		68		10		144	
37		5.0		3.8		3.28		46		11		146	
38		5.9		4.2		2.48		53		12		139	
39		5.6		4.3		3.38		70		14		156	
40		6.3		4.7		2.92		73		14		153	
Mean		5.84		4.30		2.914				62.0		12.2	
+S.D.		0.57		0.34		0.419				11.8		1.8	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
1000 (mg/kg/day)													
51		6.2		4.3		2.17		56		4		129	
52		5.9		4.3		2.63		59		8		143	
53		6.7		4.6		2.14		81		8		106	
54		6.0		4.3		2.52		55		4		130	
55		6.4		4.3		2.16		65		12		144	
56		6.3		4.8		3.01		80		16		141	
57		5.7		4.5		3.60		54		15		122	
58		6.3		4.5		2.58		72		18		143	
59		5.7		4.3		3.19		72		13		147	
60		6.0		4.4		2.91		76		14		136	
Mean		6.00		6.24		4.50		4.36		3.058		2.324	
+S.D.		0.30		0.32		0.19		0.13		0.375		0.233	
4w													
R:2w													

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

## Appendix 8-7 Blood chemistry in female rats

Study No. : SBL79-02

Group	Anim.No.	BUN (mg/dL)		Creat. (mg/dL)		ChE (IU/L)		IP (mg/dL)		Ca (mg/dL)		Na (mEq/L)	
		4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w	4w	R:2w
<b>Control</b>													
11		17.5		0.59		2116		6.59		10.2		141	
12		18.3		0.55		1371		4.52		9.7		142	
13		13.4		0.46		2183		4.77		10.0		144	
14		17.9		0.57		933		6.01		9.8		144	
15		19.8		0.50		1156		7.59		9.8		141	
16	22.5		0.46		1233		7.51		9.6		144		
17	21.0		0.49		1364		8.59		10.1		144		
18	22.9		0.53		1331		7.66		10.0		144		
19	21.4		0.58		1837		7.41		10.3		143		
20	26.9		0.57		1824		8.12		9.6		145		
Mean	22.94	17.38	0.526	0.534	1517.8	1551.8	7.858	5.896	9.92	9.90	144.0	142.4	
+S.D.	2.35	2.39	0.051	0.053	289.5	567.7	0.491	1.277	0.31	0.20	0.7	1.5	
<b>Polyoxyethylene p-nonylphenyl ether</b>													
20 (mg/kg/day)													
26	21.9		0.51		2286		7.92		10.1		145		
27	22.1		0.49		1201		8.55		9.9		145		
28	22.2		0.50		1730		9.55		10.5		147		
29	20.3		0.45		2212		7.54		10.6		146		
30	18.3		0.43		1478		8.89		10.0		144		
Mean	20.96		0.476		1781.4		8.490		10.22		145.4		
+S.D.	1.68		0.034		466.8		0.793		0.31		1.1		
<b>Polyoxyethylene p-nonylphenyl ether</b>													
200 (mg/kg/day)													
36	25.1		0.54		1823		8.18		10.6		145		
37	23.3		0.52		676		8.46		10.2		146		
38	20.0		0.50		1274		7.97		10.3		145		
39	18.5		0.55		1778		7.17		9.8		144		
40	25.4		0.63		1483		7.20		10.7		143		
Mean	22.46		0.548		1406.8		7.796		10.32		144.6		
+S.D.	3.08		0.050		466.0		0.584		0.36		1.1		
<b>Polyoxyethylene p-nonylphenyl ether</b>													
1000 (mg/kg/day)													
51	18.0		0.57		1568		5.70		9.8		145		
52	21.0		0.58		1290		7.16		9.8		142		
53	20.1		0.57		1945		6.00		10.1		142		
54	17.2		0.54		1786		6.08		9.7		142		
55	18.6		0.69		1415		6.28		9.6		144		
56	27.2		0.54		1505		7.66		10.1		147		
57	25.1		0.60		1362		9.55		10.7		144		
58	31.2		0.68		1769		9.11		10.6		141		
59	18.5		0.45		1946		8.60		10.5		146		
60	23.4		0.46		1085		9.64		10.4		147		
Mean	25.08	18.98	0.546	0.590	1533.4	1600.8	8.912	6.244	10.46	9.80	145.0	143.0	
+S.D.	4.69	1.55	0.097	0.058	338.0	266.9	0.813	0.553	0.23	0.19	2.5	1.4	

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

## Appendix 8-8 Blood chemistry in female rats

Study No. : SBL79-02

Group	Anim.No.	K (mEq/L)		Cl (mEq/L)	
		4w	R:2w	4w	R:2w
<b>Control</b>					
11		3.8		104	
12		4.0		104	
13		3.5		107	
14		3.6		107	
15		4.1		103	
16		3.8		105	
17		3.5		104	
18		4.0		106	
19		3.9		106	
20		3.9		105	
Mean		3.82	3.80	105.4	105.0
+S.D.		0.19	0.25	0.9	1.9
<b>Polyoxyethylene p-nonylphenyl ether</b>					
20 (mg/kg/day)					
26		4.1		107	
27		3.6		108	
28		3.6		106	
29		3.5		107	
30		3.9		105	
Mean		3.74		106.6	
+S.D.		0.25		1.1	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
200 (mg/kg/day)					
36		3.9		106	
37		3.7		109	
38		3.7		106	
39		3.6		107	
40		4.1		106	
Mean		3.80		106.8	
+S.D.		0.20		1.3	
<b>Polyoxyethylene p-nonylphenyl ether</b>					
1000 (mg/kg/day)					
51		3.9		108	
52		3.4		105	
53		3.6		105	
54		3.7		105	
55		3.0		105	
56		3.8		108	
57		3.9		107	
58		3.7		105	
59		3.7		109	
60		4.1		110	
Mean		3.84	3.52	107.8	105.6
+S.D.		0.17	0.34	1.9	1.3

**Gross Autopsy Findings**

**Grade**

- : No abnormal changes
- + : Slight
- ++ : Moderate
- +++ : Marked
- P : Non-graded changes

## Appendix 9-1 Gross autopsy findings in male rats (End of drug administration)

Study No. : SBL79-02

Findings	Animal No.	Control					Polyoxyethylene p-nonylphenyl ether														
							20			200				1000							
		6	7	8	9	10	21	22	23	24	25	31	32	33	34	35	46	47	48	49	50
<b>Lung</b>																					
Black focus, single		-	-	-	-	P	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Black focus, several		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	P	-	-	-	-
Red focus, several		P	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Red focus, single		-	-	-	-	-	-	-	-	-	P	-	-	-	P	-	-	P	-	-	-
<b>Liver</b>																					
White focus, single		-	-	-	-	-	-	-	P	-	-	-	P	-	-	-	-	-	-	-	-
<b>Kidney</b>																					
Cyst, single, right		-	-	-	-	-	-	-	-	P	-	-	-	-	-	-	-	-	-	-	-

## Appendix 9-2 Gross autopsy findings in female rats (End of drug administration)

Study No. : SBL79-02

Findings	Animal No.	Control					Polyoxyethylene p-nonylphenyl ether														
							20			200				1000							
		16	17	18	19	20	26	27	28	29	30	36	37	38	39	40	56	57	58	59	60
Lung																					
Red focus, single		-	-	-	-	P	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liver																					
White focus, single		P	P	-	-	-	-	-	-	-	-	-	-	P	-	-	P	P	-	-	-
Kidney																					
Cyst, single, right		-	-	-	-	-	-	-	-	-	-	-	-	P	-	-	-	-	-	-	-

## Appendix 9-3 Gross autopsy findings in male rats (End of recovery test)

Study No. : SBL79-02

Findings	Animal No.	Control					Polyoxyethylene p-nonylphenyl ether						
		Dose (mg/kg/day)					20	200	1000				
		1	2	3	4	5			41	42	43	44	45
Lung													
Black focus, several		-	-	-	P	-			-	-	-	-	-
Liver													
White focus, single		-	-	P	-	P			-	-	-	P	-
Adrenal													
Asymmetry, size		-	-	-	-	-			-	P	-	-	-

## Appendix 9-4 Gross autopsy findings in female rats (End of recovery test)

Study No. : SBL79-02

Findings	Group	Control	Polyoxyethylene p-nonylphenyl ether											
			Dose (mg/kg/day)					20	200	1000				
			Animal No.	11	12	13	14	15	51	52	53	54	55	
Lung				-	-	-	-	-	-	-	P	-		
Black focus, several				-	-	-	-	-	-	-	-	P	-	
Liver				-	-	-	-	-	-	-	P	-	P	
White focus, single				-	-	-	-	P	-	-	P	-	P	

**Organ weight**

Adre.R	Adrenal (Right)
Adre.L	Adrenal (Left)
Testi.R	Testis (Right)
Testi.L	Testis (Left)
Ovary.R	Ovary (Right)
Ovary.L	Ovary (Left)
Kid.R	Kidney (Right)
Kid.L	Kidney (Left)
Epid.R	Epididymis (Right)
Epid.L	Epididymis (Left)

## Appendix 10-1 Organ weight in male rats (End of drug administration)

Study No. : SBL79-02

Group	Anim.No.	Adre.R mg	Adre.L mg	Testi.R mg	Testi.L mg	Thymus mg	Spleen mg	Brain mg	Heart mg	Liver g	Kid.R mg	Kid.L mg	Epid.R mg
<b>Control</b>													
	6	18.2	20.1	1316	1343	371	519	1774	872	7.39	1071	1028	310
	7	35.8	35.8	978	1354	583	958	2084	1405	13.04	1684	1588	211
	8	30.6	31.5	1645	1645	643	681	2035	1077	11.59	1489	1424	382
	9	32.8	32.7	1418	1388	552	579	1939	1120	10.60	1443	1362	384
	10	29.2	27.1	1441	1449	623	624	1963	1239	11.31	1315	1353	409
	Mean	29.32	29.44	1359.6	1435.8	554.4	672.2	1959.0	1142.6	10.786	1400.4	1351.0	339.2
	+S.D.	6.70	6.08	244.4	124.0	108.4	170.5	118.4	197.6	2.096	226.9	203.7	80.6
<b>Polyoxyethylene p-nonylphenyl ether</b>													
	20 (mg/kg/day)												
	21	22.6	23.9	1311	1299	443	696	1817	1101	9.38	1231	1264	388
	22	25.7	24.5	1419	1415	626	634	2049	1140	10.52	1382	1426	418
	23	25.7	28.7	1554	1490	427	707	1948	1102	8.68	1363	1391	413
	24	29.7	31.2	1577	1543	552	673	1931	1084	10.18	1330	1289	387
	25	26.1	32.4	1443	1469	438	550	1962	1105	9.45	1345	1208	389
	Mean	25.96	28.14	1460.8	1443.2	497.2	652.0	1941.4	1106.4	9.642	1330.2	1315.6	399.0
	+S.D.	2.52	3.84	108.0	92.7	88.0	63.5	83.1	20.5	0.723	58.8	90.6	15.2
<b>Polyoxyethylene p-nonylphenyl ether</b>													
	200 (mg/kg/day)												
	31	28.6	30.6	1516	1519	399	674	1992	1274	9.92	1268	1279	416
	32	28.3	33.1	610	650	437	747	1945	1110	10.43	1347	1339	310
	33	26.7	26.8	1430	1434	409	678	2046	1195	11.09	1382	1394	411
	34	25.2	31.6	1305	1278	388	610	1862	1083	8.75	1156	1129	375
	35	29.2	30.2	1483	1484	347	440	1913	1003	7.56	1003	945	342
	Mean	27.60	30.46	1268.8	1273.0	396.0	629.8	1951.6	1133.0	9.550	1231.2	1217.2	370.8
	+S.D.	1.63	2.33	376.9	360.2	32.9	116.6	70.9	104.5	1.404	154.3	181.5	45.3
<b>Polyoxyethylene p-nonylphenyl ether</b>													
	1000 (mg/kg/day)												
	46	28.2	31.9	1626	1610	729	664	2073	1055	10.35	1418	1378	409
	47	37.4	33.3	1253	1306	747	843	1821	1233	11.35	1706	1689	353
	48	22.4	25.4	1491	1481	602	721	1874	1129	12.21	1366	1447	400
	49	32.5	30.4	1197	1267	567	891	1993	1117	13.51	1438	1419	310
	50	39.4	40.6	1370	1369	323	551	1780	984	8.53	1256	1283	387
	Mean	31.98	32.32	1387.4	1406.6	593.6	734.0	1908.2	1103.6	11.190	1436.8	1443.2	371.8
	+S.D.	6.91	5.51	174.8	139.6	170.2	137.0	122.0	92.5	1.886	166.2	150.8	40.6

## Appendix 10-2 Organ weight in male rats (End of drug administration)

Study No. : SBL79-02

Group	Anim.No.	Epid.L mg
-------	----------	--------------

## Control

6	315
7	281
8	403
9	365
10	404

Mean 353.6  
+S.D. 54.5

Polyoxyethylene p-nonylphenyl ether  
20 (mg/kg/day)

21	386
22	409
23	398
24	343
25	368

Mean 380.8  
+S.D. 26.0

Polyoxyethylene p-nonylphenyl ether  
200 (mg/kg/day)

31	396
32	293
33	419
34	384
35	361

Mean 370.6  
+S.D. 48.2

Polyoxyethylene p-nonylphenyl ether  
1000 (mg/kg/day)

46	409
47	335
48	416
49	323
50	357

Mean 368.0  
+S.D. 42.5

## Appendix 10-3 Organ weight in male rats (End of recovery test)

Study No. : SBL79-02

Group	Anim.No.	Adre.R mg	Adre.L mg	Testi.R mg	Testi.L mg	Thymus mg	Spleen mg	Brain mg	Heart mg	Liver g	Kid.R mg	Kid.L mg	Epid.R mg
<b>Control</b>													
	1	26.6	27.6	1340	1369	527	703	1955	1439	12.92	1596	1506	540
	2	30.1	32.1	1458	1490	609	666	1934	1065	10.90	1404	1384	540
	3	36.4	39.5	1404	1391	457	615	1949	1303	10.51	1339	1392	520
	4	30.3	33.4	1367	1355	648	915	2068	1447	15.54	1753	1749	508
	5	27.9	30.7	1576	1578	431	645	1931	1373	10.70	1421	1393	540
	Mean	30.26	32.66	1429.0	1436.6	534.4	708.8	1967.4	1325.4	12.114	1502.6	1484.8	529.6
	+S.D.	3.76	4.39	93.3	95.1	93.8	119.6	57.1	156.7	2.147	169.2	156.1	14.9
<b>Polyoxyethylene p-nonylphenyl ether</b>													
	1000 (mg/kg/day)												
	41	24.7	26.7	1290	1284	385	572	1922	1198	9.07	1107	1102	413
	42	13.6	31.8	1741	1718	534	817	2014	1281	13.64	1666	1709	589
	43	31.7	33.6	1508	1510	465	760	2167	1379	11.58	1593	1633	476
	44	35.3	40.7	1580	1614	514	790	2029	1317	11.72	1621	1704	526
	45	28.1	26.5	1506	1523	422	617	1889	1347	12.24	1386	1459	532
	Mean	26.68	31.86	1525.0	1529.8	464.0	711.2	2004.2	1304.4	11.650	1474.6	1521.4	507.2
	+S.D.	8.31	5.84	162.4	160.8	62.1	109.6	108.7	69.7	1.656	231.9	255.3	66.2

## Appendix 10-4 Organ weight in male rats (End of recovery test)

Study No. : SBL79-02

Group	Anim.No.	Epid.L mg
Control		
1		530
2		553
3		480
4		499
5		538
Mean		520.0
+S.D.		29.8
Polyoxyethylene p-nonylphenyl ether 1000 (mg/kg/day)		
41		422
42		625
43		490
44		487
45		531
Mean		511.0
+S.D.		74.7

## Appendix 10-5 Organ weight in female rats (End of drug administration)

Study No. : SBL79-02

Group	Anim.No.	Adre.R mg	Adre.L mg	Ovary.R mg	Ovary.L mg	Thymus mg	Spleen mg	Brain mg	Heart mg	Liver g	Kid.R mg	Kid.L mg
<b>Control</b>												
	16	35.2	35.7	54.5	45.1	608	608	1756	810	7.34	966	994
	17	34.2	38.2	50.7	46.6	649	564	1845	979	8.54	1090	1076
	18	24.8	26.4	48.3	44.5	399	415	1972	746	6.40	821	889
	19	26.4	31.5	33.5	35.9	544	529	1872	761	6.43	920	832
	20	26.8	29.9	40.4	42.7	413	444	1815	826	6.49	900	826
	Mean	29.48	32.34	45.48	42.96	522.6	512.0	1852.0	824.4	7.040	939.4	923.4
	+S.D.	4.84	4.68	8.45	4.19	112.9	81.0	79.7	92.6	0.925	99.2	108.7
<b>Polyoxyethylene p-nonylphenyl ether</b>												
	20 (mg/kg/day)											
	26	28.7	29.4	39.7	44.6	494	405	1820	658	5.55	769	736
	27	39.4	38.9	63.4	52.9	539	509	1829	753	7.11	1008	1043
	28	29.7	32.9	36.9	35.2	454	481	1804	747	6.77	866	838
	29	30.8	29.6	37.3	37.2	539	561	1869	776	6.60	930	892
	30	35.4	44.9	49.4	46.6	565	431	1972	806	7.13	1018	1013
	Mean	32.80	35.14	45.34	43.30	518.2	477.4	1858.8	748.0	6.632	918.2	904.4
	+S.D.	4.49	6.67	11.30	7.20	44.1	62.0	67.7	55.4	0.646	103.9	126.4
<b>Polyoxyethylene p-nonylphenyl ether</b>												
	200 (mg/kg/day)											
	36	31.6	40.8	46.5	36.5	444	455	2049	846	6.70	890	855
	37	33.1	36.5	53.3	43.3	323	398	1834	858	6.27	955	945
	38	35.3	42.2	48.9	55.9	478	517	1857	944	8.11	1117	1126
	39	37.3	36.2	29.7	47.5	300	511	1814	738	5.77	757	705
	40	37.5	39.3	35.4	43.4	390	404	1660	802	6.85	897	917
	Mean	34.96	39.00	42.76	45.32	387.0	457.0	1842.8	837.6	6.740	923.2	909.6
	+S.D.	2.59	2.63	9.84	7.11	76.2	56.6	138.8	75.8	0.874	130.4	152.5
<b>Polyoxyethylene p-nonylphenyl ether</b>												
	1000 (mg/kg/day)											
	56	31.2	27.8	31.4	26.1	569	440	1781	834	7.50	964	939
	57	32.7	33.9	31.9	52.9	371	461	1854	817	6.68	860	830
	58	28.6	32.2	51.2	46.9	587	447	1792	784	7.39	873	866
	59	41.4	44.9	47.9	50.6	471	473	1699	768	6.75	801	811
	60	32.9	35.9	37.1	37.6	615	401	1780	881	6.90	912	951
	Mean	33.36	34.94	39.90	42.82	522.6	444.4	1781.2	816.8	7.044	882.0	879.4
	+S.D.	4.81	6.32	9.16	11.02	100.6	27.4	55.2	44.4	0.377	60.7	63.2

## Appendix 10-6 Organ weight in female rats (End of recovery test)

Study No. : SBL79-02

Group	Anim.No.	Adre.R mg	Adre.L mg	Ovary.R mg	Ovary.L mg	Thymus mg	Spleen mg	Brain mg	Heart mg	Liver g	Kid.R mg	Kid.L mg
<b>Control</b>												
	11	32.3	28.5	46.4	56.5	392	578	1850	874	6.89	959	983
	12	25.4	26.5	21.9	36.2	370	487	1790	746	6.19	895	904
	13	35.8	36.4	50.3	51.6	530	574	1903	894	8.55	1060	1084
	14	24.4	30.1	51.2	44.8	347	571	1859	852	6.51	944	914
	15	25.5	29.8	47.1	41.2	386	494	1978	739	6.14	984	977
	Mean	28.68	30.26	43.38	46.06	405.0	540.8	1876.0	821.0	6.856	968.4	972.4
	+S.D.	5.07	3.71	12.18	8.09	72.0	46.1	69.8	73.2	0.993	60.6	71.9
<b>Polyoxyethylene p-nonylphenyl ether 1000 (mg/kg/day)</b>												
	51	30.7	39.5	37.2	37.2	357	428	1832	844	5.80	894	877
	52	32.5	33.1	35.9	31.6	387	357	1856	811	6.52	940	938
	53	34.3	36.7	52.2	41.2	299	506	1883	771	6.20	835	796
	54	36.2	36.6	56.4	47.6	500	406	1816	804	5.99	833	805
	55	33.3	30.8	64.2	47.4	491	543	1839	844	7.32	965	895
	Mean	33.40	35.34	49.18	41.00	406.8	448.0	1845.2	814.8	6.366	893.4	862.2
	+S.D.	2.05	3.40	12.32	6.84	87.0	75.6	25.5	30.6	0.596	59.9	60.6

## Appendix 10-7 Relative organ weight in male rats (End of drug administration)

Study No. : SBL79-02

Group	Anim.No.	BW (g)	Adre.R mg/100gBW	Adre.L mg/100gBW	Testi.R mg/100gBW	Testi.L mg/100gBW	Thymus mg/100gBW	Spleen mg/100gBW	Brain mg/100gBW	Heart mg/100gBW	Liver g/100gBW	Kid.R mg/100gBW	Kid.L mg/100gBW	Epid.R mg/100gBW
<b>Control</b>														
	6	( 264)	6.9	7.6	498	509	141	197	672	330	2.80	406	389	117
	7	( 380)	9.4	9.4	257	356	153	252	548	370	3.43	443	418	56
	8	( 334)	9.2	9.4	493	493	193	204	609	322	3.47	446	426	114
	9	( 345)	9.5	9.5	411	402	160	168	562	325	3.07	418	395	111
	10	( 329)	8.9	8.2	438	440	189	190	597	377	3.44	400	411	124
	Mean	(330.4)	8.78	8.82	419.4	440.0	167.2	202.2	597.6	344.8	3.242	422.6	407.8	104.4
	+S.D.	( 42.1)	1.08	0.87	98.0	63.4	22.8	30.9	48.5	26.5	0.296	21.0	15.5	27.5
<b>Polyoxyethylene p-nonylphenyl ether</b>														
20 (mg/kg/day)														
	21	( 296)	7.6	8.1	443	439	150	235	614	372	3.17	416	427	131
	22	( 340)	7.6	7.2	417	416	184	186	603	335	3.09	406	419	123
	23	( 292)	8.8	9.8	532	510	146	242	667	377	2.97	467	476	141
	24	( 328)	9.1	9.5	481	470	168	205	589	330	3.10	405	393	118
	25	( 308)	8.5	10.5	469	477	142	179	637	359	3.07	437	392	126
	Mean	(312.8)	8.32	9.02	468.4	462.4	158.0	209.4	622.0	354.6	3.080	426.2	421.4	127.8
	+S.D.	( 20.7)	0.69	1.34	43.3	36.2	17.6	28.3	30.7	21.3	0.072	26.2	34.2	8.8
<b>Polyoxyethylene p-nonylphenyl ether</b>														
200 (mg/kg/day)														
	31	( 296)	9.7	10.3	512	513	135	228	673	430	3.35	428	432	141
	32	( 338)	8.4	9.8	180	192	129	221	575	328	3.09	399	396	92
	33	( 328)	8.1	8.2	436	437	125	207	624	364	3.38	421	425	125
	34	( 278)	9.1	11.4	469	460	140	219	670	390	3.15	416	406	135
	35	( 251)	11.6	12.0	591	591	138	175	762	400	3.01	400	376	136
	Mean	(298.2)	9.38	10.34	437.6	438.6	133.4	210.0	660.8	382.4	3.196	412.8	407.0	125.8
	+S.D.	( 35.8)	1.39	1.48	155.3	150.0	6.3	21.0	69.3	38.5	0.162	12.9	22.5	19.8
<b>Polyoxyethylene p-nonylphenyl ether</b>														
1000 (mg/kg/day)														
	46	( 311)	9.1	10.3	523	518	234	214	667	339	3.33	456	443	132
	47	( 349)	10.7	9.5	359	374	214	242	522	353	3.25	489	484	101
	48	( 344)	6.5	7.4	433	431	175	210	545	328	3.55	397	421	116
	49	( 362)	9.0	8.4	331	350	157	246	551	309	3.73	397	392	86
	50	( 269)	14.6	15.1	509	509	120	205	662	366	3.17	467	477	144
	Mean	(327.0)	9.98	10.14	431.0	436.4	180.0	223.4	589.4	339.0	3.406	441.2	443.4	115.8
	+S.D.	( 37.5)	2.99	2.98	86.2	76.3	45.3	19.1	69.4	22.1	0.230	42.1	38.5	23.3

試験結果報告書の内容に関するお問い合わせには応じかねますので御了承下さい。

## Appendix 10-8 Relative organ weight in male rats (End of drug administration)

Study No. : SBL79-02

Group	Anim.No.	Epid.L mg/100gBW
<b>Control</b>		
6		119
7		74
8		121
9		106
10		123
Mean	(330.4)	108.6
+S.D.	( 42.1)	20.5
<b>Polyoxyethylene p-nonylphenyl ether</b>		
20 (mg/kg/day)		
21		130
22		120
23		136
24		105
25		119
Mean	(312.8)	122.0
+S.D.	( 20.7)	11.9
<b>Polyoxyethylene p-nonylphenyl ether</b>		
200 (mg/kg/day)		
31		134
32		87
33		128
34		138
35		144
Mean	(298.2)	126.2
+S.D.	( 35.8)	22.7
<b>Polyoxyethylene p-nonylphenyl ether</b>		
1000 (mg/kg/day)		
46		132
47		96
48		121
49		89
50		133
Mean	(327.0)	114.2
+S.D.	( 37.5)	20.5

## Appendix 10-9 Relative organ weight in male rats (End of recovery test)

Study No. : SBL79-02

Group	Anim.No.	BW (g)	Adre.R mg/100gBW	Adre.L mg/100gBW	Testi.R mg/100gBW	Testi.L mg/100gBW	Thymus mg/100gBW	Spleen mg/100gBW	Brain mg/100gBW	Heart mg/100gBW	Liver g/100gBW	Kid.R mg/100gBW	Kid.L mg/100gBW	Epid.R mg/100gBW
<b>Control</b>														
	1	( 406)	6.6	6.8	330	337	130	173	482	354	3.18	393	371	133
	2	( 358)	8.4	9.0	407	416	170	186	540	297	3.04	392	387	151
	3	( 354)	10.3	11.2	397	393	129	174	551	368	2.97	378	393	147
	4	( 435)	7.0	7.7	314	311	149	210	475	333	3.57	403	402	117
	5	( 346)	8.1	8.9	455	456	125	186	558	397	3.09	411	403	156
	Mean	(379.8)	8.08	8.72	380.6	382.6	140.6	185.8	521.2	349.8	3.170	395.4	391.2	140.8
	+S.D.	( 38.8)	1.45	1.66	58.1	58.8	18.9	14.9	39.6	37.6	0.236	12.5	13.1	15.8
Polyoxyethylene p-nonylphenyl ether 1000 (mg/kg/day)														
	41	( 328)	7.5	8.1	393	391	117	174	586	365	2.77	338	336	126
	42	( 422)	3.2	7.5	413	407	127	194	477	304	3.23	395	405	140
	43	( 384)	8.3	8.8	393	393	121	198	564	359	3.02	415	425	124
	44	( 377)	9.4	10.8	419	428	136	210	538	349	3.11	430	452	140
	45	( 380)	7.4	7.0	396	401	111	162	497	354	3.22	365	384	140
	Mean	(378.2)	7.16	8.44	402.8	404.0	122.4	187.6	532.4	346.2	3.070	388.6	400.4	134.0
	+S.D.	( 33.5)	2.35	1.48	12.3	14.9	9.6	19.3	45.3	24.3	0.189	37.3	43.9	8.2

## Appendix 10-10 Relative organ weight in male rats (End of recovery test)

Study No. : SBL79-02

Group	Anim.No.	Epid.L mg/100gBW
Control		
1		131
2		154
3		136
4		115
5		155
Mean	(379.8)	138.2
+S.D.	( 38.8)	16.8
Polyoxyethylene p-nonylphenyl ether 1000 (mg/kg/day)		
41		129
42		148
43		128
44		129
45		140
Mean	(378.2)	134.8
+S.D.	( 33.5)	8.9

## Appendix 10-11 Relative organ weight in female rats (End of drug administration)

Study No. : SBL79-02

Group	Anim.No.	BW (g)	Adre.R mg/100gBW	Adre.L mg/100gBW	Ovary.R mg/100gBW	Ovary.L mg/100gBW	Thymus mg/100gBW	Spleen mg/100gBW	Brain mg/100gBW	Heart mg/100gBW	Liver g/100gBW	Kid.R mg/100gBW	Kid.L mg/100gBW
<b>Control</b>													
	16	( 233)	15.1	15.3	23.4	19.4	261	261	754	348	3.15	415	427
	17	( 249)	13.7	15.3	20.4	18.7	261	227	741	393	3.43	438	432
	18	( 207)	12.0	12.8	23.3	21.5	193	200	953	360	3.09	397	429
	19	( 202)	13.1	15.6	16.6	17.8	269	262	927	377	3.18	455	412
	20	( 216)	12.4	13.8	18.7	19.8	191	206	840	382	3.00	417	382
	Mean	( 221.4)	13.26	14.56	20.48	19.44	235.0	231.2	843.0	372.0	3.170	424.4	416.4
	+S.D.	( 19.4)	1.22	1.21	2.95	1.38	39.4	29.4	96.8	17.9	0.161	22.4	20.7
<b>Polyoxyethylene p-nonylphenyl ether</b>													
20 (mg/kg/day)													
	26	( 190)	15.1	15.5	20.9	23.5	260	213	958	346	2.92	405	387
	27	( 216)	18.2	18.0	29.4	24.5	250	236	847	349	3.29	467	483
	28	( 211)	14.1	15.6	17.5	16.7	215	228	855	354	3.21	410	397
	29	( 211)	14.6	14.0	17.7	17.6	255	266	886	368	3.13	441	423
	30	( 224)	15.8	20.0	22.1	20.8	252	192	880	360	3.18	454	452
	Mean	( 210.4)	15.56	16.62	21.52	20.62	246.4	227.0	885.2	355.4	3.146	435.4	428.4
	+S.D.	( 12.6)	1.60	2.37	4.84	3.46	18.0	27.5	43.9	8.8	0.139	27.1	39.6
<b>Polyoxyethylene p-nonylphenyl ether</b>													
200 (mg/kg/day)													
	36	( 216)	14.6	18.9	21.5	16.9	206	211	949	392	3.10	412	396
	37	( 198)	16.7	18.4	26.9	21.9	163	201	926	433	3.17	482	477
	38	( 244)	14.5	17.3	20.0	22.9	196	212	761	387	3.32	458	461
	39	( 183)	20.4	19.8	16.2	26.0	164	279	991	403	3.15	414	385
	40	( 213)	17.6	18.5	16.6	20.4	183	190	779	377	3.22	421	431
	Mean	( 210.8)	16.76	18.58	20.24	21.62	182.4	218.6	881.2	398.4	3.192	437.4	430.0
	+S.D.	( 22.8)	2.44	0.90	4.35	3.34	19.1	34.9	104.3	21.5	0.083	31.1	39.8
<b>Polyoxyethylene p-nonylphenyl ether</b>													
1000 (mg/kg/day)													
	56	( 235)	13.3	11.8	13.4	11.1	242	187	758	355	3.19	410	400
	57	( 216)	15.1	15.7	14.8	24.5	172	213	858	378	3.09	398	384
	58	( 224)	12.8	14.4	22.9	20.9	262	200	800	350	3.30	390	387
	59	( 214)	19.3	21.0	22.4	23.6	220	221	794	359	3.15	374	379
	60	( 208)	15.8	17.3	17.8	18.1	296	193	856	424	3.32	438	457
	Mean	( 219.4)	15.26	16.04	18.26	19.64	238.4	202.8	813.2	373.2	3.210	402.0	401.4
	+S.D.	( 10.4)	2.58	3.43	4.31	5.39	46.5	14.0	43.1	30.3	0.098	24.0	32.0

## Appendix 10-12 Relative organ weight in female rats (End of recovery test)

Study No. : SBL79-02

Group	Anim.No.	BW (g)	Adre.R mg/100gBW	Adre.L mg/100gBW	Ovary.R mg/100gBW	Ovary.L mg/100gBW	Thymus mg/100gBW	Spleen mg/100gBW	Brain mg/100gBW	Heart mg/100gBW	Liver g/100gBW	Kid.R mg/100gBW	Kid.L mg/100gBW
<b>Control</b>													
	11	( 228)	14.2	12.5	20.4	24.8	172	254	811	383	3.02	421	431
	12	( 226)	11.2	11.7	9.7	16.0	164	215	792	330	2.74	396	400
	13	( 256)	14.0	14.2	19.6	20.2	207	224	743	349	3.34	414	423
	14	( 228)	10.7	13.2	22.5	19.6	152	250	815	374	2.86	414	401
	15	( 221)	11.5	13.5	21.3	18.6	175	224	895	334	2.78	445	442
	Mean	(231.8)	12.32	13.02	18.70	19.84	174.0	233.4	811.2	354.0	2.948	418.0	419.4
	+S.D.	( 13.8)	1.65	0.96	5.15	3.20	20.5	17.4	54.9	23.7	0.244	17.7	18.5
<b>Polyoxyethylene p-nonylphenyl ether</b>													
1000 (mg/kg/day)													
	51	( 210)	14.6	18.8	17.7	17.7	170	204	872	402	2.76	426	418
	52	( 221)	14.7	15.0	16.2	14.3	175	162	840	367	2.95	425	424
	53	( 205)	16.7	17.9	25.5	20.1	146	247	919	376	3.02	407	388
	54	( 210)	17.2	17.4	26.9	22.7	238	193	865	383	2.85	397	383
	55	( 235)	14.2	13.1	27.3	20.2	209	231	783	359	3.11	411	381
	Mean	(216.2)	15.48	16.44	22.72	19.00	187.6	207.4	855.8	377.4	2.938	413.2	398.8
	+S.D.	( 12.0)	1.37	2.34	5.34	3.17	36.0	33.2	49.7	16.5	0.138	12.3	20.5

**Histopathological Findings**

**Grade**

- : No abnormal changes

± : Very slight

+ : Slight

++ : Moderate

+++ : Marked

P : Non-graded change

U : Unexamined

N : Negative

## Appendix 11-1 Histopathological findings in male rats (End of drug administration) - [H.E. staining]

Study No. : SBL79-02

Findings	Group	Control					Polyoxyethylene p-nonylphenyl ether						
		Dose (mg/kg/day)					20	200	1000				
	Animal No.	6	7	8	9	10			46	47	48	49	50
Heart													
Myocardial degeneration, focal	-	-	-	-	-	+			-	-	-	-	-
Spleen													
Extramedullary hematopoiesis	-	+	+	-	-				+	+	+	+	-
Thymus			-	-	-	-			-	-	-	-	-
Femoral bone marrow		-	-	-	-	-			-	-	-	-	-
Sternal bone marrow		-	-	-	-	-			-	-	-	-	-
Lymph node (Mesenteric)	-	-	-	-	-				-	-	-	-	-
Lymph node (Submandibular)													
Hyperplasia, plasma cell	-	+	-	-	-				-	-	-	-	+
Lung													
Foamy cell aggregation, alveolus	-	-	-	-	+				-	-	+	+	-
Trachea													
Mononuclear cell infiltration, mucosa	+	-	-	-	-				-	-	-	-	-
Bronchus/Bronchiale		-	-	-	-	-			-	-	-	-	-
Stomach		-	-	-	-	-			-	-	-	-	-
Duodenum		-	-	-	-	-			-	-	-	-	-
Jejunum		-	-	-	-	-			-	-	-	-	-
Ileum		-	-	-	-	-			-	-	-	-	-
Cecum		-	-	-	-	-			-	-	-	-	-
Colon		-	-	-	-	-			-	-	-	-	-
Rectum		-	-	-	-	-			-	-	-	-	-
Liver													
Mononuclear cell infiltration	+	+	+	-	-				+	+	+	+	+
Kidney													
Eosinophilic body, renal tubule	-	+	+	-	+				+	+	+	-	+
Mineralization, renal tubule		-	-	+	-	+			-	-	-	-	-
Basophilic change, renal tubule		-	-	-	-	-			+	-	-	-	+

Findings	Group Animal No.	Control	Polyoxyethylene p-nonylphenyl ether											
			Dose (mg/kg/day)					20	200	1000				
			6	7	8	9	10	46	47	48	49	50		
Kidney														
Hyaline cast, dilated tubule		-	-	-	-	-	-	-	-	+	-	-		
Mononuclear cell infiltration		-	-	-	+	+		-	-	-	-	-		
Urinary bladder		-	-	-	-	-	-	-	-	-	-	-		
Testis														
Atrophy, seminiferous tubule, bilateral		-	++	-	-	-	-	-	-	-	-	-		
Epididymis														
Absence, sperm, unilateral		-	P	-	-	-	-	-	-	-	-	-		
Seminal vesicle		-	-	-	-	-	-	-	-	-	-	-		
Prostate		-	-	-	-	-	-	-	-	-	-	-		
Pituitary		-	-	-	-	-	-	-	-	-	-	-		
Adrenal														
Cyst, cortex		-	-	-	-	-	+	-	-	-	-	-		
Hypertrophy, cortical cell, focal		-	-	-	+	+	-	-	+	+	-	-		
Thyroid														
Ultimobranchial body		-	-	P	-	P	P	P	-	-	-	-		
Parathyroid		-	-	-	-	-	-	-	-	-	-	-		
Cerebrum		-	-	-	-	-	-	-	-	-	-	-		
Cerebellum		-	-	-	-	-	-	-	-	-	-	-		
Sciatic nerve		-	-	-	-	-	-	-	-	-	-	-		
Brain stem		-	-	-	-	-	-	-	-	-	-	-		
Spinal cord (Thoracic)		-	-	-	-	-	-	-	-	-	-	-		
Eyeball (Optic n.)		-	-	-	-	-	-	-	-	-	-	-		
Harderian gland		-	-	-	-	-	-	-	-	-	-	-		
Femur														
Brown pigment, periosteum		-	-	+	-	-	+	-	-	-	+	-		
Sternum		-	-	-	-	-	-	-	-	-	-	-		

## Appendix 11-3 Histopathological findings in female rats (End of drug administration) - [H.E. staining]

Study No. : SBL79-02

Findings	Animal No.	Group		Control		Polyoxyethylene p-nonylphenyl ether							
				Dose (mg/kg/day)		20		200		1000			
		16	17	18	19	20		56	57	58	59	60	
Heart													
Myocardial degeneration, focal		-	-	-	-	-	+						-
Spleen													
Extramedullary hematopoiesis		-	+	-	-	-							+
Thymus		-	-	-	-	-							-
Femoral bone marrow		-	-	-	-	-							-
Sternal bone marrow		-	-	-	-	-							-
Lymph node (Mesenteric)		-	-	-	-	-							-
Lymph node (Submandibular)													
Hyperplasia, plasma cell		-	-	-	-	-			+	-	-		-
Lung		-	-	-	-	-							-
Trachea		-	-	-	-	-							-
Bronchus/Bronchiole		-	-	-	-	-							-
Stomach		-	-	-	-	-							-
Duodenum		-	-	-	-	-							-
Jejunum		-	-	-	-	-							-
Ileum		-	-	-	-	-							-
Cecum		-	-	-	-	-							-
Colon		-	-	-	-	-							-
Rectum		-	-	-	-	-							-
Liver													
Microvacuolization, hepatocyte, periportal		+	+	-	-	+			+	-	-	-	-
Mononuclear cell infiltration		+	+	+	+	-			+	+	+	+	+
Kidney													
Mineralization, renal tubule		-	+	-	+	-			+	+	+	-	-
Basophilic change, renal tubule		-	+	-	+	+			+	+	+	-	-

## Appendix 11-4 Histopathological findings in female rats (End of drug administration) - [H.E. staining]

Study No. : SBL79-02

Findings	Animal No.	Control					Polyoxyethylene p-nonylphenyl ether						
		Dose (mg/kg/day)					20	200	1000				
		16	17	18	19	20			56	57	58	59	60
Kidney													
Mononuclear cell infiltration		-	-	-	-	-			-	-	+	-	+
Urinary bladder		-	-	-	-	-			-	-	-	-	-
Ovary													
Mononuclear cell infiltration		-	-	-	-	-			-	-	-	+	-
Uterus													
Dilatation, lumen		-	-	-	-	-			-	-	-	-	+
Vagina		-	-	-	-	-			-	-	-	-	-
Pituitary		-	-	-	-	-			-	-	-	-	-
Adrenal													
Hypertrophy, cortical cell, focal		-	-	-	+	+			+	-	-	-	-
Thyroid													
Ultimobranchial body		P	P	-	P	-			-	-	-	-	-
Parathyroid		-	-	-	-	-			-	-	-	-	-
Cerebrum		-	-	-	-	-			-	-	-	-	-
Cerebellum		-	-	-	-	-			-	-	-	-	-
Sciatic nerve		-	-	-	-	-			-	-	-	-	-
Brain stem		-	-	-	-	-			-	-	-	-	-
Spinal cord (Thoracic)		-	-	-	-	-			-	-	-	-	-
Eyeball (Optic n.)		-	-	-	-	-			-	-	-	-	-
Harderian gland		-	-	-	-	-			-	-	-	-	-
Femur													
Brown pigment, periosteum		-	-	-	-	-			-	-	+	-	-
Sternum		-	-	-	-	-			-	-	-	-	-

## Appendix 11-5 Histopathological findings in male rats (End of recovery test) - [H.E. staining]

Study No. : SBL79-02

Findings	Group	Control					Polyoxyethylene p-nonylphenyl ether						
		Dose (mg/kg/day)					20	200	1000				
	Animal No.	1	2	3	4	5			41	42	43	44	45
Heart		-	-	-	-	-			-	-	-	-	-
Spleen													
Extramedullary hematopoiesis		-	-	-	+	-			-	+	-	-	+
Thymus		-	-	-	-	-			-	-	-	-	-
Femoral bone marrow		-	-	-	-	-			-	-	-	-	-
Sternal bone marrow		-	-	-	-	-			-	-	-	-	-
Lymph node (Mesenteric)		-	-	-	-	-			-	-	-	-	-
Lymph node (Submandibular)		-	-	-	-	-			-	-	-	-	-
Lung													
Hemorrhage, focal		-	-	-	-	-			-	-	+	-	-
Osseous metaplasia		-	-	-	-	+			-	-	-	-	-
Foamy cell aggregation, alveolus		+	-	-	+	-			-	-	-	-	-
Mineralization, pulmonary artery		+	-	-	-	-			-	-	+	-	-
Trachea		-	-	-	-	-			-	-	-	-	-
Bronchus/Bronchiale		-	-	-	-	-			-	-	-	-	-
Stomach		-	-	-	-	-			-	-	-	-	-
Duodenum		-	-	-	-	-			-	-	-	-	-
Jejunum		-	-	-	-	-			-	-	-	-	-
Ileum		-	-	-	-	-			-	-	-	-	-
Cecum		-	-	-	-	-			-	-	-	-	-
Colon		-	-	-	-	-			-	-	-	-	-
Rectum		-	-	-	-	-			-	-	-	-	-
Liver													
Microvacuolization, hepatocyte, periportal		-	-	-	+	-			-	-	-	-	-

Findings	Group	Control					Polyoxyethylene p-nonylphenyl ether							
		Dose (mg/kg/day)					20	200	1000					
		Animal No.	1	2	3	4	5			41	42	43	44	45
Liver														
Mononuclear cell infiltration			+	+	+	+	-			+	+	-	+	-
Necrosis, focal			-	-	-	-	-			-	+	-	-	-
Kidney														
Eosinophilic body, renal tubule			-	+	+	-	+			+	+	+	+	+
Basophilic change, renal tubule			-	-	-	+	-			-	+	-	+	-
Urinary bladder			-	-	-	-	-			-	-	-	-	-
Testis			-	-	-	-	-			-	-	-	-	-
Epididymis			-	-	-	-	-			-	-	-	-	-
Seminal vesicle			-	-	-	-	-			-	-	-	-	-
Prostate														
Mononuclear cell infiltration			-	-	-	-	-			-	+	-	-	-
Pituitary			-	-	-	-	-			-	-	-	-	-
Adrenal			-	-	-	-	-			-	-	-	-	-
Thyroid														
Ectopic thymus			-	-	-	-	-			-	-	-	-	P
Ultimobranchial body			P	-	P	-	P			P	-	-	-	-
Parathyroid			-	-	-	-	-			-	-	U	-	-
Cerebrum			-	-	-	-	-			-	-	-	-	-
Cerebellum			-	-	-	-	-			-	-	-	-	-
Sciatic nerve			-	-	-	-	-			-	-	-	-	-
Brain stem			-	-	-	-	-			-	-	-	-	-
Spinal cord (Thoracic)			-	-	-	-	-			-	-	-	-	-
Eyeball (Optic n.)			-	-	-	-	-			-	-	-	-	-
Harderian gland			-	-	-	-	-			-	-	-	-	-
Femur														
Brown pigment, periosteum			-	+	+	+	+			+	+	+	+	+

Findings	Animal No.	1	2	3	4	5	Polyoxyethylene p-nonylphenyl ether							
							Control		20	200	1000			
							Dose (mg/kg/day)				41	42	43	44
Femur														
Hemorrhage, periosteum		-	-	+	+	-			+	+	-	-	-	-
Sternum		-	-	-	-	-			-	-	-	-	-	-

## Appendix 11-8 Histopathological findings in female rats (End of recovery test) - [H.E. staining]

Study No. : SBL79-02

Findings	Animal No.	Dose (mg/kg/day)	Control		Polyoxyethylene p-nonylphenyl ether									
								20	200	1000				
			11	12	13	14	15			51	52	53	54	55
Heart														
Mononuclear cell infiltration		+	-	-	-	-	-			-	-	-	-	-
Spleen														
Extramedullary hematopoiesis		-	+	+	+	+	-			-	-	-	-	-
Thymus			-	-	-	-	-			-	-	-	-	-
Femoral bone marrow			-	-	-	-	-			-	-	-	-	-
Sternal bone marrow			-	-	-	-	-			-	-	-	-	-
Lymph node (Mesenteric)			-	-	-	-	-			-	-	-	-	-
Lymph node (Submandibular)			-	-	-	-	-			-	-	-	-	-
Lung														
Osseous metaplasia		-	-	-	-	-	-			-	-	-	-	+
Foamy cell aggregation, alveolus		-	-	-	-	-	-			-	+	-	+	-
Mineralization, pulmonary artery		-	-	-	-	-	-			-	+	-	-	-
Inflammation, perivascular		-	-	-	-	-	-			-	-	-	+	-
Trachea			-	-	-	-	-			-	-	-	-	-
Bronchus/Bronchiole			-	-	-	-	-			-	-	-	-	-
Stomach			-	-	-	-	-			-	-	-	-	-
Duodenum			-	-	-	-	-			-	-	-	-	-
Jejunum			-	-	-	-	-			-	-	-	-	-
Ileum			-	-	-	-	-			-	-	-	-	-
Cecum			-	-	-	-	-			-	-	-	-	-
Colon			-	-	-	-	-			-	-	-	-	-
Rectum			-	-	-	-	-			-	-	-	-	-
Liver			+	+	+	+	+			+	+	+	-	+
Mononuclear cell infiltration		+	+	+	+	+	+			+	+	+	-	+
Necrosis, focal			-	-	-	-	+			-	-	-	-	-

Findings	Animal No.	Group	Control					Polyoxyethylene p-nonylphenyl ether						
			Dose (mg/kg/day)					20	200	1000				
			11	12	13	14	15			51	52	53	54	55
Kidney														
Mineralization, renal tubule		-	+	-	-	-	-			-	-	-	-	-
Urinary bladder		-	-	-	-	-	-			-	-	-	-	-
Ovary		-	-	-	-	-	-			-	-	-	-	-
Uterus		-	-	-	-	-	-			-	-	-	-	-
Vagina		-	-	-	-	-	-			-	-	-	-	-
Pituitary		-	-	-	-	-	-			-	-	-	-	-
Adrenal														
Hypertrophy, cortical cell, focal		-	-	-	-	-	+			-	+	-	-	-
Thyroid														
Ectopic thymus		-	P	-	-	-	-			-	-	-	-	-
Ultimobranchial body		-	-	-	-	-	-			P	P	-	-	P
Parathyroid		U	-	-	-	-	-			-	-	-	-	-
Cerebrum		-	-	-	-	-	-			-	-	-	-	-
Cerebellum		-	-	-	-	-	-			-	-	-	-	-
Sciatic nerve		-	-	-	-	-	-			-	-	-	-	-
Brain stem		-	-	-	-	-	-			-	-	-	-	-
Spinal cord (Thoracic)		-	-	-	-	-	-			-	-	-	-	-
Eyeball (Optic n.)		-	-	-	-	-	-			-	-	-	-	-
Harderian gland		-	-	-	-	-	-			-	-	-	-	-
Femur														
Brown pigment, periosteum		+	+	+	+	+	+			+	+	-	+	+
Sternum		-	-	-	-	-	-			-	-	-	-	-